## PHARMACEUTICAL SOCIETY OF IRELAND

HEARING HELD IN PUBLIC BEFORE THE PROFESSIONAL CONDUCT COMMITTEE OF THE PHARMACEUTICAL SOCIETY IN IRELAND

## PRIVATE \& CONFIDENTIAL

RE: MR JOHN O'MEARA - REGISTRATION NUMBER 7210 CASE REFERENCE NUMBER: 468.2018

## HELD REMOTELY

ON WEDNESDAY, 13 OCTOBER 2021

| Committee Members: | Mr Dermott Jewe11, Chairman |
| :--- | :--- |
| Lay member | Mr Mark Kane |
| Pharmacist: | Ms Barbara o'Conne11 |
| Legal Assessor: | Mr Eugene Gleeson |
| Counse1 for the Registrar: | Mr Frank Beatty, SC |
| Counse1 for Registrant: | Mr Ronan Kennedy, SC |
| Instructed by: | Mr Andrew Vallely |
| Transcript by D. O'Malley Stenography Ltd. |  |
| Stenographer/Logger: | Deirdre O'Malley RMR, CRR <br> Editor(s): |

## I N D E X

Proceedings ..... Page
AMANDA NEVIN
by Mr Beatty ..... 3
DR CONOR MCCRYSTAL
by Mr Beatty ..... 47
Submissions by Mr Beatty ..... 69

## PROCEED NGS COMMENCED ON VEDNESDAY, 13 CCTOBER, 2021, AS

 FQLONB:CHAIR: Everybody, you are very welcome back. We reconvene. As I understand it, Mr Beatty, we are going to be commencing with Ms Nevin's evidence, I think. MR BEATTY: That's correct. So, if I could call Ms Nevin. CHAIR: Thank you.

MS DUNNE: So, Ms Nevin has joined the call.
CHAIR: Good morning, Ms Nevin. You can see us and hear us?

MS NEVIN: I can, yes, thanks, Chair.
CHAIR: Good morning. I will introduce myself. I am Dermot Jewe11, I am the Chair of this Inquiry. Thank you for being here. Before you give your evidence, can I ask you, do you wish to do so on oath or on affirmation? MS NEVIN: On affirmation, please.

AMANDA NEVIN (affirmed) - examined by Mr Beatty

CHAIR: Thank you very much. I will pass you across to Mr Beatty.

WITNESS: My camera seems to be having difficulty there. Can you still see me?

CHAIR: we can see a frozen vision of you.
WITNESS: Yes, okay. It's gone blank on my screen.
MR MURPHY: Just for the purposes of Mr O'Meara, Chairman, I have no difficulty if Ms Nevin gives evidence without a camera, subject to whatever the Committee thinks.

CHAIR: Thank you very much, Mr Murphy, I appreciate that. MS. DUNNE: If I could just make a -- sorry to interrupt,
if I could just make a quick suggestion. Ms Nevin, if you want to just try leaving the call and rejoining again, that might resolve the issue. We'11 just give that one go. Thank you.

WITNESS: Okay, perfect. Yes.
[Pause in the record].

MS DUNNE: Ms Nevin has rejoined the cal1. If you want to turn on your camera and unmute your microphone, and we'11 see if it works.

WITNESS: I am attempting to start my camera, but it's -okay, now it looks like it might be, yes.

CHAIR: Yes, we have you. Very good. Right. I am going to pass you immediately across to Mr Beatty, then. Time is precious. Thank you.

WITNESS: Okay, thank you.
MR BEATTY: I'11 just make sure I have my microphone on. Ms Nevin, I am counsel on behalf of the Registrar. I am going to ask you a few questions, and once you're finished -- once I am finished asking you questions it may be that Mr Murphy, on behalf of the Registrant, has questions for you, and it may be that the Committee has questions for you as we11; is that all right?

WITNESS: That's fine, yes.
MR BEATTY: Excellent. Could you just outline for the Committee what your qualification is?
A. I am a pharmacist by profession. I've been registered with the Pharmaceutical Society of Ireland as, since 2007. I joined the PSI in 2014 as an authorised officer. So I am an authorised officer of the PSI under the functions of

Part 7 of the Pharmacy Act.
Q. Can you tell me, how did you come across Mr O'Meara?
A. In August of 2018, the inspection enforcement manager, Ruth McDonne11, was contacted by the Gardaí in relation to some concerns regarding Mr O'Meara. They informed her that they had identified medicines in Mr O'Meara's residence, and that there was evidence of the sale and supply of controlled drugs on his mobile telephone. This raised concerns regarding the possible diversion of medicines from the pharmacies for which Mr O'Meara was superintendent pharmacist at the time. On the basis of this information, Ms McDonne11 instructed the commencement of an investigation under the authority of Section 67 of the Pharmacy Act 2007, and I was assigned to lead the investigation.

I, accordingly, visited Wicklow CarePlus Pharmacy on the 29th of August 2018, and that was my first, if you like, investigation activity in relation to the matter, and I met Mr O'Meara in the course of that investigation visit on that date.

1 Q. I see. Can you just set out the statutory basis for that inspection?
A. It was under the authority of Section 67 of the Pharmacy Act 2007, which provides authorised officers of the PSI with powers of inspection, powers to enter a pharmacy, and to inspect and to detain evidence, if required.

2 Q. I see. And before we go into your inspection, did you get any sense, and can you give the committee any insight into the staffing of the pharmacy, this is the wicklow pharmacy?
A. Well, I wouldn't -- the registered information, or the registered details for the pharmacy in relation to staffing held by the PSI would generally include only those positions in governance and supervision in a pharmacy. So, the superintendent pharmacist, who is the pharmacist who is in overa11 control of the management of a pharmacy and of the management of the supply of medicines from the pharmacy, and the supervising pharmacist, who is the pharmacist in day-to-day control of the management and administration of a pharmacy.

So, the information that was on record for the PSI was that John O'Meara was the superintendent pharmacist for wicklow CarePlus Pharmacy, so in overall control, and the supervising pharmacist was Ms Andrea Doyle, so she was the pharmacist in day-to-day control of the management of the pharmacy.
3 Q. That's very helpful. Again, before we just go into the actual inspection, can you just identify for the Committee what the -- the documents that you were looking for and what those documents would normally contain?
A. Yes. So, because we were reviewing the sale and supply of medicines from the pharmacy, with a view to determining whether there were any medicines unaccounted for at the pharmacy, the documents that were requested and reviewed primarily related to sale and supply of medicines. So, documents to identify incoming quantities of medicines from wholesalers, such as invoices. However, a lot of that information was obtained through the HPRA subsequently, as invoices are not generally retained in a pharmacy
potentially for very long, and in order to ensure that accurate information was received on incoming quantities.

At the pharmacy, then, the documents requested included documents which would show details of legitimate supplies of medicines from the pharmacy. So, that includes a document called a Drug usage Analysis, which presents a summarised, overall account of the total quantities of each medicine supplied from the pharmacy over a given period. It also included Dispensed Drug Reports for individual medicines, which detail each individual supply of the particular medicine supplied from the pharmacy over a given period, so it would list each patient that had been supplied with the medicine and the quantity supplied.

I also reviewed the Controlled Drugs Register. So, the misuse of drugs regulations, it sets up a scheme for the regulation of drugs which are subject to misuse and abuse, and it categorises medicines into five schedules, depending on the potential for serious misuse of the drug.

Schedule 1 includes drugs which are generally not available for legal supply in any context, such as heroin or cocaine, illicit medicines. Schedule 2, then, is the highest level of control of a medicine which can be supplied in legitimate circumstances, such as morphine-type drugs. Schedule 2, therefore, is the highest level of control of a controlled drug within a pharmacy for drugs that are available on prescription and classified as schedule 2 controlled drugs.

These drugs have to be stored in a safe in the pharmacy and the transactions of them have to be recorded in a register within 24 hours of the transaction taking place, so that there is a running account of the quantity of medicine in the pharmacy and an account of every amount that comes in and out of the pharmacy.

So, I reviewed, it's called the Controlled Drugs Register, and I reviewed that Register in the course of the inspection. I also reviewed the Duty Register, which is the record of what pharmacist provided cover at the pharmacy on any given day. (Indiscernible cross-talk.)

4 Q. Sorry, I interrupted you there, sorry. Were there any other documents?
A. AS I recal1, they were the documents reviewed.

5 Q. That's very helpful. And you said there that you carried out inspection on the 29th of August 2018. Was that the on7y inspection that you carried out?
A. No, that was the first inspection carried out. There was a second inspection carried out in -- on the 22nd of October, if I recal1; is that the correct date?
6 Q. It is.
A. So, on --

7 Q.
What I am putting to you -- sorry.
A. Please go ahead.

8 Q.
What I am going to do for the Committee is, I am going to bring you through the two reports that you prepared on the basis -- the two separate reports on the basis of those
inspections.
A. Perfect, yes.

9 Q.
I am hoping that you will have access to a Core Book there, and it's -- you will find it under the Court Bundles, and you'11 see, and the Committee wil1 see, that tab 12 refers to an authorised officer's report. Do you see that?
A. Are you addressing myself --
Q. Yes, I am.
A. -- Mr Beatty, or the Committee?

I don't actually have access to the Core Book, but I can see what's on screen, so ...
11 Q. Yes. We can get it up on screen, that's helpful. So, I am learning about this process myself as well, so that's helpful. The first thing I am going to do is bring you to the very final page of that report, which is the page 15.
A. I do have access to the report itself, so ...
Q. I am sure neither the Committee nor Mr Murphy will have any difficulty with you referring to the report, as you have it as well.
A. Very good.

MR MURPHY: Sorry, Mr Beatty. I have no difficulty
whatsoever. If it assists you and it assists the
Committee, you can lead this witness, and I will intervene if there's any difficulty.
MR BEATTY: Thank you very much.
13 Q. That's your signature; is that right?
A. That's my signature, yes.

14 Q. And it's dated the 3rd of September 2018; is that correct?
A. That's correct.

15 Q. If I could bring you to paragraph 6.1 of that report, which
is on page 9.
A. Yes.

16 Q. If you could just go through that and explain what occurred in relation to your visit on the 29th of August?
A. So, on the 29th of August myself and John Bryan, who is also an authorised officer of the PSI presented at wicklow CarePlus Pharmacy under the authority of Section 67 of the Pharmacy Act. As I explained earlier, the purpose of our visit was to review the sale and supply of medicines from the pharmacy due to the concerns that had been raised by the Gardai regarding the possibility of diversion of medicines from the pharmacy.

So, shortly after we arrived -- Mr John O'Meara was on duty at the pharmacy on the day, and we introduced ourselves and explained the purpose of our visit. Mr O'Meara quite quick7y began to state that he hadn't been completely compliant with his prescriptions. At that point I cautioned him and he continued later in the visit to explain that he had been prescribed Efexor a number of years previously by a consultant, and that he had been obtaining supplies of this medicine from the pharmacy, but had not been obtaining prescriptions from it and had not been recording it on his patient medication record within the pharmacy as having been supplied from the pharmacy. He stated that his GP was aware that he was taking the Efexor, but he hadn't been obtaining any prescriptions for the medicine.

He also stated that he had also been prescribed Ritalin
tablets, and that he had obtained prescriptions for this medicine and had recorded it on his patient medication record. I subsequently reviewed Mr o'meara's patient medication record. so, a patient medication record details all supplies of a medicine made to a particular patient over the time period that you select for it to display. I noted that there were records of supply of Ritalin included on the record, and there were no supplies of Efexor.

17 Q. I see. If you look at paragraphs 6.3 and 6.4 , you carried out an investigation, which I have no doubt you'11 te11 the Committee about now, and it was in relation to dates, 1 January 2018 to 29 August 2018. What was the relevance of those dates?
A. Yes. So those dates -- we11, the 29th of August was the date that we were in the pharmacy. So, we wanted to review the sale and supply of medicines from the start of that year, so we chose the 1st of January to the 29th of August as the date range for which we would look at the quantities of medicines coming into the pharmacy and the quantities of medicines legitimately recorded as having left the pharmacy.

Having reviewed the documents which provided us with that information, we were, on the day, limited as to the information we had regarding the medicines which had been obtained into the pharmacy from wholesalers. The HPRA assisted us and did provide us with the quantities of four medicines which had been supplied into the pharmacy from the two major wholesalers, Uniphar and United Drug.

So, on the day in the pharmacy, we were able to review those four medicines in detail with the result that, for the medicine, Xanax, we were able to identify that there were approximately 174 boxes of Xanax 1 mg tablets, which is the highest strength of Xanax, and they come in 100 tablet boxes, unaccounted for at the pharmacy in 2018 over the course of that period, from the 1st of January to the inspection on the 29th of August.

18 Q. I see. If I could just bring you to paragraph 6.3, just to start with, there's a reference to the Drug Usage Analysis report, and you have given evidence as to what that is. You will find that, or at least the Committee will find that at tab 12B, and we might just put it up on the screen so that you can explain what it says.
A. So, this is the Drug Usage Analysis report, and you can see that it displays in alphabetical order a number of medicines. In the second column, it displays a quantity, and that is the quantity for this report of that medicine that was recorded on the dispensing system as having been supplied from Wicklow CarePlus Pharmacy over the period from the 1st of January to 29th of August 2018. And you will see that Mr O'Meara has confirmed that on the side there in handwriting.

19 Q. That's his signature, is it?
A. That's his signature, yes. He wrote, "I confirm that this covers from $1 / 1 / 2018$ to $29 / 8 / 2018$ ", and I asked him to do that because the report does not state the dates in and of itself. So, he confirmed that they were the parameters that he entered into the computer when requesting the report to generate.

20 Q. I see. It could be that the Committee have some questions in relation to that report, but I am going to go on to the next report that you refer to, which is the Dispensed Drugs Report, and the Committee will find that at tab 12C. If that could be put up just so that you can explain what that te11s you?
A. This particular document that's displaying currently is not a Dispensed Drug Report. It is a template that I had prepared in advance of the inspection with a list of medicines for which I was going to request a Dispensed Drug Report. I see. Was there a Dispensed Drug Report that was obtained following this?
A. Yes, so there were Dispensed Drug Reports obtained for each of the medicines on the document you are looking at now, beside which John O'Meara has signed his name. So, there would have been one for concerta XL 18, one for XL 27, one for each medicine. They are probably --
23 Q. If you scroll down from that page, that's page 2 of 4 , what are those reports? Or, sorry, what is that document I should ask?
A. It's page $9 \ldots$... it's still on the same document currently.

24 Q. If we scroll down a little bit further?
A. Yes, now you are into the Dispensed Drug Report. So, this
is a Dispensed Drug Report for Concerta XL 18mg tablets, and it details -- you can see the patient name has been redacted. So, it will detail the name of the patient in each instance and the date on which the medicine was supplied to that patient and the quantity supplied to the patient.

25 Q. I see. That continues on, and it may be that the Committee have particular questions in relation to that in due course, but that continues on. But that is the Dispensed Drug Report, and it explained what that informs you of; isn't that correct?
A. Yes, it informs you of each individual supply of a given medicine recorded as having been legitimately supplied from the pharmacy on the dispensing system at the pharmacy over whatever date period you select.
26 Q. Then you carried out a stock inventory; is that correct?
A. That's correct, yes. For the medicines under review, I counted the quantity of stock present at the pharmacy at the time.

27 Q. We'11 have that put up. But -- (audio cut out) -- is that correct?
A. Pardon, Mr Beatty, I think I might have missed -Sorry, I just have -- I just had it put up on the screen. I am just letting the Committee know where they would find it, but we've put it up on the screen for you so that you can just bring the Committee through it and inform them as to what it tells you as regards your investigation?
A. Yes. Okay. So, this is the template that I had prepared in advance of the inspection with the medicines that I intended to review. It is set out just to assist in the
actual counting of the medicines within the pharmacy. So, you can see I've filled in the name of the pharmacy and the date, the quantity in open boxes, the quantity in closed boxes, then added those together, and I have signed -that's my initials, 'AN', that I have counted each of those medicines. I also, for a number of medicines, I asked for assistance from the pharmacy manager and technician, sinéad Moran, as I was unable to locate any of -- some of the medicines within the pharmacy, and I just sought her assistance in confirming that there either were none or -she did locate, I think, the Phenergan, she did locate some Phenergan tablets that I hadn't been able to locate, and she confirmed that the others, that there was no stock. So, the total quantity there along in that column is the quantity of that medicine that was in the pharmacy on the 29th of August.
29 Q. All right. That's very helpful. What information were you provided for by Mr Smullen? If you would just explain who Mr Smullen is and what information you were provided for by him?
A. Yes. Mr Smullen is an enforcement officer with the Health Product Regulatory Authority. So, the HPRA is the regulator of medicines in Ireland, and they regulate both pharmaceutical manufacturers and wholesalers and distribution. So, they have access to the wholesalers and the information that wholesalers would hold regarding the medicines that they have supplied to a pharmacy or pharmacies. So, in this instance, Mr Smullen presented at the pharmacy in the course of our visit to see if we needed any assistance in that regard, and I requested information
regarding the medicines under review from him. He explained that it would take some time to provide comprehensive information, so I requested that in the initial instance on that day if he could provide me with information regarding the quantities of four medicines; namely Xanax, 1 mg tablets, Ritalin, 10 mg tablets, Stilnoct, 10 mg tablets, and Zimovane, 7.5 mg tablets. I asked him if he could get information from the main wholesalers, uniphar and United Drug, regarding the quantities of those medicines supplied into wicklow Careplus Pharmacy in 2018 from 1st of January to the date of the inspection, 29th August, which he did. That then gave me the information regarding the amounts of those medicines that had come into the pharmacy over that period.

30 Q. So, if one looks at paragraph 6.6 of your report, you asked him to obtain that information in relation to the drugs that are identified -- sorry, I should bring it up for the Committee -- if one looks at paragraph 6.6, your request of Mr Smullen was for the quantities of medicine that had been provided by the wholesalers in relation to the four drugs that are identified in that paragraph, for the period 1st January 2018 to 29th August 2018; is that right?
A. That's correct, yes.

31 Q. Now, at paragraph 6.7 and onwards -- so, at 6.7, you dea1 with the issue of xanax. At 6.10, you deal with the issue of Ritalin. In 6.12, you start in relation to Stilnoct and I think at 16.14, you go back into the issue of Ritalin. And Cialis is dealt with at 6.18. I'd ask you to be conscious that the Committee have had this documentation, and I have no doubt they have gone
through it, but if you could just treat them as not yet having gone through this documentation, because there is, as you would imagine, a significant amount of documentation, and if you could explain to the Committee what your findings were, starting at paragraph 6.7 of your report?
A. Okay, yes. So, 6.7 deals with Xanax, and Xanax is a medicine which contains the active ingredient or the active medicinal product, Alprazolam. It's a benzodiazepine, and it's licensed for anxiety, but only when the disorder is severe. It is available in three strengths, so it's available in 250 microgram tablets, 500 microgram tablets and 1 mg tablets. So, the 1 mg tablets are the highest strength and they would, in my experience, be the less commonly prescribed and used strength of xanax.
32 Q. Ms Nevin, I don't mean to interrupt you. I am just seeing that there is just some small difficulty in relation to the reception from Ms O'Connel1 and Mr Kane. I am going to just make sure that they can hear this evidence, and that there's no difficulty.
MR KANE: Mr Beatty, I wasn't aware of any difficulty. I can see 6.7 and I can see you. I can see -mS O'CONNELL: Yes, I can see everything as well and hear everything.
MR BEATTY: I'm sorry, I was just getting some feedback saying there might be a difficulty. Sorry. Ms Nevin, if you just continue, then?
A. No problem. So, as I noted earlier, Xanax was one of the medicines reviewed at the inspection of the 29th of August. The information obtained from Mr Smullen stated that there
had been 11,100 tablets of Xanax supplied by United Drug to the pharmacy over that period, and 6,700 Xanax tablets supplied from Uniphar over the period. That is a quantity of 17,800 , which is approximately 178 boxes, they come in boxes of 100 tablets. So, 178 boxes of Xanax 1 mg tablets supplied into the pharmacy from the 1st of January to 29th of August 2018. Then, a review of the Drug Analysis Report, which showed how many of those tablets were supplied out of the pharmacy to patients on the dispensing system, showed that 111 tablets had been recorded as supplied, so that's just over one box. There were also 279 tablets in stock at the pharmacy on that date, so just short of three boxes.

So, to summarise, there were 178 boxes supplied to the pharmacy, approximately one box legitimately supplied out of the pharmacy, and just under three boxes still in stock in the pharmacy, which left a balance of 174 boxes of Xanax 1 mg tablets which were not accounted for at the pharmacy. They had been supplied into it, they weren't at it, but there was no legitimate account of where they had gone at the pharmacy. That's 174 boxes of 100 tablets, is over 17,000 Xanax 1mg tablets.

I completed a similar exercise for Ritalin 10 mg tablets. Ritalin contains the medicine Methylphenidate, and it's a central nervous stimulant, and a schedule II controlled drug due to, as I was explaining earlier, the Misuse of Drugs Regulations and its potential for abuse and misuse. So, because Ritalin is a schedule II controlled drug, the
records that have to be kept are even more detailed than in the case of other medicines. Each individual transaction has to be recorded in the Controlled Drugs Register to show each quantity that comes into the pharmacy and each quantity that leaves the pharmacy.

So, I reviewed the Controlled Drugs Register, as this would be more accurate for the purpose of determining if there were any of this medicine unaccounted for. At the time of the inspection, on that day in the pharmacy, Mr Smullen was able to tell me that eight packs of Ritalin 10 mg , so they're 30 -tablet packs, eight packs had been supplied since the 1st of January into the pharmacy from Uniphar and 14 packs had been supplied into the pharmacy from United Drug. So, that's 22 packs.

When I reviewed the Controlled Drug Register, I was able to identify that there were records for eight packs of Ritalin 10mg having been supplied by Uniphar, those were recorded, but there were only records in the Controlled Drugs Register of four packs of Ritalin coming into the pharmacy from United Drug. So, the information from the HPRA was that there were 14 packs of Ritalin supplied by United Drug since the 1st of January, and the information recorded in the Controlled Drugs Register was that there were only four received from United Drug; so there was a discrepancy of 10 packs of Ritalin 10 mg tablets.

The quantity of Ritalin in the pharmacy was checked and corresponded with the CD register. There was no indication
that there were any inaccuracies in the CD register. So, the final result of this review was that there were 10 packs of Ritalin 10mg tablets unaccounted for at the pharmacy on 29 August 2018.
33 Q.
Thank you, Ms Nevin. If I could just stop you there. So, you've just accounted for the xanax and you've accounted for Ritalin. I should have just -- before you went off Ritalin, I should have brought the committee to tab 12E, and you might put that up on the screen. If you could just explain what that is?
A. That is a copy of an invoice which, if I recall, this invoice -- yes, it's an invoice that I detained from the pharmacy on the 29th of August in the course of the inspection. I had requested invoices from Mr O'Meara on presentation at the pharmacy, and he did supply me with some invoices present at the pharmacy. On review, I noted a number of supplies of Xanax 1 mg on these invoices. So, supplies into the pharmacy or receipts by the pharmacy. And this particular invoice shows a supply of seven boxes of Xanax 1 mg tablets from -- it's a United Drug invoice into wicklow Careplus Pharmacy, and it's dated the 2nd of August. So, seven boxes of Xanax into Wicklow CarePlus Pharmacy on 2nd of August from wholesaler, United Drug. 34 Q. I see. So, that document, and it's not just the one page, but it goes on, but just for the committee, and they may have questions in relation to it, but this is the document that shows what was supplied by United Drug; is that right?
A. That's correct, yes. That's the document that was present in the pharmacy.
35 Q. And it goes on also to deal with the supply by Uniphar; is

## that correct?

A. Yes. There are a number of invoices from Uniphar also, which include supplies or receipts into the pharmacy of Xanax 1 mg tablets, yes.
That's great, thank you. And you had accounted also for Ritalin. And I notice -- and you've accounted for Ritalin, if one looks at your report, essentially up to paragraph 6.11 , as I understand the position, and 6.12 goes on to the issue of Stilnoct. The Ritalin issue arises again at paragraph 6.14, so I think, for ease of the Committee, if we could stick on the Ritalin and continue with the investigations that were carried out and are set out at paragraph 6.14 of your report?
A. Sure, yes. So, I suppose there's an account of Ritalin to a point, because that was the point at -- to which I could bring it on the day of the inspection, on the 29th of August. I carried out a similar reconciliation for Stilnoct and Zimovane on the day of the inspection at the pharmacy, but there didn't appear to be any stock of those medicines unaccounted for.

So, I proceed then in the report to elaborate on the Ritalin matter because, subsequent to the inspection, I was able to obtain copies of the individual invoices for Ritalin 10 mg tablets via the HPRA from the wholesalers. So, subsequent to the inspection I was able to obtain that documentation and review it at the offices of the PSI. On reviewing that information, I noted that there were three invoices involved from -- yes, that's it, from United Drug, there were three invoices. From Uniphar, there
were -- Uniphar, yes, sorry, we have already established that Uniphar were accounted for. United Drug involved three invoices. And when I reviewed the details of those invoices against the entries in the Controlled Drugs Register, I was able to identify that the invoice dated the 14th of June 2018 for a quantity of 10 boxes of Ritalin 10mg tablets, had not been entered into the controlled Drugs Register. The other two invoices had been entered into the Controlled Drugs Register. And that was identified, if you like, the individual supply into the pharmacy of Ritalin 10 mg tablets that was ultimately unaccounted for at the pharmacy. The 10 boxes supplied on 14th of June 2018 had not been recorded in the controlled Drugs Register.
37 Q. I see. Then I suppose I just bring you to -- or the Committee to tab 12G, just in support of your findings. This is the CD register entries for Ritalin 10mg tablets. If you could explain to the Committee what this -- the entire of this document is, and obviously we can scroll down, if necessary. 12G. So, what does this document tell you?
A. As I understand it, you're looking for the Controlled Drugs Register, and that's not what is currently being displayed. 38 Q. Yes, I am just seeing that.
A. It's appendix 13 of that report, but I don't have the core Book to get the ...
39 Q. Possibly, if we scroll down, maybe, I am just trying to ... Keep scrolling down, please. It's a 90-page document, so once we come to the Controlled Drugs Register, you can let the Committee know. Is it there? I'11 come back to that.

[^0]Don't worry about that for the moment, and I'11 come back to that. Just continuing then at paragraph 6.16.
A. Yes. So, on reviewing the three invoices, which included Ritalin 10 mg tablets from United Drug, I noted that, I suppose, in summary, the two invoices which were for two packs each of Ritalin which had been entered into the Controlled Drugs Register, they also included other products which had been supplied on the same invoice. However, the invoice dated the 14th of June 2018, which included the 10 packs of Ritalin 10 mg tablets which had not been entered in the CD register, did not contain any other medicines ordered at the same time. It was the only item ordered on that invoice.

When I reviewed subsequently the Duty Register for 2018, so the records of the pharmacist on duty on a given date, I noted that Mr John O'Meara was recorded in the Duty Register as being the only pharmacist on duty on the 14th of June 2018.

40 Q. And that Duty Register can be found at tab 12I, and we'11 just put that up for you.
A. Yes. So, you can see there that this is two pages from June 2018 covering the week from Monday, the 11th to Saturday, the 16th. And on Thursday, the 14th of June, the register is signed by Mr O'Meara as having been the pharmacist on duty from 9.00 to 7.00 , and there is no other pharmacist recorded or pharmaceutical assistant recorded as having been on duty on that date, the date that the Ritalin was ordered.

41 Q. And what did that tell you?
A. That told me that the order for ten packs of Ritalin which had not been entered in the Controlled Drugs Register had been ordered on a date on which John O'Meara was the sole pharmacist on duty, and, accordingly, would indicate that Mr O'Meara was the person who ordered the medicines, or certainly the person responsible for the sale and supply of medicines at the pharmacy on that day -- date.

42 Q. I see. I have to come back to that drug register. But before I do that, I am going to deal with the investigations that you carried out in relation to Stilnoct and Cialis. In relation to Stilnoct, you will see that at paragraph 6.12 of your statement, and if you could just account for that?
A. Yes. As I explained, on the day of the inspection, we could obtain limited information regarding the quantities of medicines which had been obtained into the pharmacy from wholesalers. So, I asked Mr Smullen to obtain information for four medicines; Xanax, as we've discussed, Ritalin 10mg, as we've discussed, because there were indicators within the pharmacy that those medicines -- that there might have been an issue with those medicines. I also asked for Stilnoct 10 mg tablets and Zimovane 7.5 mg tablets, because these are sleeping tablets, benzodiazepine-1ike sleeping tablets, which have quite a high potential for abuse and misuse, and, therefore, were included in the medicines which were being reviewed. However, when I carried out a reconciliation of incoming quantities versus outgoing legitimate supplies and the stock at the pharmacy, no issues arose in relation to Stilnoct 10 mg tablets or Zimovane 7.5 mg tablets. There

[^1]was no indication that any stock of those medicines was unaccounted for at the pharmacy on 29th of August 2018. Subsequent to the visit -- that was on the day of the visit. Subsequent to the visit further information was received. Now, at the time of writing this first report, comprehensive information was only received from the wholesaler, United Drug, but, even in the absence of receipt of information from Uniphar, an analysis of the information showed that there were also 79 -- approximately 79 boxes of cialis 20 mg tablets unaccounted for.
43 Q. I think, Ms Nevin, you deal with that in your subsequent report; is that correct?
A. I deal with it in more detail, yes. As I said, we didn't have full information at this point.
44 Q. Yes.
A. We were still awaiting information from Uniphar.

45 Q. That's right.
A. So, it did develop further. But even at this point of writing, we were able to identify that additional discrepancy as arising at the pharmacy.
46 Q. Yes. And the United Drug information you received, I don't think we need to go through it, but the Committee can see that at tab 12F. So, moving on then to Cialis. And just before I do that, I think now I can get, in relation to Ritalin, I can get the drug register up for you, and the Committee should find it as a separate document just after the Amanda Nevin statements.

If you could just bring the Committee through this in respect of the Ritalin issue. You may have to look at the
document in more detail.
A. Yes. I think that this may be a copy of the entire Controlled Drugs Register -- oh, no, it's not. We're there. Scrol1 down another page, please. Yes, there's the record for Ritalin 10mg. So, as you can see, this register records the date of the supply, the name and address of where the supply was either made, the patient it was made to, or the wholesaler it was obtained from, and the amount obtained or supplied. And then, to the far right, there's a running balance, the running stock balance maintained. These entries are 2013. So, if you can scroll down another couple of pages, we should come to the more recent transactions.

47 Q. Again, I think scrol1 down to -- again, keep scrolling, and keep going, please. Keep going. Keep going. Just that page -- sorry, the last page that you -- if you could go back one. Yes, just there.
A. So, you can see that the transactions for 2017 and 2018 are included on this page. So, it was 2018 we were reviewing at the time. I could see there are supplies recorded on the 12 th of January, 28th of March and 4th of May, each to a named patient. Then the receipts from wholesalers are included, also. So, you have a receipt on the 28th of March from Uniphar and a receipt on 5th of May for United Drug. Oh, I think, yes, I think they then started a new register. So, we probably do need to keep scrolling down to see where an entry should be for June. Okay, yes, that's it, yes. So we can see there entries in June and July of 2018 -48 Q. All right.
A. -- which include incoming quantities from Uniphar and United Drug on the 21st of June and 13th of July, but do not include, neither on that previous page of the register or this one, is there a record for the ten packs obtained from United Drug on the 14th of June.

49 Q. Al1 right. We11, I think that is sufficient, unless the Committee have any specific queries. What I am going to do then is, I am going to bring you back to the final issue in relation to your first report, which is the issue of Cialis.
A. Yes. So, subsequent to the inspection, the HPRA requested more complete information from the wholesalers regarding medicines supplied into wicklow CarePlus Pharmacy in 2018. Due to the large quantities of Xanax 1 mg tablets and Ritalin 10 mg tablets, which had been identified as being unaccounted for on 29th of August, there was quite an urgency in getting this information to the Registrar. Accordingly, this first report was written and completed on 3rd of September before information had been received from Uniphar regarding all of the medicines under review. The information had been received, however, for United Drug, and I conducted a reconciliation for those medicines to see if any additional discrepancies arose. I identified from the information that -- so, the information from United Drug stated that 468 tablets of Cialis 20 mg had been supplied by them to Wicklow CarePlus Pharmacy over the period from January to August 2018. They're packs of four, so that is just over 110 to 120 packs.

The Drug Analysis Report, which shows how many units of a
medicine were supplied from the pharmacy legitimately, showed that 132 tablets had been supplied to patients, and there were 20 tablets in stock at the pharmacy; that's five packs of four. So, reconciling those figures showed that there were 316 Cialis 20 mg tablets which remained unaccounted for at wicklow CarePlus Pharmacy as of 29th of August 2018. That's 79 boxes of Cialis 20 mg , four-tablet boxes. Cialis contains Tadalafil, it is a medicine used for the treatment of erectile dysfunction. But it is -yeah, it is occasionally, I believe, subject to diversion and supply on other markets.
50 Q. I see. Ms Nevin, that's very helpful, and that brings you to the first inspection, and you made it clear that you were still waiting for information. And there was a second inspection then, which you have given evidence in relation to, and that resulted in the creation of a second report; is that right?
A. That's correct. When we had received both the information requested from Uniphar and the additional information obtained during the second inspection, a second more comprehensive report was compiled with up-to-date figures and additional information.
51 Q. Dated 22nd of November 2018. And I'11 have that put up for you, Ms Nevin. And again, I am going to bring you first to the final page so you can simply confirm that it is you that authored the report and the date of the report?
A. That's still the first report that's displaying there.

52 Q. Yes, it should be tab 13, if we could have that. We'11 put that up in just a few minutes. Before we put that up, moving the matter on, did this investigation, did it still
cover the period from the 1st of -- you might remember the period, the relevant period that was covered in the first report was the period of the 1st of January 2018 until the date of the inspection. Did that remain the relevant period?
A. The period was extended to include 2017. So, the overal1 period reviewed was from the 1st of January 2017 to, depending on the medicine, either the 29th of August or the date of the second inspection, the 22nd of October.

I see. And we just have that in front of you now, or at least I hope it's in front of you, which is -- that is your report; is that correct?
A. Yes, that's my report. That's my signature.

And then if I could bring you to paragraph -- sorry, to page 13 of that report.
A. Page 13, yes.

55 Q. You refer to the visit at paragraph 5.6 and the Dispensed Drug Report for the period 1st of January 2017 to 31st of December 2017, and I can te11 the Committee they'11 find that book 5 at tab 13 F , and we can put that up on the screen, and if you can just tel1 the Committee what that is?
A. So, again, the document that's displaying currently is the template I prepared in advance just as --

56 Q. Yes. And we'11 just scroll down and let you explain to the Committee what the entire document deals with.
A. So, yes, this is the Dispensed Drug Report for Xanax 1 mg for 2017. So, at the previous inspection, we had requested the same report for the 2018 period, but the decision was made to extend the time period under review to include

2017, to examine if there were also quantities which appeared to be unaccounted for from that period.

57 Q. I see. And you liaised, then, you say at paragraph 5.7, with the HPRA, and you received information from them?
A. That's correct. So, yes, similarly to -- as we were discussing with the previous inspection visit, the HPRA assisted our enquiries by obtaining information from the wholesalers outlining supplies of medicines under review to wicklow CarePlus Pharmacy in 2017. we had already obtained the information for 2018, so it was extended to include 2017. August.
"The PSI authorised officers conducted an analysis of all of the information received for the medicines listed in the table at paragraph 5.4 for the years 2017, 2018."
So, if we could just go back to 5.4 of that report.
A. So, essentially, 5.4 presents the results of the analysis conducted for the 2018 period. For those medicines we extended the period to 2017 to see did the issue extend back into 2017, were there additional supplies of these medicines unaccounted for if we looked at 2017 as we11.

60 Q. I see. Going back to paragraph 5.19, having carried out that exercise, you provide a table that explains what your findings were and if you could just bring the committee through that, please.
A. So, having obtained -- it is 5.9, I am sorry, where you were previously was correct.

61 Q. It is.
A. The table at 5.9.

62 Q. Sorry, 5.9?
A. Yes, that's it, thank you. So, having received complete information for 2017 and 2018, both from the wholesalers and from the pharmacy by virtue of the two inspection visits, the reconciliation was carried out for each of the seven medicines listed in this table to identify what, if any, of those medicines was unaccounted for at the pharmacy over that period. This is, if you like, the final results of the analysis for these medicines and is for the period 1st of January 2017 to the date of that first inspection visit on 29th of August 2018. The result was that there were 300 tablets per ten boxes of 30 tablets of Ritalin 10mg unaccounted for and, as we discussed earlier, that did not change. The number of Xanax 1 mg tablets rose to 20,790 tablets, that is 208 boxes approximately of 100 tablets. If you'11 reca11, for 2018 that was 174, so it did increase. However, the majority of the unaccounted for medicines appeared to be unaccounted for in 2018 rather than in 2017. There was approximately 9 boxes, 258 tablets of the medicine Zimovane 7.5 mg tablets which contains Zopiclone, a sleeping tablet, unaccounted for. There were 956 or approximately 239 boxes of Cialis 20 mg , we mentioned that at the end of the first report that based on the United Drug information it was apparent that there were approximately 79 boxes unaccounted for in 2018, however, extending that to 2017 and including the Uniphar data, that
increased to 239 boxes of the Cialis, the erectile dysfunction medicine. There were also four boxes of Efexor XL 150mg, there are 28 capsule boxes unaccounted for, 109 capsules. That is one of the medicines Mr O'Meara stated that he had been taking from the pharmacy without prescription.

Similarly, they were 79 boxes of Efexor 37.5 mg capsules. Those boxes only contained seven capsules each, they are a sma11er pack size, but there were 79 boxes of those unaccounted for. Mr O'Meara stated that he was taking that medicine from the pharmacy also at the first inspection.

Then the final medicine unaccounted for was Tylex capsules, Tylex contains, it is a painkiller, an analgesic containing Paracetamol and Codeine. Codeine is converted in the body to morphine, so it can be subject to abuse and misuse. There were 565 capsules of Tylex unaccounted for at the pharmacy which is approximately six boxes, they come in 100 capsule boxes. So, that was the final tally of medicines which were unaccounted for at wicklow CarePlus pharmacy over the period 1st of January 2017 to the 29th of August 2018, a total of 23,500 units of medicines.

63 Q. How would you characterise that?
A. It's an extremely large number of medicines to be unaccounted for at a pharmacy, particularly medicines each of which has the potential for abuse or misuse with the exception perhaps of the Efexor which Mr O'Meara did state he had been taking from the pharmacy and had been at some point prescribed. It was extremely concerning at the time,
yes.
64 Q. I see. Then just carrying on at paragraph 5.10, what was your findings in relation to that?
A. It's essentially a reiteration of the information regarding the recording of the Ritalin in the Controlled Drugs Register which shows it is the receipt of Ritalin 10 mg tablets on the 14th of June 2018 which has not been entered in the Controlled Drugs Register as is required under the Misuse of Drugs Regulations.
Q. Then at 5.11 you refer to the Duty Register of the pharmacy and that can be found for the Committee at tab 13J, and if that might be just brought up. What did that inform you?
A. Again, this is a reiteration of what was in the first report that Mr O'Meara was the pharmacist on duty on the 14th of June 2018 when those Ritalin tablets were obtained and not recorded in the register. Apologies, there's a bit of repetition in the second report in order to cover --

66 Q. Yes, that's understandable. Then you investigated unlicensed, unauthorised and exempt medicinal products. Could you just explain for the Committee what those are and account for your investigation in relation to those?
A. Yes, so to provide a little bit of background context, when the Gardaí provided information to Ruth McDonne11, they provided her with details of the some of the medicines that they had seized at Mr O'Meara's residence and they included testosterone injections. Testosterone injection -- because of that, that medicine and some similar medicines were included in the review conducted at the first inspection visit, however there was no stock available at the pharmacy and no issues were identified.

On this second inspection visit, it came to my attention that there was stock of testosterone injections at the pharmacy. Accordingly, I requested more detailed information regarding the quantities of those medicines which had been obtained into the pharmacy. So, the testosterone injections in question are Androtardyl and Testovis and they are classified as exempt medicinal products. In genera1, all medicines supplied from a pharmacy must be authorised for sale or supply in Ireland. There is an exemption to allow for a medicinal product that is not licensed here to be obtained by a pharmacy and supplied from a pharmacy, but only on foot of a specific order of a registered medical or dental practitioner for the treatment of a patient under their care to fulfil the special needs of that patient. So, it's very specific. With most medicines a pharmacy can order quantities of medicines required from a wholesaler without any additional requirement, except to place their order. with these medicines, because they are not licensed for sale here, the pharmacist is required to order them on a special order form where they provide some additional information to support the legitimacy of them obtaining those products.

As I said, on the second visit some of these unlicensed testosterone injections were identified at the pharmacy and I, accordingly, requested the pharmacist on duty on the day, which was the supervising pharmacist, Andrea Doyle, to obtain some information from the wholesalers regarding the supplies of these medicines which had been made to the
pharmacy over the period, the 2017 and 2018 period. So, from 1st of January 2017 to the date of, in this case the second inspection, the 22nd of October.

I reviewed a number of medicines based on what had been identified at Mr O'Meara's residence and what was present in the pharmacy on this second date. Similar to the other medicines reviewed, I obtained the same kind of reports from the pharmacy, so reports of the legitimate supply of these medicines through the dispensing system. Liaising with the HPRA, I obtained information from the various suppliers of unlicensed medicines. It includes the main suppliers, Uniphar and United Drug, which were referenced previously, and also includes a supplier called Medisource which specialises in exempt or unlicensed medicinal products, and through the HPRA was able to obtain information from each of those wholesalers regarding exempt medicines supplied to Wicklow CarePlus Pharmacy. Medisource were also able to supply a copy of the order forms that they had received from wicklow CarePlus Pharmacy requesting these supplies of unlicensed medicines.

At the pharmacy when I requested reports of these medicines supplied legitimately through the dispensing system, there were no results to show. So, none of the medicines under review, namely Androtardy1, Testovis, Spiropent, Proviron and Dexamphetamine Sulphate, they hadn't been supp1ied from the pharmacy in the 2017 and 2018 according to the records kept at the pharmacy.

67 Q. I see.
A. When I reviewed the information from the wholesalers I was able to identify, and you'11 see this in the table at paragraph 5.21, that 152 ampules of Androtardy 1 had been ordered into the pharmacy over that period, 2017 to 2018, 200 ampules of Testovis, both of these medicines contain testosterone. 500 tablets, or five packs of Spiropent, and 150 tablets or five packs of Proviron tablets. Each of these medicines, these quantities were received into the pharmacy, but there was no records of supply of them from the pharmacy and they were not present at the pharmacy. 68 Q. Thank you, Ms Nevin. Then at paragraphs 5.22 to 5.26 you explain what these medicines are, if you could just explain to the Committee what they are?
A. Yes. So, the testosterone containing medicines are medicines which can be used by healthcare providers to treat hormonal issues or diseases such as muscle loss. However, testosterone is what is classed as an anabolic steroid. Testosterone, as probably most people will be aware of, can be misused by athletes and bodybuilders in an attempt to boost their performance or improve their physical appearance. As I said, these medicines are unlicensed, so they are not commonly used or prescribed. Testosterone would occasionally be prescribed and used, and I would be familiar with that. I was not at the time of writing familiar with the medicines, Spiropent and Proviron. However, I did some research on them and the Proviron tablets contains a medicine, an active ingredient called Mesterolone which, similar to testosterone, is a steroid or hormonal-type drug and it, like testosterone, is used for its androgenic effects. The medicine, Spiropent,
contains the active ingredient clenbuterol which, on researching it, I was able to obtain information which stated that it is a stimulant and that it is used by performance and image enhancing drug users to aid fat burning and muscle definition.
69 Q. I see, that's very helpful. Just looking at the table then again at 5.21, I see the total units are 1,002 units, how would you characterise that?
A. They are very, very large quantities, particularly, as explained, these medicines are not medicines that you would see every day as a pharmacist working in a pharmacy. I don't have specialist knowledge of the use of illicit use of medicines for the purpose of performance and image enhancing, so I can't really comment on the spiropent and Proviron, they are not -- it's five packs of each, so 500 tablets of Spiropent, but I don't have knowledge of how many of those tablets someone would take if they were using them for that purpose. The testosterone certainly is an extremely high quantity, there are 350 testosterone injections unaccounted for. That's a lot of testosterone, I would imagine, but again I don't have the specialist knowledge to know what the quantities used by some in performance and image enhancing would be.
70 Q. I see. Just moving on to paragraph 5.28, you refer to the orders that were placed. Can you just explain to the Committee what your investigation found in that respect?
A. Yes. So, as I explained, these medicines are not licensed for sale and supply in Ireland. They have to be under an exemption of the legislation to allow them to be sourced and supplied by a pharmacy, but in order to meet this
exemption the suppliers generally require an order form to be filled out. Medisource were able to provide copies of the order forms that they had received for these medicines in 2017 and 2018, and I reviewed these order forms and noted that each of the order forms, of which there were nine in total, five in 2017 and four in 2018, each of them was signed by John O'Meara, either with his signature and included his professional pharmacist registration number, 7210. Each of the forms included a declaration that the medicines were being sourced by or to the order of a registered medical practitioner to fulfil the special needs of a patient under his care and that they would only be used in accordance with that exemption in the legislation.

71 Q. I see. If I could bring you on -- sorry?
A. Yes.

72 Q. Sorry, were you finished, Ms Nevin?
A. Just from that information, the medicines were ordered by mr o'meara and a review of the order forms also show that quantities of 50 Testovis and Androtardy 1 injections at a time were placed, which are large orders for those testosterone containing injections.
73 Q. I am going to move on to the last medicine now which is Sudafed, and you will see that from paragraphs 5.30 of your report. Before I do that, could you just explain to the Committee the nature of sudafed?
A. Yes. So, Sudafed is an over-the-counter medicine. It contains Pseudoephedrine and it is licensed for the treatment of congestion in cough and cold medicines, so it is a decongestant medicine. It can, however, be used as a precursor material in the production of Methamphetamine or
crystal meth, and because of this potential for its diversion for illicit purposes, there are limitations on its sale and supply. The maximum quantity in a pack of Pseudoephedrine tablets is $12,12 \times 60 \mathrm{mg}$ tablets and no more than one pack per transaction can be supplied to a patient without a prescription. So, Pseudoephedrine mirrors some of the effects of Ephedrine, which is a stimulant, which can be used similar to the stimulant medicine we mentioned earlier, Spiropent and Clenbuterol can be used by performance and image enhancing drug users to speed up metabolism and burn fat.

There is also an alternate potential use for Pseudoephedrine in cocaine users who sniff cocaine to counteract the nasal stuffiness that such cocaine use can cause. So, over-the-counter decongestants are sometimes used for that purpose by cocaine users. In the course of -- how this came to our attention, I suppose. In the course of reviewing the information that we obtained from United Drug and Uniphar, the supplies of Sudafed to the pharmacy stood out. There were particularly large supplies of, around about 200 boxes at a time, of Sudafed recorded as having been supplied into the pharmacy which raised concerns in relation to the medicine.

So, at that second investigation visit on the 22nd of October, we reviewed in more detail the sale and supply of Sudafed to identify whether all of those supplies which had been made to the pharmacy were accounted for as sale at the pharmacy.

74 Q. Supplies can be found, just for the Committee, at tab 13P,
and we might just have that put up for the Committee. It should be 13P. I am not sure that's the document. We can move on for the time being, and I can find out where you'd find that document. But just moving on, you --
A. So -- yes. So similar to the other medicines, I obtained information at the pharmacy in relation to the legitimate supplies made from the pharmacy. Now, this is a nonprescription medicine, so we checked dispensing records just to -- for completion, but there were no records of any Sudafed having been supplied on foot of prescriptions. Then I reviewed sales recorded as having been made through the till system. So, the electronic point of sale system, which records each box of medicine scanned through the till when it's being sold to a customer, and obtained the information recorded on that system as to how many boxes of Sudafed had been supplied over the counter from the pharmacy.

So again, reconciling the figures for what came into the pharmacy, the stock present in the pharmacy on the date of the inspection, on 22nd of October, and the records of what had been supplied through the till system or the prescription system, reconciling those figures identified that there were over 34,000 tablets of sudafed 60 mg unaccounted for at the pharmacy, which equates to about 2,900 boxes of sudafed 60 mg tablets. The -Sorry, Mr Beatty, I can't hear you there.

75 Q. Sorry. The Committee will see from tab 13Q the sale of Sudafed from the pharmacy. Is that the document, Ms Nevin? I am going to have to come back to the Committee in
relation to these documents. I am not sure why they're -I will identify, I am not sure I need this witness to go through it, because the documents are agreed, but I wil1 identify where those documents can be found, the ones that I have referred to at tab 13 P and 13 Q , and, in fact, we will have those put up, and put up separately, and we can go through them, if necessary, if the Committee needs to go through them.

So sorry, Ms Nevin, just continuing then in relation to the dispensing software of sudafed, and that's identified at paragraph 5.36. You said there were no records in the pharmacy dispensing software of sudafed 60 mg tablets having been dispensed to a patient from the pharmacy in 2017 or 2018; is that correct?
A. Yes, that's correct. Yes.

76 Q. You engaged then, you say, at paragraph 5.37 , with the HPRA. And what did that tell you?
A. That gave me the information regarding the number of Sudafed tablets supplied into the pharmacy in 2017 and 2018.

77 Q. Thank you. You carried out your analysis, and you refer to that at paragraph 5.38. And what were the findings of those as set out at paragraph 5.39 of your report?
A. So, the result of the analysis was that there were 34,788 Sudafed 60mg tablets unaccounted for at Wicklow CarePlus Pharmacy over the period from 1st of January 2017 to 22nd of October 2018.

78 Q. I see. And how would characterise that volume?
A. It's enormous. It's a huge quantity of sudafed to be
unaccounted for from a pharmacy over a period. I've never encountered that on any other occasion.

79 Q.
Q. I see. Then at paragraph 5.4, you account for the period of -- sorry, you account for the -- so, you reviewed the United Drug and Uniphar supply information for the same period?
A. Yes. So, as we discussed, the HPRA provided the supply information. So, in reviewing it, I think I noted previously some -- some large orders stood out, orders of, you know, circa 200 packs at a time of sudafed. So, those orders, the dates that those orders were placed on were reviewed against the Duty Register at the pharmacy, the record of who was on duty on those dates. It was noted that on -- in 2017 John O'Meara was the pharmacist on duty for four of the five dates in 2017 when a quantity of 200 sudafed 60 mg -- 200 boxes, I should say, of sudafed 60 mg tablets was ordered. And in -- yes.
80 Q. Then you carried out a reconciliation with the Duty Register in 2017 --
A. Sorry, Mr Beatty, I think the order maybe in the report is not ideal. I did this same exercise with both 2017 and 2018. So, if there was a large order of, you know, circa 200 boxes placed in either 2017 or 2018, I checked the date that that order was placed against the Duty Register with the pharmacy, with the result that it was identified that Mr o'meara was on duty on four of the five such dates in 2017. If you go back to paragraph 5.34, he was recorded as being the pharmacist on duty on nine of ten dates in 2018 on which such large quantities were placed. So, on a total of 15 occasions, 13 of those occasions of these large
orders of 200 boxes, Mr O'meara was the pharmacist on duty at the pharmacy.
81 Q. I see. And, Ms Nevin, that has been very, very helpful. I just want to deal with two matters just very, very briefly. The first is, in relation to the sales and the analysis that you carried out in relation to the Sudafed, and I'm sorry to the Committee that there was confusion there, and I make no criticism of the Respondent in this regard, I am simply explaining that -- I think the Core Book was agreed very late, and I think we're just suffering the consequences of that, and I understand why that is the case, it is simply by way of explanation, not by criticism. But I can now tell the Committee that at tab 13T and U , and I might just have those put up on the screen so that you can just go through those for completeness.
Can you just explain what these documents are? And I appreciate that I am taking you slightly out of context here, so --
A. No problem. So, these are reports generated from the electronic point of sale, or the till system at wicklow CarePlus Pharmacy, providing the overall total of Sudafed tablets, packs of 12 , supplied from the pharmacy. There's two pages there. The first one is the report of such sales for 2017, and the second one is the report of such sales for 2018, up until the 22nd of October, which was the date on which the report was generated.
oh, actually, it was until -- it's until the 21st of October. We went with the day before, just to -- not to cause any confusion with the day of the inspection itself.
82 Q. I see. And then the analysis carried out, I think, is at

U , tab U , if we can put that up on the screen.
A. Yes. So, we can see there that United Drug provided information that 8,280 tablets had been supplied to wicklow CarePlus Pharmacy in 2017; Uniphar in 2017, 6,456; United Drug in 2018, 9,912; Uniphar in 2018, 17,112. So, they're a11 the supplies into the pharmacy.

Then what was recorded through the till system as having been supplied from the pharmacy: In 2017, 3,768; in 2018, 2,988 . Those are the figures from those reports we just looked at. And then what was in stock in the pharmacy on 22nd of October was 216 tablets. So, the discrepancy, when you reconcile what came in with what as we recorded as going out through the till system and what is in stock at the pharmacy is 34,788 tablets.
83 Q. Thank you very much. Then just the last thing I want to do with you, Ms Nevin, is the statements, which the Committee will find there are bundles of Amanda Nevin's statements, or bundles is probably a scarier word than it needs to be, but there are two statements that were provided for you. I can just have them put up on the screen. These are the 21st of November 2018 and 31st of August 2018, and you might just confirm that these are your statements?
A. These are my statements, yes.

84 Q. I understand that those are agreed, both as regards their admission and also as regards their content, and Mr Murphy might just confirm that in due course?
MR MURPHY: Yes, I confirm that's the case, Mr Beatty.
85 Q. MR BEATTY: So, thank you very much, Ms Nevin, because that was all very, very detailed, necessary, but detailed. I
have no doubt that Mr Murphy may have questions for you, and, if he doesn't, that the Committee will have. So, thank you.

WITNESS: Thank you, Mr Beatty.
MR MURPHY: Thank you, Ms Nevin. I have no questions for you. Thank you.
CHAIR: Thank you, Mr Murphy. Can I ask the Committee members have they any questions for Ms Nevin?

MR KANE: Yes, chair. Just one question. It does seem that, from the investigation that Ms Nevin carried out, that the Registrant was cooperative in the early stages, and I am just wondering if she would like to speak to that again, in fairness to the Registrant?
MS NEVIN: Yes, no problem. Yes, the only occasion on which I encountered Mr O'meara was that first inspection visit of the 29th of August 2018, when Mr O'Meara was the pharmacist on duty, and he was completely cooperative throughout. I believe that I have stated that unequivocally in my statement, towards the end of my statement for that visit. I -- yes. So, paragraph 30 of my statement dated 31st of August 2018, "Mr Bryan and I thanked Mr O'Meara for his assistance, acknowledged his complete cooperation throughout the day, and departed the pharmacy at approximately 4:00." Mr o'meara did cooperate throughout that visit. MR KANE: Thank you very much. They're all the questions I have.

CHAIR: Ms o'Connell, nothing from yourself? MS O'CONNELL: No.

CHAIR: No. Ms Nevin, al1 that remains is for me to thank
you for your time and your evidence. It's been much appreciated. Thank you very much. Take care. WITNESS: Thank you very much, Chair. Thank you. Good-bye.
CHAIR: I am going to -- that was a lengthy contribution. I am going to guide that we take a break. I think it's not a bad idea at this stage. we' 11 resume at 12 o'clock. Thank you very much, everybody.

## Short break

MS DUNNE: I see Mr murphy joined and the logger is present on the call also. So you're good to go. Thank you, chair. CHAIR: welcome back, everybody, and good afternoon. Mr Beatty, I am assuming you are heading to your next witness?

MR BEATTY: I am. Just a housekeeping matter. And that is that, you will see from the last witness, there were two reports at tabs 12 and 13 , and I specifically went from page 9 of the report at tab 12 , and $I$ think it was page 13 of the report at tab 13, and in those is a number of exhibits referred to, and I think what will be easiest for the Committee is if we were to put a bundle of those exhibits together so at least they're not being -- it would be a net -- it would make it a more net issue, if that was of any help?

CHAIR: That's very good help, and appreciated. Thank you for that.

MR BEATTY: Al1 right. So, that's the first matter. And the second matter, yes, is my next witness. Just before I
cal1 my next witness, I should say that I am quite conscious that I have engaged the committee in what is evidence that is agreed, but still quite detailed, and I think that was necessary, but I am conscious that you've heard a great deal of evidence.

The report of the expert, Mr McCrystal, what it does is it includes, understandab7y, a lot of the narrative that you have heard either from Inspector Ryan or from Ms Nevin. So, I propose, really, just keeping this down to what his comments are. Obviously, the report is available to you, and it is agreed, but I think it would be, in circumstances where you've heard al1 the factual evidence, so to speak, it would be the appropriate way to proceed.

CHAIR: That makes perfect sense. Thank you for that. You're muted, Mr Beatty. MR BEATTY: I call Dr Conor McCrystal.

CHAIR: Good afternoon, Dr McCrystal. Can you see us and hear us?

WITNESS: Yes. Good afternoon, Chair. How are you?
CHAIR: I am wel1, thank you. And yourself, I hope. Dr McCrystal, just before you give evidence, can I ask you, do you want to do so on oath or affirmation?

WITNESS: Affirmation, please, Chair.

DR CONOR MCCRYSTAL (affirmed) - examined by Mr Beatty

86 Q. Thank you, Chair. Dr McCrystal, thank you for attending today. I am just going to go through your report as briefly as I can, because your report is agreed, but simply
to just inform the Committee as to what your opinion is, if that is all right?
A. Certainly.

89 Q. Yes, 1 to G, thank you. And then at the very last sentence of that executive summary, you say that your view that the offences are the more serious end of the professional misconduct, and that is your view, is it?
A. Yeah, that was my view when I reviewed the Book of Evidence. I've obviously been listening in on this, the second day of this Inquiry, so it remains my opinion that it is at the more serious end of professional misconduct.
90 Q. Thank you, Dr McCrystal. Paragraph 1.1, you provide your CV. I don't propose to go into that, because I don't think there is any issue in relation to that. obviously, the Committee may have questions for you in relation to your cv. So, I'm just going to go on to what you say was the
summary of your brief, and we've gone through that, which is the allegations at paragraph 1, and not paragraph 2; isn't that correct?
A. That's correct.

91 Q. Then, in relation to the definition of professional misconduct, you provide the definition as included in the Act; isn't that correct?
A. That's correct, yes, as per the Act 2007.

92 Q. Yes. At paragraph 5, you note that the High court has stated that, before a finding of professional misconduct can be made, the act or omission in question must be considered to be serious; isn't that correct?
A. That's correct.

At paragraph 1.4, you deal with the parties involved, and obviously today is confined to the issue of Mr o'meara. I suppose I would just remind you of that, I know you're aware of that, but I would just remind you of that. Then you account for the appendices, appendix 2,3 and 4 , which relate to the chronology of the events, the relevant documents and the brief that was provided to you. I don't think any issue arises in relation to that. So, I am going to move on, if that's all right?
A. That's fine.

94 Q. At the next part of your report you deal with the allegations and you set them out, but we propose dealing with them one by one. So, I am going to move on from there. And at paragraph 8, you refer to the allegation of professional misconduct, and you identify the three grounds of professional misconduct that are advanced against Mr O'Meara. One is that the conduct is infamous and/or
disgraceful in a professional respect; 2 involves moral turpitude and/or fraud and/or dishonesty of a nature or degree which bears on the carrying on of the professional pharmacist and/or, 3, is a breach of principles, 1, 4 and/or 6 of the code of conduct; isn't that correct?
A. Yes, that's correct. Any one of those will ground a finding of professional misconduct.
95 Q. Yes. You go through Appendix A and Appendix B, which are identical to those contained in the Notice of Inquiry; isn't that right?
A. That's correct.

96 Q. And then, as regards the substance of your report, at page 11 of your report, under paragraph 3.1, you identify allegation 1(a) of the Notice of Inquiry?
A. Correct.

97 Q. And you find that there is professional misconduct, and at paragraph 3.12 you say that your reason is based on the assumption that all factual allegations have been proven, and they have now been admitted. You go on to say that PSI officers carried out an investigation to each of the three CarePlus Pharmacies on the 29th of August 2018. You refer to that, and the Committee have heard about that investigation from Ms Nevin, so I am going to move on to page 12 of your report.

You say, at the second paragraph of that, you say, "It appears that the unaccounted for medicines were primarily sourced through wicklow CarePlus Pharmacy, where John o'meara worked as a pharmacist. Mr o'meara was also the Superintendent Pharmacist of wicklow CarePlus Pharmacy at
this time. The Superintendent Pharmacist is in overall control of the management of the pharmacy, including its professional and clinical management, and management of the administration of the sale and supply of medicines. John o'Meara is the accountable person in this case, and must assume full responsibility for the medications that cannot be accounted for."

And that's your opinion, is it?
A. Yes, that remains my position on that. In relation to this allegation, you identify in the next paragraph that the drugs were listed in table 3, and they are significant drugs of abuse. Can you just give the Committee some understanding of where you are coming from in relation to that?
A. Yes. In my report, I've listed the drugs in Appendix A. I have called it table 3 in my report. I suppose I have given some details on each individual drug and how they can be used and, I suppose, abused. I suppose, the one that catches my eye there would be the 207 boxes of xanax. Now, Xanax is a common benzodiazepine given out and dispensed in community pharmacy. The 1 mg strength would be unusual, you wouldn't see it very often. You'd normally see the lower strengths, 500 micrograms, 250 micrograms, so, you know, this was a huge amount of a medication that wouldn't be dispensed that often that was missing in the pharmacy.

Xanax would be a common drug of abuse on the streets. It would be diverted through different channels, and certainly there would be a demand for it.

I suppose al1 the drugs there, you know, in particular the likes of the anabolic and androgenic steroids, testosterone, Mesterolone and Clenbuterol, also, al1 drugs of abuse on the street, and there were significant quantities of those drugs that were unaccounted for in the pharmacy.

I suppose I should also mention Sudafed. You know, the amount of Sudafed that had gone through the pharmacy, that appears unaccounted for, is, I think I used the word "Staggering" there. A huge amount of medication. It's well flagged up in pharmacy that such medication can be abused, and, therefore, it's tightly controlled. only one box of 12 can be sold in an individual transaction, and yet here we have a case where we have nearly 3,000 packs of this unaccounted for. So, all in a11, there was quite a supply of medication there that was unaccounted for, and medication that would be of interest and would be well known in pharmacy as being drugs that would be in demand on the street.

99 Q. I see. Then you go on at paragraph 3.1.3 to deal with the threshold of seriousness. And what is your view in that respect?
A. I have gone through professional misconduct. Does it meet the standard in the literature? (Indistinct speech) -Medical Council? You know, I clearly believe the threshold of seriousness has been reached in this case. It's clearly a matter concerning conduct, and I believe it's a case of professional misconduct. It's a serious matter.

100 Q. That's at the top of page 14 of your report, and you
identify the three grounds, which I think are all three contained in the Notice of Inquiry in relation to this allegation; is that correct?
A. Yes, that's correct. So, I have identified that Mr O'Meara had engaged in a pattern of behaviour that is infamous or disgraceful in a professional respect. And number B involved moral turpitude and/or fraud and/or dishonesty of a nature or degree which bears on the carrying on of the profession of a pharmacist. And then I've listed breaches of the Code of Conduct, including principle 1, principle 4 and principle 6. I've also listed some of the sub-principles, also.
refer to the keeping of registers for Schedules 1 and 2 of controlled drugs. Can you just go into that in a little bit of detail?
A. So, in a pharmacy, drugs are in Schedule 1 and Schedule 2. Schedule 1 drugs are rarely stopped in pharmacy. Mainly Schedule 2 drugs, these drugs are kept in a controlled drug safe, and when drugs come into the pharmacy and when they're signed out and dispensed to patients, notification is kept in a register, so they're tightly controlled because of the nature of the drugs.
A. That's correct.
Q. You identified the principles of the Code of Conduct that you are relying on, and that are evident to the Committee, and those are your findings; isn't that right?
A. That's correct.

111 Q. Thank you, Dr McCrystal. In relation, then, moving on to allegation 1 (c), your finding is stated at paragraph 3.3.1 of professional misconduct. Again, that's on the assumption that all factual allegations have been proven; is that right?
A. That's correct.

112 Q. You refer to the search by the Gardaí, and again, the Committee have heard great detail of that from both Inspector Ryan's statement and his evidence, and you rely on that?
A. Correct.

113 Q. Then you go on to say, "cocaine is classified as a Schedule 2 controlled drug under the Misuse of Drugs Regulation 2017 SI 173/2017. A pharmacist may have a Schedule 2 controlled drug in his or her possession when carrying on a retail pharmacy business and can possess controlled drugs through certain exemptions as detailed in SI No. 173, and you account for those and identify them as 8.3 and 10.1 , which can be seen at the bottom of page 19 and the top of page 20 ; is that correct?
A. That's correct.

114 Q. You identify then that, "Cocaine is not licensed as a medicine on the Irish market", and you identify the breach of Section 3 and 27 of the Misuse of Drugs Act 1977, as amended?
A. That's correct.
Q. And at the bottom of paragraph 20, you state, "Cocaine is a drug of abuse that is currently freely available in Ireland and has damaged many individuals and families across the state. Pharmacists are encouraged to be role models and provide leadership against the huge backdrop of illegal drugs used in the State. Pharmacists who participate in the use of illegal drugs, such as cocaine, has breached the trust that the public have in the pharmacy profession. It is my personal opinion that such pharmacist is not a fit person to be on the pharmacy register."

When you refer to your personal opinion, can the Committee take that also as your professional opinion?
A. Yes, it's my personal and it's also my professional opinion that such a pharmacist is not fit to be on the Register.

116 Q. I see. And then in relation to the opinion as to professional misconduct, which is referred to at page 21 of your report, you refer to the breach of the Code of Conduct and the -- sorry, you refer to the professional misconduct on the following grounds: (A) that he has engaged in a pattern of behaviour that is infamous or disgraceful in a professional respect, and (B) in breaching the code of pharmacists, and specifically you identify the principles which are readily discernible to the committee; is that correct?
A. That's correct.

117 Q. If I could move on to allegation $1(\mathrm{~d})$, and your finding is at the top of page 22 , and it's a finding of professional misconduct; is that correct?
A. That's correct.

118 Q. Again, that's on the basis that the factual allegations have been proven, and you refer to the fact that the prescription-only medicines listed in Appendix B were all found in Mr O'Meara's private residence at a search by the Gardaí on the 24 August 2018. And again, the Committee have Inspector Ryan's evidence in relation to that. About halfway down that paragraph, you state the following: "The fact of the matter is that many of these drugs are common drugs of abuse on the streets. It would appear from the Book of Evidence that many of these drugs were procured from Wicklow CarePlus Pharmacy by John O'Meara who worked there as a pharmacist. Mr O'Meara was also the superintendent pharmacist at Wicklow CarePlus Pharmacy at the time. The superintendent pharmacist is in overall control of the management of the pharmacy, including its professional and clinical management, and management of the administration, sale and supply of medicines." And you go on in the next sentence, or the one after that, you say, "John O'Meara is the accountable person in this case and must assume full responsibility for the medications that were sourced and supplied to himself in the absence of a prescription."
And is that your position?
A. That remains my position.

119 Q. You refer then to the Pharmacy Business Regulations 2008, both in relation to staff, equipment and procedures, and management and supervision -- sorry -- supervision of a retail pharmacy business. You might just account briefly for those to the Committee, because I think they feature again in your report?
A. Yes. I suppose that particular one, 4.1 (a), it talks about what a pharmacy owner must provide. I suppose the key part is what I've underlined at the end of -- the end of that section, which is, "He or she shall not use, for any such purposes, premises other than those that constitute his or her retail pharmacy business and which have been specified in his or her application for registration under Section 17 of the Act." Basically means, when a pharmacy is registered, the retail pharmacy business is registered on that footprint. So, you know, it's inappropriate to store medicines other than at the retail pharmacy business that has been registered with the PSI.

120 Q. Account for that by way of narrative on the second last paragraph of page 23, you say, "It is not appropriate to store prescription only medicines elsewhere other than at the registered retail pharmacy business, and it is the responsibility of the pharmacy owner and the Superintendent Pharmacist that the sale and supply of medicinal products is carried out in accordance with all legal requirements."
A. That's correct.

121 Q. Is that your opinion on the basis of what you have outlined?
A. Yes.

122 Q. In relation to professional misconduct, the grounds are in relation to all three identified in the Notice of Inquiry; is that correct?
A. That's correct.

123 Q. Then you identify, insofar as it is a breach of the code of Conduct, at page 24 , you identify the Code of Conduct in
question in your opinion; is that correct?
A. That's correct.

124 Q. Then just moving on to allegation 1(e) of the Notice of Inquiry, again at paragraph 3.5.1, which is at page 25 , you find that constitutes professional misconduct?
A. Correct.

125 Q. Again, on the basis that the factual allegations have been proven to the Committee?
A. Correct.

126 Q. You go on to say, "The prescription-only medicine listed in Appendix B were all found in Mr O'Meara's private residence after a search by the Gardaí." And "It is not appropriate to store prescription only medicines elsewhere other than at the registered retail pharmacy business and it is the responsibility of the pharmacy owner and the Superintendent Pharmacist that the sale and supply of medicinal products is carried out in accordance with all legal requirements." And that was your opinion; is that right?
A. Yes, and that remains my opinion.

127 Q. And you have given your opinion in relation to SI 488, both in relation to staff, premises, equipment and procedures, and to management and supervision of a retail pharmacy, and I think the Committee have heard that. But you go on to say then, about halfway through on page 26 , that, "Some of the medicines were controlled drugs, Xanax 1mg, Ritalin 10mg, Dexamfetamine. Some were unlicensed in Ireland Testovis, Pro-viron, Androtardyl and Spiropent, and others were so-called PIEDs, performance and image-enhancing drugs, e.g., Proscar. The fact of the matter is that many of these drugs have a known street value, and it is of
great concern that a11 these medicines were found in the private residence of a registered pharmacist." Could you just expand on that a little?
A. Yes. I suppose I've listed the drugs there, and the issue is that these drugs would be known on the streets, they would be in demand. So, a pharmacist certainly should not keep drugs of that nature anywhere apart from in the retai 1 pharmacy business. You know, those drugs should on7y be ordered in. They should only be supplied on foot of valid prescriptions, and certainly, if no valid prescriptions existed, there's no reason why those drugs should be in the residence of a registered pharmacist.

128 Q. I see. And then, as regards your opinion of professional misconduct, you find on all three grounds identified in the Notice of Inquiry, which can be seen at paragraphs 26 and 27 of your report?
A. Correct.

129 Q. You might just confirm that for the transcript. Yes. Then on the -- as regards the Code of Conduct, you refer to -sorry, you identify the principles, and they can be read by the Committee; is that right?
A. That's correct.

130 Q. Then just in relation to allegation 1(f), and I have brought the Committee -- I am not sure if you were in attendance, I am sure you were -- but I brought to the Committee's attention that 1 (f)(a), as identified by you at page 28 of your report, is not, in fact, an allegation, clearly, that wasn't known to you, so there's no criticism of you in that respect, but it wasn't an allegation, so we're dealing only with allegation $1(f)(b)$; is that
correct?
A. That's correct.
Q. You find that as an instance of professional misconduct?
A. That's correct.
Q.

Again, the assumption is based on all factual allegations having been proven to the Committee?
A. Correct.
Q. Then you go on to say, "It is clear that John O'Meara had a large quantity of the controlled drug methylphenidate 10 mg tablets, which is Ritalin, and Alprazolam 1 mg tablets, Xanax in his possession on 24 August 2018. The quantity stockpiled would appear to be such that it is likely they were for personal use."
Can you just expand on that a little?
A. Yes. I suppose we're talking in particular about the Xanax here, the Alprazolam. So, there were 17 packets, each containing 100 tablets. That's a lot of medication. Now, I know in Mr O'Meara's testimony he talked about some of the quantities of Xanax that he had been taking, but I suppose you have to equate this with the whatsApp messages that you'11 probably come on to now in a minute, where people were obviously looking for Xanax, and Mr O'Meara was supplying it to them. So, there was a lot of xanax on the premises. Were they all for him? Probably unlikely, on -- in viewing this and everything, what we've heard, in terms of everything that we've heard.
134 Q. Yes, then in relation to the Ritalin, you rely on the evidence of Ms Lynch, which is available to the Committee and some of which was read into the record, and the evidence of Ms Andrea Doyle. Again, that is available to
the Committee and portions of which have been read into the record. You go on to deal with the possession of controlled drugs for unlawful sale or supply at page 29, and if you could just account for that in some more detail?
A. That is in relation to the Misuse of Drugs Act 1977. So, under possession of controlled drugs for un1awful sale or supply 15.1, in relation to section 29 of the Act: "It is an offence under subsection 1 of this section where it is proven that a person was in possession of a controlled drug and the court having regard to the quantity of the controlled drug which the person possessed or to such other matter as the court consider relevant is satisfied that it is reasonable to assume that the controlled drug was not intended for the immediate personal use of the person, he shal1 be presumed, until the court it satisfied to the contrary, to be in the possession of a controlled drug for the purpose of selling or otherwise supplying it to another in contravention of regulations under section 5 of the Act."

135 Q. That's very helpful. You deal in relation to this issue then at paragraph 30 and you say: "It is clear from WhatsApp messages provided in evidence by Sergeant Seamus Ryan (now Inspector Seamus Ryan) that Mr O'Meara was involved in the sale and supply of Xanax 1 mg tablets to other persons, fig $2(a)$ to (d) Appendix 3 of this report", and a 11 of these messages have been made available. Then you say, "res ipsa loquitur", what do you mean by res ipsa loquitur?
A. Really that the facts speak for themselves in this case, because the whatsApp messages clearly show the interaction
between Mr O'Meara and third parties.
136 Q. I see. You go on to say that this is a breach section 15 and 27 of the Misuse of Drugs Act which you have identified?
A. Correct.

137 Q. You find professional misconduct only in relation to $1(f)(b)$ which in fact is simply just $1(f)$ now because there is no (a), as we went through, and you do so on the three grounds that are identified in the Notice of Inquiry; is that right?
A. That's correct.

138 Q. In relation to the Code of Conduct, you identified the principles and those are available to the Committee?
A. Correct.

139 Q. Then if I could go on to allegation $1(\mathrm{~g})$ of the Notice of Inquiry, you state that this constitutes professional misconduct; isn't that right?
A. Correct.

140 Q. You rely on the whatsApp messages that have been advanced by Inspector Ryan in that respect; is that correct?
A. That's correct.

141 Q. At the top of page 32 you give an account of the drugs and the nature of the drugs. The first paragraph, if you could just either read that out or account exactly what it is that you are saying to the Committee in respect of this allegation?
A. So, it would appear from the whatsApp that third parties were looking for certain drugs from Mr O'Meara. These would include Xanax, which is a benzodiazepine hypnotic, again a common drug of abuse on the streets known as
purples in this, so it is 1 mg Xanax. Then, Stilnoct which contains the drug zolpidem, which is a controlled drug, also schedule 4, it is a sleeping tablet. Zimovane zopiclone, this is a $Z$ drug, it's a controlled drug as we11, CD 4, that is also a sleeping tablet. Some other drugs were listed, they are prescription-on7y medicines such as Difene, which is nonsteroidal anti-inflammatory drug. Then Cialis/Tadalafil which is a drug for the treatment of erectile dysfunction. I suppose effectively Mr O'Meara was supplying these drugs to third parties, as shown in the whatsApp messages.
142 Q. You characterise that as he was functioning as a dealer of drugs with a known street value in direct contravention of al1 legislation governing the sale and supply of such medicines and pharmacists, is that your professional opinion?
A. It is, because certainly the public see pharmacists in a particular light. This isn't a way that pharmacists should operate a business and, I suppose, if the public were to see pharmacists acting in this regard, it is certainly a poor reflection on how the public would view the pharmacy profession as a whole. It's certainly extremely inappropriate. It's not normal behaviour and it's certainly not behaviour that could be tolerated by someone who says they are a pharmacist, it wouldn't be acceptable behaviour.

143 Q. I see. You go into the trust between the public and the pharmacist, and if you could just expand on that?
A. Yes, it would be fair to say that the public are very trusting of pharmacists and this has been highlighted
especially over the last 18 months in terms of the pandemic. Listen, obviously this happened before that, but the public would not expect to see pharmacists behaving this way. Pharmacists are in a particular position in that they have access to this medication. of course, it is all tightly -- there are regulations in place that control how pharmacists deal with and dispense this medication. The public would not expect to see a pharmacist supplying medication in this way outside the regulations to third parties.
144 Q. Thank you, Dr MCCrystal, you identify SI 540 and you conclude that this constitutes professional misconduct on the three grounds identified in the Notice of Inquiry; is that right?
A. That's correct.

145 Q. You identify the principles of the Code of Conduct that you are relying on and those are available to the committee; is that right?
A. That's correct.

146 Q. There are two further aspects of your report, one under the heading "Overall Conduct" which you can see at page 34, and then the second is your opinion and your conclusions. I am not going to deal with the opinion and conclusions because it simply goes through what you and I have just gone through now. If I could just bring you to page 34 of your report, specifically paragraph 3.3 , which refers to the overall conduct.

You found these, each of these instances, each allegation 1 through to (g) is individually professional misconduct; is
that right?
A. That's correct.

147 Q. At the second last paragraph on page 34 you say: "John O'Meara's overall conduct when all seven allegations are considered together amount to professional misconduct', is that right?
A. Correct.
Q. Then you go on to say: "I am of the view that the offences are at the more serious end of professional misconduct. John O'Meara, through his actions, clearly had no regard for the profession of pharmacy, the Code of Conduct for pharmacists", and you set out what that is?
A. Correct.

Again, you focus on the trust that exists between the public and the profession at the end of the first paragraph at page 35 of the report?
A. Correct.
Q. In the second paragraph of that page 35 you say in the second sentence: "John O'Meara showed no respect for pharmacists and ancillary staff employed" and you refer to Andrea Doyle, who you say got very little support and was ignored when she raised the issues of professional concern. You go on to refer to Ms Claire Lynch, who stopped working in the pharmacy because she didn't want to be involved in what was going on, and the Committee have heard the evidence in that respect insofar as those excerpts of the respective witnesses was read out, and is that your opinion?
A. Yes, that's my opinion. Andrea Doyle was left in a very difficult situation because clearly she had raised her
concerns, which were ignored. Claire Lynch was a relief pharmacist who worked in that group, she was aware what was going on and she chose to stop her employment because she was aware that what was going on was not meeting the standard and it was outside what would normally be expected, it was outside of normal practice.
151 Q. Dr McCrystal, that's very, very helpful. Thank you for your evidence. It may be that Mr Murphy has a few questions for you and it may be that the Committee has questions for you, so thank you.
A. Thank you.

MR MURPHY: I have no questions for you, thank you very much.

CHAIR: Have members of the Committee any questions for Dr McCrystal? No, Dr McCrystal, there are no questions and none from myself. It only remains for me, on behalf of the Committee, to thank you and for your time and for your contribution to the evidence, it is very much appreciated. Thank you.

DR MCCRYSTAL: Thank you very much, Chair.
CHAIR: So, Mr Beatty.
MR BEATTY: The Committee will be glad to hear that that is the end of the Registrar 's case. The Registrar is anxious to make submissions in relation to sanction in this matter. However, I would appreciate just a little bit of time to maybe do that and in fact I may discuss the matter with Mr Murphy as well just to ascertain exactly what his position is. It won't take long, I wouldn't have thought more than half an hour. We can either take a lunch break
at this stage, if it suits the Committee, or we can -- we can take a lunch break now if that suits the Committee and it can be a short lunch break or it can be a long lunch break, that is a matter for the Committee and I can come back and make submissions.

CHAIR: Thanks for that, that makes perfect sense. I think the best solution is to break now and take a break for lunch. From what I can see, it's 12.40. I would suggest that we would come back at a quarter to two, unless somebody has made arrangements whereby they are committed up to 2 o'clock. If not, then I suggest we come back at a quarter to two. Are we good on that? I see nobody put up their hands. So, that's it. we will adjourn for now and reconvene at a quarter to two. Thank you very much.

LUNCHEON ADJOURNMENT

THE HEARING RESUMED AFTER THE LUNCHEON ADJOURNMENT AS FOLLOWS:

MS DUNNE: Good afternoon, Chair. I hope you can hear me. You'11 be able to see we are still waiting on Mr Kane to join the cal1. I'11 just give him a quick call myself to see if he's having any technical difficulties.
CHAIR: Good. Thank you, Catherine.
MS DUNNE: Just a quick update for everyone. I have spoken to Mr Kane and he will be joining the meeting in just a moment.

CHAIR: Is the logger in place?
MS DUNNE: The logger is in place, she is active on the
call, and she can let us know if she has any issues, but yes, everyone is present. As soon as Mr Kane joins the cal1, you are ready to go.

CHAIR: Thanks very much.
MR KANE: My apologies for that, chair. I was caught on a call. My apologies.

CHAIR: These things happen. No problem, Mr Kane. welcome back everybody. we can recommence the Inquiry, and I will go directly to Mr Beatty.
MR BEATTY: Thank you, Chair. Sorry, before I suggested that we go to sanction after lunch, it hadn't been formally stated by Mr Murphy whether he wished to adduce any evidence or whether he wished to make submissions, and I should have afforded him that opportunity, so I am sorry about that, and maybe that is something that should be done.

MR MURPHY: There's no difficulty. I don't propose to go into evidence, Mr Chair.

CHAIR: Thank you, Mr Murphy, for that.
MR MURPHY: In fairness to Mr Beatty, he had actually canvassed that to me. He just hadn't formally said it. CHAIR: Very good.

MR BEATTY: Essentially, I just want to make some brief submissions in relation to the issue of sanction, and I am, I suppose, making a presumption in that respect. I will just explain what that assumption is. If one looks at section 47 of the Act, you will see: "On completion of an inquiry, a Committee of Inquiry shall make a written report to the Council." subsection 2 says: "The report shal1 specify the subject matter of the complaint, the evidence
presented and the Committee's finding.
3. The report may include such additional matters as the committee considers appropriate." I am presuming that the Committee may make recommendations in relation to sanction and for that reason I am making these submissions, and I am obviously in the Committee's hands in that respect.

I would also refer to section 48 and read in sections 48 (1) and 48 (2), I don't propose reading section 48 (3) because it doesn't apply to this situation. Section 48.1 provides: "within 30 days after considering the report", that is the report of section 47, "... the Council shal1 -
(a) if the committee finds that the complaint is not substantiated, dismiss the complaint, or
(b) if the Committee finds that the complaint is substantiated, impose one or more of the following disciplinary sanctions on the registered pharmacist or the pharmacy owner-
(i) an admonishment or censure,
(ii) the attachment of conditions to the registration of the pharmacist or retail pharmacy business, which may include restrictions on practice or, as the case may be, the carrying on of the business,
(iii) the suspension of the registration for a specified period,
(iv) the cancellation of the registration,
(v) a prohibition for a specified period on applying for restoration to the register."

Before I advise the Committee as to what the Registrar's position is, I'11 just read out subsection 2 , which is relevant to the case at hand, and that is: "The Council may not cancel the registration of a pharmacist or retail pharmacy business on the grounds of a conviction for an offence unless, in the Council's opinion, the nature of the offence or the circumstances in which it was committed are such that, where the pharmacist or pharmacy owner applying for registration, the Council would refuse the registration."

So, those are the options available to the Council. If the Committee is going to make recommendations, that is what is available to you.

The Registrar is looking for the cancellation of the registration and a prohibition for a period of seven to ten years on applying for registration -- sorry, for restoration to the register. I suppose I'11 give the Committee the rationale behind that. The Committee will be familiar with the principles that apply to the sanctioning of a registrant where findings have been made against them, and they can be found in the case of Medical Council $v$ Murphy, the President, Finlay $P$, it was an unreported judgment of 29 June 1984. That case identified four principles that the Council should look at, and obviously in that case it was the Medical Council. Of course, the primary objective was to protect the protection of the public. In addition to that, it was to demonstrate the serious view taken of the extent and the nature of the
misconduct so as to deter a practitioner from repeating that conduct once they resumed practice.

The third consideration was to point to the gravity of the offence to other members of the profession, which is one that I had alluded to earlier on in the hearing.

Then there is the obligation to assist the practitioner with as much leniency as possible. Those principles have been endorsed in the case of Herman v Medical Council which is reported [2010] IEHC 414, and in the case of Dowling v An Bord Altranais which is reported at [2017] IEHC. In the case of Dowling v An Bord Altranais, Ni Raifeartaigh J emphasised the issue of mitigation and she stated that that is something that the Committee or the Council, but I suppose the Committee if they are making recommendations, should consider. That stands to reason if there are issues that mitigate the offence. They have been identified, such as remorse, insight and whether it's a once-off incident. obviously those feature in this case so I want to just touch on those because there was, I suppose, on one level there was, one would argue, quite compelling evidence in favour of Mr o'meara in that respect.

Before I go into my submissions as to why that sanction is appropriate, I would, and I have no doubt the Committee know I would just refer them to the guidance on sanctions which they will find -- I can put it up, if you wish, that's probably the easiest thing to do because I am just worried that I am going to get the tab number wrong. Can
that be put up for the Committee? It is tab 38 of the booklet, if it can be put up there, which is helpful.
That deals with the issues that I have addressed and you'11 see at page 5 it deals at paragraph numbers 8(a), (b) and (c): "To protect the public from a risk of harm, to promote the health and safety of the public, to promote and maintain the public confidence in the pharmacy profession in the delivery of pharmacy services and its regulation." I say that's important obviously. "To promote and maintain proper professional standard and conduct for the members of the profession and those who operate pharmacies." I don't propose to do any more than identify at page 6 the issues, proportionality and leniency.

Then at page 7, mitigation and aggravating factors which you can obviously have consideration to.

Then at page 9, the aggravating factors include, and it refers to different factors that apply; 27, 28 and 29, and I suppose I would specifically be relying on, in light of the evidence, paragraphs 31,32 and 33 which is the abuse of a position of trust, the position within the pharmacy and, in this case, not only was Mr O'Meara a pharmacist, but he was indirectly the owner of the pharmacy but also he was the superintendent pharmacy. Then 33 deals with particular aggravating circumstances such as dishonesty, drug or alcohol abuse.

Those are available to the Committee and if one looks at page 12, you' 11 see also the relevance of criminal
convictions and the nature of those convictions. If one looks then at page 17, it gives you some guidance into the cancellation of registration, and you' 11 see at 76 there is: "Where the sanction is imposed, the Registrant's name will be removed from the register and they will no longer be able to work as a pharmacist or operate the pharmacy. Cancellation of registration is a sanction of last resort for serious, deliberate or reckless acts, such as those involving abuse of trust, dishonesty or persistent failures. It should be used where there is no other way to protect the pub1ic..." and that is something that I will be addressing you in relation to.
"...for example, due to a lack of insight or an inability or unwillingness to resolve matters."
"77. Cancellation may be appropriate even where the Registrant does not present a risk to the public but the nature and gravity of the allegations are such that any lesser sanction would lack the deterrent effect or undermine confidence in the profession or in the regulatory process."

Again, I'11 be emphasising that in many submissions.

Then at 78: "Cancellation will be appropriate if a Registrant's behaviour is fundamentally incompatible with being a registered professional."

I will also refer you to paragraphs 79(a), (b), (c), (f),
(h), (i), (j), (k) and (1) which a11, I say, support a cancellation in this instance. why do I say that cancellation in a prohibition is appropriate? I say it's appropriate because if one looks at the allegations, and because of the admissions this can be, I suppose, overlooked -- and I suppose that goes to Mr O'Meara's credit -- but the allegations, as you will see, are really terribly, terribly serious and they go to the fundamentals of what a pharmacist should be doing and, more particularly, should not be doing. So, I would ask you to just look at the nature and the extent of the allegations because I think that is relevant. I say that because I think the primary consideration must be, in this instance, the protection of the public and whether cancellation or prohibition is necessary for that purpose.

In that respect, I would refer you to two bits of evidence yesterday which I think were telling. One was from Inspector Ryan and at page 87 from line 12 , it went through the whatsApp messages and he stated in one of the whatsApp messages: " 10 minutes, I'11 be there." we'11 see the conversations and, "don't tell anybody about this, with my job I would get into serious trouble." Inspector Ryan, I think correctly, stated that that would indicate that Mr o'meara was aware of the ramifications of what he was engaging in. So, he wasn't blind to the fact, he knew exactly what he was doing when he was doing it.

If one looks then at page 98 from line 13 when he was being cross-examined by Mr Murphy, Inspector Ryan, the question
was: "Now, I think you very fairly said at the conclusion of the period of detention you had a conversation with Mr O'Meara and I think he expressed his gratitude and words to the effect that he was in some way grateful that he was caught, isn't that fair to say?" The response was: "A. Yeah, that would be correct", this is the response of Inspector Ryan. "Yeah, that would be correct. I think he felt he knew that the day was coming, when this would happen..." so, these offences, if found to have occurred, and they have been admitted, that was the context and, in my respectful submission, that context cannot be ignored, nor is it in any way diluted or sanitised by his mitigation since that date. The truth is Mr o'Meara knew what he was doing and it was very serious, what he was doing.

I would also ask the Committee to look at the evidence today and if one specifically looks at Ms Nevin's evidence, at tab 13 she refers to her report. She brought to your attention paragraph 5.9, and there's a table in paragraph 5.9 which demonstrates that there were 23,531 units taken from the pharmacy and she stated that that was extremely large. That is the uncontroverted evidence, in fact it's not only uncontroverted, but, again to Mr O'Meara's credit, and Mr Murphy's credit, that evidence has been accepted, it has been admitted and it has not been tested.

Then that features again at paragraph 5.21 of that report. At 5.21 there are additional medications and you will see

1,002 units, and Ms Nevin stated that that was very large quantities and in relation to testosterone it was extremely high.

Then, again, if one looks at paragraph 5.39 which relates to the sudafed, there is a quantity of 34,788 tablets and Ms Nevin states that that was enormous, it was a huge quantity not to be accounted for. The extent of the wrongdoing must be, and I have no doubt it is, but it must be appreciated when recommending the sanction.

Also, when one looks at the expert report, that is Dr McCrystal today in his evidence, there were two portions of his evidence which I would just emphasise. The first is in relation to his report at page 12, and he repeated this today, where in relation to Pseudoephedrine he stated that the amount that was unaccounted for was "staggering". So, not only was this conduct that was being engaged in by Mr O'Meara where the uncontroverted evidence is that he knew what he was doing was wrong and he knew that it would eventually catch up with him, but the extent of the wrongdoing was really quite remarkable. Again, this evidence has not been -- nobody has taken evidence with the description by the expert, Dr McCrystal, at page 32, and he refers to all of the different drugs, and he states, and this is just really, really fundamental to where the Registrar finds himself in relation to just the seriousness of these allegations. He says, "Mr O'Meara was effectively functioning as a dealer of drugs with a known street value in direct contravention of all legislation governing the

[^2]sale and supply of such medicines by pharmacists. This behaviour by a registered pharmacist is wholly
inappropriate and is a breach of trust between the public and a pharmacist." To be honest, my submissions could end there, because no matter what the mitigation is, I don't think there would be anything that would be appropriate other than a sanction and a prohibition for between seven and ten years.

But I do want to deal with the issue of leniency at mitigation, and I want to deal with it because it is real. There is absolutely no doubt on the evidence that Mr o'Meara has, since these allegations were made, cooperated with both the Gardaí and the Pharmaceutical Society. That cooperation must go to his credit, and hopefully it is what it is presented as being, which is an indication that he has turned his life around. That certainly seems to be supported by the evidence of Inspector Ryan and the limited medical evidence that you have, albeit the medical evidence was advanced for the purpose of an adjournment. So, the Registrar does not want to in any way dilute that, and it certainly goes to his credit.

But, unfortunately, the issue here is that that mitigation does not, as I say, dilute or sanitise the need in order to protect the public and to demonstrate the gravity of the offence to other members, but that this should be a cancellation. I suppose, and I don't want to appear harsh on Mr O'Meara, but his improvement since 2018 is only a
limited indicator. It is a three-year period, and I hope, and indeed the Registrar hopes, that it will continue. But for the purpose of the sanction, we say that that three-year period is just simply too short for the purpose of giving any lesser sanction than cancellation and prohibition.

Also, unfortunately, it is not supported by way of professional evidence. So, there's no evidence before you to say that this addiction is no longer existing, and of course I'm not suggesting that it is. I am simply saying that, for the purpose of the sanction, you must obtain comfort that not only has he mitigated and not only has he straightened out his life, but it is something that is likely to continue for a number of years. Because, if you don't have that information, you simply cannot give him the benefit of the mitigation, because it doesn't protect the public and it doesn't highlight his conduct to other members.

When one looks -- at first blush, this seems terribly harsh. However, in this case, it's not, in fact, harsh. Because, again, when Mr Murphy was discussing the matter with Inspector Ryan yesterday, you'11 see from page 100, line 19 of the transcript, and Mr Murphy quite rightly asked the following question, "And at all times in his dealings with you, he certainly indicated he was very well aware that there was a significant chance, if not an almost inevitability, that he would have his registration as a pharmacist removed, he was always aware of that and
realistic about it, isn't that fair to say?" And Inspector Ryan said that it was.

There's no doubt that it is, because -- and that is evident from his petition where he stated that he doesn't wish to practise again. I think it was paragraph 39 of the petition. He stated that he doesn't wish to practise -- I better just -- in fairness to him, I better just get exactly what he said. So, at paragraph 39 of the petition, he states, "He has already made clear he has no intention of ever working as a pharmacist again."

So, whilst it may seem harsh not to give Mr O'Meara the credit of his mitigation and the credit of leniency, in this instance, and one could say to the credit of Mr O'Meara, again, it doesn't, in fact, prejudice him. I certainly know that he is agreeable to cancellation. I'11 let Mr Murphy set out his position, because I just didn't get a position from Mr Murphy before we sat. So, it is the Registrar's submission that that's -- the only sanction is that cancellation, the prohibition. I suppose the reason for that is that it is unlikely, but not impossible, that Mr O'Meara, for whatever reason, if there was no prohibition, if, for whatever reason, decides to have a change of mind and to reapply again, he has the pharmacies, of which he's a shareholder of the holding company, and there is, and I'm not suggesting that there's any evidence, because there isn't, but a relapse is -sorry -- a reapplication without a prohibition is foreseeable in circumstances where he owns businesses. If that transpired, it is not impossible that there would be a relapse, and there's certainly no evidence before you
to suggest that a relapse is not a risk. So, for the purpose of protecting both the pub7ic and the regulatory process, we say that the appropriate sanction is a cancellation and a prohibition.

So, unless -- I'11 just check if there's any other matters which the Registrar wishes me to deal with, but unless the Committee, or -- unless the Committee or Mr Gleeson wishes me to address anything, those are my submissions.

CHAIR: Thank you very much, Mr Beatty. I would go to Mr Farrell to see if he has any submission to make at this point.

MR MURPHY: I'm sorry, do you mean me?
CHAIR: Mr Murphy. I beg your pardon. Yes, absolutely. MR MURPHY: I haven't taken Silk yet, unfortunately. I don't have any formal submissions to make on foot of my instructions, save to point out, very briefly, just a number of facts, I suppose more for the record than anything else.

I'm very conscious of what Mr Beatty says, and he's representing the PSI's position, and I understand that, in respect of addiction and relapse. I would just like to reiterate that whilst, of course, there is always a risk in respect of relapse from somebody who has been an addict, there's no evidence before this Committee that there is any more of a risk with Mr O'Meara than there would be for anybody else who has suffered with addiction. I would just like to place that on the record. In respect of Mr O'Meara's position, Mr O'Meara's position
is that he is very realistic, as I have said all along, in respect of what this Committee may ultimately recommend. I would ask the Committee to accept that he has cooperated fully with the Inquiry. Almost every piece of evidence proffered by the PSI, by the Registrar, has been agreed, and insofar as any witness has been questioned, and I think -- I think, I'm subject to correction, I think the only witness that was questioned was, in fact, Inspector Ryan, and I think that is more for the purposes of clarification and perhaps teasing out various issues, rather than in any way challenging any evidence that is proffered by Mr Beatty on behalf of the Registrar and the PSI.

It has been indicated that there's been almost constant communication between Mr Vallely, my solicitor, and the Registrar in respect of the fact that Mr O'Meara is not resisting, I suppose, the ultimate sanction, and I think that has been set out. I apologise, I can't quite put my hand on the date of that correspondence, but certainly for a period of over a year, if not longer, it has been the position that Mr O'Meara was very realistic in terms of what might ultimately happen, and he indicated that he would not be resisting any such application. That remains the position.

There was full cooperation with the Gardaí, and, in fact, I'm grateful -- I should place this on the record, I am very grateful to Inspector Ryan in respect of his evidence. I think he gave very fair evidence, both in terms of the
gravity of Mr O'Meara's offending, but also the significant mitigating factors that I know that the Committee will take into account.

Finally, Mr Chairman, I think Mr O'Meara wishes me to state for the record that he is very, very well aware that he finds himself in this position today entirely through his own actions. He is a man -- I would ask the Committee to accept, he is a man who, again, through his own actions, has fallen very, very far. He has lost -- or it seems very likely then that he will lose his profession, his career. He wishes to state on the record that he has let himself down, that he has let his family down, and he also wishes to place on the record that he feels that he has let the profession, the pharmacists' profession down, and he wishes to place that on the record.

He is, as the Committee will be aware, he is a second generation pharmacist, and I suppose that makes him even more aware of the high standards, the appropriately high standards to which pharmacists should be held and to which Mr O'Meara, unfortunately, through -- during this period of his professional life, did not reach.

Ultimately, I have nothing else to say, Mr Chairman. Just Mr O'Meara asked me to place those various points on the record. We are not resisting the application that is being made by Mr Beatty.

CHAIR: Thank you very, very much, Mr Murphy. That's appreciated. Mr Beatty, you have nothing to add?

MR BEATTY: No, I don't.
CHAIR: Thank you very much. Before I hand to the Legal Assessor, I will just ask if there are any questions from -- I have none. I just ask the Committee members if they have any further questions at this point. Mr. Kane? MR KANE: It's a question for Mr Beatty. In respect of the prohibition that is suggested for seven to ten years, is that taking fully into account all the mitigation that you yourself have highlighted, and also the matters that Mr Murphy has highlighted?

MR BEATTY: Yes, it has. That is, on the basis of the -as should be clear from the Registrar's submissions, the mitigation -- it is the Registrar's view that the mitigation only goes so far. The real issue that is required is the protection of the public, and the highlight -- sorry, in highlighting the Registrant's conduct to other members of the profession. We say that due to the gravity of the allegation, that even with the mitigation and because of the risks that I say that remain, that, in order to protect the public, the prohibition of seven to ten years is necessary.

CHAIR: Thank you very much, Mr Beatty.
MR KANE: Thank you.
CHAIR: Ms O'Conne11? No? No. Very good. Thank you very much. It just remains for me then to hand across to Mr Gleeson for his advice to the Committee and in the presence of al1 the parties.

MR GLEESON: In the circumstances, I think the appropriate step to take is for the Committee to retire and make its decision on the issues that are before it. Thankfully, as

I understand it, all of the allegations in the Notice of Inquiry have been admitted, and I take it that -- I haven't seen the current Notice of Inquiry, but I take it it has been amended so that $1(f)$ appears alone, and we don't have 1 ( $f$ (a) and 1( $f$ )(b) as before? MR BEATTY: That's correct.

MR GLEESON: Thank you, Mr Beatty. Mr Murphy, am I also correct in understanding that, in respect of each individual allegation which is admitted, it is also admitted that they constitute professional misconduct? MR MURPHY: That is the case, Mr Gleeson. MR GLEESON: Yes. Thank you. We11, in those circumstances, it really seems to me that it's a matter for the Committee to retire and start the preparation of its report. I have to say, the way the case was presented in both sides has been refreshingly clear and even in a very difficult case it's lovely to see such cordial relationships between respective legal teams.

CHAIR: Thank you very much, Mr Gleeson. what I am going to do just at this -- at this moment -- sorry, there's a talk-back in my ear.
MR BEATTY: Sorry, Chair. I don't mean to interrupt you, Chair. I should just formally say that I agree with those advices, just for the record, and thank Mr Gleeson for his comments.

MR MURPHY: Yes. Just for the record, I agree as we11, and, equally, I thank Mr Gleeson.

CHAIR: Thank you both very much, and thank you, mr Gleeson. what I am just going to do is ask the Committee members and the Legal Assessor to meet me in the
private hearing room for five minutes, for clarification of a particular issue, and we will be back to you. So, no more than that. we will be back in a few moments. Thank you.

## Short break

CHAIR: Catherine, as usual, I'11 rely on your advice as to when we are in a position to resume.
MS DUNNE: Yes. Good afternoon, chair. I think we are just waiting on Mr Beatty to return -- oh, he has just actually joined the call there, and the logger is on the cal1 and active, so you are good to go. Thanks very much. CHAIR: Thanks very much. Thanks, Catherine. Thank you all for your patience, and apologies for any delay beyond the time I had suggested.

The Committee have no further questions or clarifications at this point. So, as I had outlined at the beginning of this Inquiry, the Committee will, in due course, prepare a report for counsel which will set out its findings and any other matters that they consider important within the specifics of this Inquiry.

At this point, all that remains for me is to thank everybody who has contributed, who has given evidence. Thank you all for your very strong and, as was pointed out, very much appreciated contributions and representations. I now formally close this Inquiry.
Thank you again.

> D. O'Ma1ley Stenography Ltd.

MR MURPHY: Thank you, Mr Chairman.
MR BEATTY: Thank you, Mr Chairman.

THE HEARING CONCLUDED

6
7

Certified to be a complete and correct transcript of the record of the proceedings herein:
D. O'Malley Stenography Ltd.

| ' | 13P [3] - 39:30, 40:2, 41:5 |
| :---: | :---: |
|  | 13Q [2] - 40:28, 41:5 |
| 'AN' [1] - 15:5 | 13T [1] - 43:13 |
|  | 13th [1] - 27:2 |
| 1 | 14 [3] - 19:14, 19:23, 52:30 |
| 1 [22] - 7:22, 11:11, 12:4, | 14th [8] - 22:6, 22:13, |
| 21:4, 27:14, 48:12, | 23:9, 23:18, 23:24, 27:5, |
| 48:13, 48:16, 48:18, | 33:7, 33:15 |
| 49:2, 50:4, 53:10, 54:1, | 15 [3] - 9:15, 42:30, 63:2 |
| 54:4, 54:5, 54:26, 55:7, | 15.1 [1]-62:7 |
| 61:10, 62:8, 65:29, 85:5 | 150 [1] - 36:7 |
| 1(a [1] - 50:14 | 150mg [1] - $32: 3$ |
| 1(b [1] - 53:17 | 152 [1] - 36:3 |
| 1(d) 1 ]-56:27 | 16[1] - 53:30 |
| 1(e [1] - 59:3 | 16.14 [1] - 16:27 |
| 1(f[3] - 60:23, 63:7, 85:4 | 16th [1] - 23:24 |
| 1(f)(a [1] - 60:26 | 17 [4]-54:14, 58:8, 61:16, |
| $\mathbf{1}(\mathbf{f})(\mathbf{b}[3]-60: 30,63: 7,$ | 74:2 |
| 85:5 | 17,000[1]-18:23 |
| 1(g [1] - 63:15 | 17,112 [1] - 44:5 |
| 1,002 [2] - 37:7, 77:1 | 17,800 [1] - 18:4 |
| 1.1 [1] - 48:26 | 173 [2]-54:11, 55:23 |
| 1.4 [1] - 49:14 | 173/2017 [1] - 55:19 |
| 1/1/2018 [1] - 12:26 | 174 [4] - 12:4, 18:18, |
| 10 [6] - 19:27, 20:2, 22:6, | 18:22, 31:20 |
| 22:12, 23:10, 75:21 | 178 [3] - 18:4, 18:5, 18:15 |
| 10.1 [1]-55:24 | 18 [3] - 13:23, 54:27, 65:1 |
| $100[7]-12: 5,18: 5,18: 22$, | 18mg [1] - 14:1 |
| 31:19, 32:19, 61:17, | $19[2]-55: 24,79: 25$ |
| 79:24 | 19.1 [1]-54:12 |
| 109 [1] - 32:4 | 1977 [2]-55:29, 62:5 |
| 10mg [22]-16:6, 16:7, | 1984 [1] - 71:25 |
| 18:25, 19:11, 19:19, | $\begin{gathered} \text { 1mg [14] - 16:6, 17:13 } \\ 18: 5,18: 19,18: 23 \end{gathered}$ |
| $22: 11,22: 17,23: 4$ | $20: 17,20: 20,29: 27$ |
| 23:10, 24:19, 24:22, | 31:18, 51:21, 59:25, |
| 24:30, 26:5, 27:15, | 62:24, 64:1 |
| 31:17, 33:6, 59:26, 61:9 | 1st [17]-11:17, 12:7, |
| 11 [1]-50:13 | 12:21, 16:11, 16:22, |
| 11,100 [1] - 18:1 | 18:6, 19:13, 19:24, 29:1, |
| 110[1]-27:28 | 29:3, 29:7, 29:18, 30:16, |
| 111 [1]-18:10 | 31:14, 32:22, 35:2, |
| 11th [1]-23:23 | 41:27 |
| $\begin{gathered} 12[12]-9: 5,39: 4,43: 22, \\ 46: 7,46: 19,46: 20, \end{gathered}$ | 2 |
| $\begin{aligned} & 50: 24,52: 14,73: 30, \\ & 75: 19,77: 15 \end{aligned}$ | $\begin{gathered} \mathbf{2}[17]-7: 24,7: 27,7: 29, \\ 13: 25,48: 15,49: 2, \end{gathered}$ |
| 12.40 [1] - 68:8 | $49: 18,50: 1,54: 1,54: 4$ |
| 120[1]-27:28 | $54: 6,54: 16,55: 18$ |
| 12B [1] - 12:13 | 55:20, 68:11, 69:29, |
| 12C [1] - 13:4 | 71:2 |
| 12E [1] - 20:8 | 2(a [1] - 62:25 |
| 12F [1] - 25:23 | $2,900[1]-40: 26$ |
| 12G [2]-22:16, 22:20 | 2,988 [1] - 44:10 |
| 121 [1] - 23:20 | 20 [6] - 25:10, 27:25, 28:3, |
| 12th [1]-26:21 | 28:5, 55:25, 56:2 |
| 13 [12]-1:15, 3:1, 22:25, | 20,790 [1] - 31:18 |
| 28:28, 29:15, 29:16, | 200 [7]-36:5, 39:22, |
| 42:30, 46:19, 46:20, | 42:10, 42:15, 42:16, |
| 46:21, 75:29, 76:19 | 42:23, 43:1 |
| 132 [1]-28:2 | 2007 [4]-4:28, 5:14, 5:25, |
| 13F [1] - 29:20 | 49:8 |
| 13J [1] - 33:11 | 2008 [1] - 57:25 |

$2010[1]-72: 11$
$2013{ }_{[1]}-26: 11$
2014[1]-4:29
2017 [41]-26:18, 29:6,
29:7, 29:18, 29:19,
29:28, 30:1, 30:9, 30:11, 30:16, 30:20, 30:24,
30:25, 30:26, 31:7,
31:14, 31:23, 31:30, 32:22, 35:1, 35:2, 35:28, 36:4, 38:4, 38:6, 41:15, 41:20, 41:27, 42:14, 42:15, 42:19, 42:21, 42:23, 42:27, 43:24,
44:4, 44:9, 54:11, 55:19, 72:12
2018[64]-5:3, 5:18, 8:19, 9:28, 11:12, 12:6, 12:21, 16:10, 16:22, 18:7, 20:4, 22:6, 22:13, 23:9, 23:15, 23:19, 23:23, 25:2, 26:18, 26:19, 26:29, 27:13, 27:27, 28:7, 28:23, 29:3, 29:29, 30:10, 30:20, 30:23, 31:7, 31:15, 31:20, 31:22, 31:29, 32:23, 33:7, 33:15, 35:1, 35:28, 36:4, 38:4, 38:6, 41:15, 41:21, 41:28, 42:22, 42:23, 42:28, 43:25, 44:5, 44:9, 44:22, 45:16, 45:21, 50:21, 53:28, 57:5, 61:11, 78:30
2021[2]-1:15, 3:1
207 [1]-51:19
208[1]-31:19
20mg [2] - 28:7, 31:26
21 [1] - 56:17
216 [1] - 44:12
21st [3]-27:2, 43:27,
44:22
22 [2] - 19:15, 56:28
22nd [9]-8:22, 28:23,
29:9, 35:3, 39:25, 40:21,
41:27, 43:25, 44:12
23 [1] - 58:15
23,500 [1] - 32:23
23,531 [1] - 76:21
$239[2]-31: 26,32: 1$
24 [4] - 8:4, 57:5, 58:30, 61:11
25 [1] - 59:4
250 [2] - 17:12, 51:23
258[1]-31:23
$26[2]-59: 24,60: 15$
27 [5] - 13:23, 55:29,
60:16, 63:3, 73:19
$279{ }_{[1]}-18: 11$
$28[3]-32: 3,60: 27,73: 19$
28th [2] - 26:21, 26:23
29 [6] - 11:12, 20:4, 62:3, 62:7, 71:25, 73:19
29/8/2018 [1]-12:26

29th [25]-5:18, 8:19, 10:4,
10:5, 11:14, 11:17, 12:8, 12:21, 15:16, 16:12, 16:22, 17:29, 18:6, 20:13, 21:16, 25:2, 27:16, 28:6, 29:8, 30:16, 31:15, 32:22, 45:16, 50:21, 53:27
2nd [2]-20:21, 20:23
$\frac{3}{3}$

3[9]-2:6, 48:7, 49:18,
50:4, 51:11, 51:16,
55:29, 62:25, 70:2
3,000 [1] - 52:15
3,768 [1] - 44:9
3.1 [1] - 50:13
3.1.3 ${ }_{[1]}-52: 21$
3.12 [1]-50:17
3.2.1 [1] - 53:18
3.3 [1]-65:26
3.3.1 [1]-55:7
3.5.1 [1] - 59:4

30 [4]-31:16, 45:20,
62:21, 70:11
30-tablet [1] - 19:12
$300[1]$ - $31: 16$
31 [1] - 73:21
$316[1]-28: 5$
31st [4]-29:18, 44:22,
45:21, 53:28
32[3]-63:22, 73:21, 77:24
33[2]-73:21, 73:25
$34[3]-65: 21,65: 25,66: 3$
34,000 ${ }_{[1]}-40: 24$
34,788[3] - 41:25, 44:15, 77:6
35 [2] - 66:16, 66:18
$350[1]-37: 19$
37.5mg [1] - 32:8

38 [1] - 73:1
39[2]-80:5, 80:8
3rd [2] - 9:28, 27:19
$\frac{\mathbf{4}}{4_{[6]-13 \cdot 25 \cdot 49 \cdot 18,50: 4}}$

4 [6] - 13:25, 49:18, 50:4, 53:10, 64:3, 64:5
4.1 [1] - 58:1

414 [1] - 72:11
468 [1]-27:25
$468.2018{ }_{[1]}-1: 11$
47 [3] - 2:8, 69:27, 70:12
$48[1]-70: 8$
48(1 [1] - 70:8
48(2 [1] - 70:9
48(3 [1] - 70:9
48.1 [1] - 70:10

488 [1] - 59:20
4:00 [1] - 45:24
4th $[1]-26: 21$

5
5 [4]-29:20, 49:9, 62:19, 73:4
$5.10[1]-33: 2$
5.11 [1]-33:10
$5.19{ }_{[1]}-30: 27$
5.21 [4]-36:3, 37:7, 76:29, 76:30
5.22 [1] - 36:11
$5.26[1]-36: 11$
$5.28[1]-37: 24$
$5.30[1]-38: 23$
5.34 [1]-42:27
$5.36{ }_{[1]}-41: 12$
5.37 [1] - 41:17
5.38 [1]-41:23
5.39 [2] - 41:24, 77:5
5.4 [4] - 30:20, 30:21, 30:22, 42:3
5.6 [1]-29:17
5.7 [1] - 30:3
5.9 [5] - 31:1, 31:4, 31:5, 76:20, 76:21
$50[1]$ - 38:19
$500[4]-17: 12,36: 6$,
37:16, 51:23
540 [1] - 65:11
$565[1]-32: 18$
5th [1]-26:24

## 6

$6[3]-50: 5,53: 11,73: 12$
6,456[1]-44:4
6,700[1]-18:2
6.1 [1] - 9:30
$6.10[1]$ - 16:25
6.11 [1] - 21:8
6.12[3]-16:26, 21:8, 24:12
$6.14[2]-21: 10,21: 13$
$6.16[1]-23: 2$
$6.18{ }_{[1]}$ - 16:28
6.3 [2] - 11:9, 12:9
6.4 [1] - 11:9
$6.6[2]-16: 15,16: 18$
6.7 [5] - 16:24, 17:5, 17:7, 17:22
60 [1] - 41:13
60 mg [6] - 39:4, 40:24, 40:26, 41:26, 42:16
67 [3] - 5:13, 5:24, 10:7
$69[1]-2: 9$

## 7

7 [2] - 5:1, 73:15
7.00 [1] - 23:26
7.5 [2]-24:22, 24:30
7.5mg [2] - 16:7, 31:24

7210[2]-1:10, 38:9
$76[1]-74: 3$
77 [1] - 74:17

78 [1] - 74:26
79 [6] - 25:9, 25:10, 28:7,
31:29, 32:8, 32:10
79(a [1] - 74:30

| $\mathbf{8}$ |
| :--- |
| $8[1]-49: 27$ |
| $8\left(\mathbf{a}_{[1]}-73: 4\right.$ |
| $8,280[1]-44: 3$ |
| $8.3[1]-55: 24$ |
| $87[1]-75: 19$ |
| $\mathbf{9}$ |
| $9[5]-10: 1,13: 28,31: 23$, |
| $46: 20,73: 18$ |
| $9,912[1]-44: 5$ |
| $9.00[1]-23: 26$ |
| $90-p a g e[1]-22: 28$ |
| $956[1]-31: 26$ |
| $98[1]-75: 29$ |

## A

able [16] - 12:1, 12:3,
15:12, 19:11, 19:17,
21:24, 21:26, 22:5,
25:19, 35:16, 35:19,
36:2, 37:2, 38:2, 68:22, 74:6
absence [2] - 25:7, 57:22
absolutely [2] - 78:12, 81:14
abuse [14]-7:18, 18:29, 24:25, 32:17, 32:27, 51:12, 51:28, 52:4, 56:3, 57:9, 63:30, 73:21, 73:27, 74:9
abused [2] - 51:18, 52:13
accept [2]-82:3, 83:9
acceptable [1] - 64:25
accepted [1] - 76:26
access [5] - 9:3, 9:10, 9:16, 15:25, 65:5
accordance [3]-38:13, 58:20, 59:17
according [1] - 35:28
accordingly [5] - 5:17, 24:4, 27:18, 34:4, 34:27 account [18] - 7:8, 8:5, 8:6, 18:21, 21:14, 24:13, 33:21, 42:3, 42:4, 49:18, 55:23, 57:28, 58:14, 62:4, 63:22, 63:24, 83:3, 84:8
accountable [2]-51:5, 57:19
accounted [10] - 18:19, 20:6, 21:5, 21:6, 22:2, 39:28, 51:7, 53:14, 77:8
accurate [2]-7:2, 19:8
acknowledged [1] - 45:22
Act [13] - 5:1, 5:14, 5:25, 10:8, 49:7, 49:8, 55:29,

58:8, 62:5, 62:7, 62:19,
63:3, 69:27
act [1] - 49:11
acting [1] - 64:20
actions [3]-66:10, 83:8, 83:9
active [6] - 17:8, 36:27, 37:1, 68:30, 86:13
activity [1] $-5: 19$
acts [1] - 74:8
actual $[3]-6: 19,13: 13$, 15:1
add [1] - 83:30
added [1] - 15:4
addict [1] - 81:25
addiction [3]-79:10,
81:23, 81:28
addition [1] - 71:29
additional [9]-25:19,
27:23, 28:19, 28:22,
30:25, 34:18, 34:22,
70:2, 76:30
address [2]-26:6, 81:9
addressed [1] - 73:3
addressing [2] - 9:7, 74:12
adduce [1]-69:12
adjourn [1] - 68:13
adjournment [1] - 78:21
ADJOURNMENT [2] -
68:16, 68:18
administration [3]-6:10,
51:4, 57:17
admission [1] - 44:26
admissions [1] - 75:5
admitted [6] - 50:19,
76:10, 76:26, 85:2, 85:9,
85:10
admonishment [1] - 70:20
advance [3] - 13:9, 14:29, 29:24
advanced [3] - 49:29,
63:19, 78:20
advice [2]-84:26, 86:8
advices [1]-85:24
advise [1] - 71:1
affirmation [4]-3:15,
3:16, 47:23, 47:24
affirmed [2] - 3:18, 47:26
afforded [1] - 69:14
AFTER ${ }_{[1]}$ - 68:18
afternoon [5]-46:14, 47:18, 47:20, 68:21, 86:10
aggravating [3] - 73:15, 73:18, 73:26
agree [2]-85:23, 85:26
agreeable [1] - 80:15
agreed $[7]$ - 41:3, 43:9,
44:25, 47:3, 47:12,
47:30, 82:5
ahead [1] - 8:27
aid [1] - 37:4
albeit [1] - 78:20
alcohol [1] - 73:27
allegation [19] - 48:9,
49:27, 50:14, 51:10,
53:3, 53:17, 54:26, 55:7,
56:27, 59:3, 60:23,
60:27, 60:29, 60:30,
63:15, 63:26, 65:29,
84:18, 85:9
allegations [21] - 48:9,
48:12, 48:13, 48:15,
48:16, 49:2, 49:25,
50:18, 53:22, 55:9, 57:1,
59:7, 61:5, 66:4, 74:19,
75:4, 75:7, 75:11, 77:28,
78:13, 85:1
allow [2] - 34:11, 37:29
allowed [2] - 30:13
alluded [1] - 72:6
almost [3]-79:28, 82:4, 82:15
alone [1] - 85:4
alphabetical [1] - 12:16
Alprazolam [3] - 17:9,
61:10, 61:16
alternate [1] - 39:13
Altranais [2]-72:12, 72:13
Amanda [2]-25:27, 44:18
AMANDA [1] - 3:18
amended [2] - 55:30, 85:4
amount [8]-8:6, 17:3,
26:8, 51:24, 52:9, 52:11, 66:5, 77:17
amounts [1]-16:13
ampules [2]-36:3, 36:5
anabolic [2] - 36:17, 52:2
analgesic [1] - 32:15
Analysis [5] - 7:7, 12:10,
12:15, 18:7, 27:30
analysis [8] - 25:8, 30:18,
30:22, 31:13, 41:22,
41:25, 43:5, 43:30
ancillary [1] - 66:20
Andrea [5] - 6:15, 34:28,
61:30, 66:21, 66:29
Andrew [1]-1:26
androgenic [2]-36:30,
52:2
Androtardyl [5] - 34:7, 35:26, 36:3, 38:19, 59:27
anti [1]-64:7
anti-inflammatory [1] 64:7
anxiety [1] - 17:10
anxious [1] - 67:24
apart [1]-60:7
apologies [4]-33:16,
69:5, 69:6, 86:15
apologise [1] - 82:19
apparent [1] - 31:28
appear [5] - 21:19, 57:9,

61:12, 63:27, 78:29
appearance [1] - 36:21
appeared [2] - 30:2, 31:22
appendices [1] - 49:18
Appendix [6] - 50:8,
51:15, 57:3, 59:11, 62:25
appendix [2] - 22:25, 49:18
application [3] - 58:7,
82:24, 83:27
apply [3] - 70:10, 71:21, 73:19
applying [3] - 70:28, 71:9, 71:18
appreciate [3]-3:29, 43:17, 67:26
appreciated [6]-46:2,
46:27, 67:19, 77:10,
83:30, 86:28
appropriate [12] - 47:14,
58:15, 59:12, 70:3,
72:26, 74:17, 74:26,
75:3, 75:4, 78:6, 81:3,
84:28
appropriately [1] - 83:20
argue [1]-72:22
arises [2] - 21:9, 49:21
arising [1] - 25:20
arose [2]-24:29, 27:23
arrangements [1] - 68:10
arrived [1] - 10:14
Article [1] - 54:11
AS [2]-3:1, 68:18
ascertain [1] - 67:28
aspects [1] - 65:20
Assessor [3] - 1:21, 84:3, 85:30
assigned [1] - 5:14
assist [2] - 14:30, 72:8
assistance [4] - 15:7,
15:10, 15:30, 45:22
assistant [1] - 23:27
assisted [2] - 11:27, 30:7
assists [2] - 9:22
assume [3]-51:6, 57:20, 62:13
assuming [1] - 46:15
assumption [5] - 50:18,
53:21, 55:9, 61:5, 69:26
athletes [1] - 36:19
attachment [1] - 70:21
attempt [1] - 36:20
attempting ${ }_{[1]}-4: 11$
attendance [1] - 60:25
attending [1] - 47:28
attention [4]-34:2, 39:18,
60:26, 76:20
audio [1] - 14:20
August [36] - 5:3, 5:18,
8:19, 10:4, 10:5, 11:12,
11:14, 11:17, 12:8,
12:21, 15:16, 16:12,

16:22, 17:29, 18:7, 20:4
20:13, 20:22, 20:23,
21:17, 25:2, 27:16,
27:27, 28:7, 29:8, 30:17,
31:15, 32:22, 44:22,
45:16, 45:21, 50:21,
53:27, 53:28, 57:5,
61:11
authored [1] - 28:26
authorised $[7]-4: 29$,
4:30, 5:25, 9:6, 10:6,
30:18, 34:10
authority [3]-5:13, 5:24, 10:7
Authority [1] - 15:22
available [15]-7:22, 7:29,
17:11, 17:12, 33:29,
47:11, 56:3, 61:28,
61:30, 62:26, 63:13,
65:17, 71:12, 71:14,
73:29
awaiting [1] - 25:16
aware [12]-10:26, 17:21,
36:19, 49:17, 67:2, 67:4,
75:25, 79:28, 79:30,
83:6, 83:18, 83:20

## B

backdrop [1] - 56:6
background [1] - 33:22
bad [1] - 46:7
balance [3]-18:18, 26:10
Barbara [1] - 1:20
based [5] - 31:27, 35:5,
50:17, 53:21, 61:5
basis [8]-5:11, 5:22,
8:30, 57:1, 58:22, 59:7,
84:11
bears [2]-50:3, 53:8
Beatty [31] - 1:23, 2:6, 2:8,
2:9, 3:4, 3:18, 3:21,
4:14, 9:9, 9:21, 14:22,
17:21, 40:27, 42:20,
44:28, 45:4, 46:15,
47:16, 47:26, 67:22,
69:9, 69:20, 81:10,
81:21, 82:12, 83:28,
83:30, 84:6, 84:22, 85:7,
86:11
BEATTY ${ }_{[17]}-3: 6,4: 17$,
4:25, 9:25, 17:25, 44:29,
46:17, 46:29, 47:17,
67:23, 69:10, 69:23,
84:1, 84:11, 85:6, 85:22,
87:2
BEFORE ${ }_{[1]}-1: 4$
beg [1]-81:14
began [1]-10:17
beginning [2]-48:5, 86:19
behalf [4]-4:18, 4:21,
67:17, 82:12
behaving [1] - 65:3
behaviour [7] - 53:5,
56:21, 64:23, 64:24,
64:26, 74:27, 78:2
behind [1] - 71:20
benefit [1] - 79:17
benzodiazepine [4]-17:9, 24:24, 51:20, 63:29
benzodiazepine-like [1] 24:24
beside [1] - 13:22
best [1] - 68:7
better [2] - 80:7
between [7]-63:1, 64:27, 66:14, 78:3, 78:7, 82:16, 85:18
beyond [1]-86:15
bit [5] - 13:29, 33:16,
33:22, 54:3, 67:26
bits [1] - 75:17
blank [1]-3:25
blind [1] - 75:26
blush [1] - 79:21
body [1] - 32:16
bodybuilders [1] - 36:19
Book [6] - 9:3, 9:10, 22:26,
43:9, 48:22, 57:10
book [1] - 29:20
booklet [1]-73:2
boost [1] - 36:20
Bord [2] - 72:12, 72:13
bottom [3] - 53:30, 55:24, 56:2
box [4]-18:11, 18:16, 40:13, 52:14
boxes [39] - 12:4, 12:6, 15:3, 15:4, 18:4, 18:5, 18:13, 18:15, 18:17, 18:18, 18:22, 20:19, 20:22, 22:6, 22:12, 25:10, 28:7, 28:8, 31:16, 31:19, 31:23, 31:26, 31:29, 32:1, 32:2, 32:3, 32:8, 32:9, 32:10, 32:19, 32:20, 39:22, 40:15, 40:26, 42:16, 42:23, 43:1, 51:19
breach [7]-50:4, 54:27, 55:28, 56:18, 58:29, 63:2, 78:3
breached [2] - 54:15, 56:8
breaches [1] - 53:9
breaching [1] - 56:22
break [9]-46:6, 46:10, 67:30, 68:2, 68:3, 68:4, 68:7, 86:6
brief [3] - 49:1, 49:20, 69:23
briefly [4] - 43:4, 47:30, 57:28, 81:17
bring [15]-8:29, 9:14, 9:30, 12:9, 14:26, 16:17, 21:16, 22:15, 25:29, 27:8, 28:24, 29:14, 30:29, 38:14, 65:25
brings [1] - 28:12
brought [5] - 20:8, 33:12, 60:24, 60:25, 76:19
Bryan [2] - 10:5, 45:21
bundle [1] - 46:23
bundles [2]-44:18, 44:19
Bundles [1] - 9:4
burn [1] - 39:11
burning [1] - 37:5
business [12] - 55:21, 57:28, 58:6, 58:10, 58:12, 58:17, 59:14, 60:8, 64:19, 70:22, 70:24, 71:5
Business [1] - 57:25
businesses [1] - 80:28
bye [1] - 46:4
C
camera $[4]-3: 22,3: 28$,
camera [4]-3:22, 3:28,
4:9, 4:11
cancel [1]-71:4
Cancellation [1] - 74:7
cancellation [13]-70:27,
71:16, 74:3, 74:17,
74:26, 75:2, 75:3, 75:14,
78:29, 79:5, 80:15, 80:19, 81:4
cannot [3] - 51:6, 76:12, 79:16
canvassed [1] - 69:21
capsule [2] - 32:3, 32:20
capsules [5] - 32:4, 32:8,
32:9, 32:14, 32:18
care [3]-34:15, 38:12, 46:2
career [1]-83:11
CarePlus [22]-5:17, 6:14, 10:7, 12:20, 16:10, 20:21, 20:22, 27:13, 27:26, 28:6, 30:9, 32:21, 35:18, 35:20, 41:26, 43:21, 44:4, 50:21, 50:28, 50:30, 57:11, 57:13
carried [20] - 8:18, 8:20,
8:21, 8:22, 11:9, 14:16, 21:12, 21:17, 24:10, 24:27, 30:27, 31:9, 41:22, 42:18, 43:6, 43:30, 45:10, 50:20, 58:20, 59:17
carrying [5] - 33:2, 50:3, 53:8, 55:21, 70:24
case [25]-19:2, 35:2, 43:12, 44:28, 51:5, 52:15, 52:27, 52:28, 57:20, 62:29, 67:24, 70:23, 71:3, 71:23, 71:25, 71:27, 72:10, 72:11, 72:13, 72:20, 73:23, 79:22, 85:11, 85:15, 85:17

CASE [1]-1:11
catch [1] - 77:21
catches [1]-51:19
categorises [1]-7:19
Catherine [3]-68:25,
86:8, 86:14
caught [2] - 69:5, 76:5
cautioned [1] - 10:19
CD [5] - 19:30, 20:1,
22:17, 23:11, 64:5
censure [1] - 70:20
central [1]-18:27
certain [2] - 55:22, 63:28
certainly [16]-24:6,
37:18, 48:3, 51:29, 60:6,
60:10, 64:17, 64:20,
64:22, 64:24, 78:18,
78:22, 79:27, 80:15,
80:30, 82:20
Certified [1] - 88:1
CHAIR ${ }_{[36]}-3: 3,3: 7,3: 9$,
3:12, 3:20, 3:24, 3:29,
4:13, 45:7, 45:28, 45:30,
46:5, 46:14, 46:27,
47:15, 47:18, 47:21,
67:15, 67:22, 68:6,
68:25, 68:29, 69:4, 69:7,
69:19, 69:22, 81:10,
81:14, 83:29, 84:2,
84:22, 84:24, 85:19,
85:28, 86:8, 86:14
Chair [16]-3:11, 3:13,
45:9, 46:3, 46:13, 47:20,
47:24, 47:28, 67:21,
68:21, 69:5, 69:10,
69:18, 85:22, 85:23,
86:10
chairman [4]-83:5, 83:25,
87:1, 87:2
Chairman [2] - 1:18, 3:26
challenging [1] - 82:11
chance [1]-79:28
change [2] - 31:18, 80:23
channels [1] - 51:29
characterise [4]-32:24,
37:8, 41:29, 64:12
check [1] - 81:6
checked [3]-19:29, 40:8, 42:23
chose [2]-11:17, 67:3
chronology [1] - 49:19
Cialis [11] - 16:28, 24:11, 25:10, 25:23, 27:10, 27:25, 28:5, 28:7, 28:8, 31:26, 32:1
Cialis/Tadalafil [1] - 64:8
circa [2] - 42:10, 42:22
circumstances [7]-7:26,
47:12, 71:7, 73:26,
80:28, 84:28, 85:13
Claire [2] - 66:23, 67:1
clarification [2]-82:10, 86:1
clarifications [1] - 86:18
classed [1] - 36:17
classified [3]-7:29, 34:8, 55:17
clear [6]-28:13, 61:8,
62:21, 80:9, 84:12,
85:16
clearly [6] - 52:26, 52:27,
60:28, 62:30, 66:10, 66:30
Clenbuterol [3]-37:1, 39:9, 52:3
clinical [2]-51:3, 57:16
close [1] - 86:29
closed [1] - 15:3
cocaine [8]-7:23, 39:14,
39:15, 39:17, 55:17,
56:2, 56:8
Cocaine [1] - 55:27
Code [12] - 50:5, 53:10,
54:25, 54:28, 55:2,
56:18, 58:29, 58:30,
60:19, 63:12, 65:16,
66:11
code [1] - 56:22
Codeine [1]-32:16
codeine [1] - 32:16
cold [1] - 38:28
column [2] - 12:17, 15:14
comfort [1] - 79:13
coming [4]-11:19, 19:21,
51:13, 76:8
COMMENCED ${ }_{[1]}-3: 1$
commencement [1]-5:12
commencing [1] - 3:5
comment [1]-37:14
comments [2]-47:11, 85:25
committed [2] - 68:10, 71:8
COMMITTEE ${ }_{[1]}-1: 5$
committee [2]-70:3, 70:14
Committee [109]-1:18,
3:28, 4:22, 4:26, 5:29, 6:19, 8:28, 9:5, 9:9, 9:17, 9:23, 11:11, 12:12, 13:1, 13:4, 14:7, 14:24, 14:26, 16:18, 16:29, 17:4, 20:8, 20:25, 21:10, 22:16, 22:18, 22:30, 25:22, 25:26, 25:29, 27:7, 29:19, 29:21, 29:26, 30:29, 33:11, 33:20, 36:13, 37:26, 38:25, 39:30, 40:1, 40:28, 40:30, 41:7, 43:7, 43:13, 44:17, 45:2, 45:7, 46:23, 47:2, 48:1, 48:29, 50:22, 51:13, 53:25, 55:3, 55:13, 56:12, 56:24, 57:5, 57:29, 59:8, 59:23, 60:21, 60:24,
61:6, 61:28, 62:1, 63:13, 63:25, 65:17, 66:25,

67:9, 67:15, 67:18,
67:23, 68:1, 68:2, 68:4,
69:28, 70:4, 70:16, 71:1,
71:13, 71:20, 72:15,
72:16, 72:26, 73:1,
73:29, 76:17, 81:8,
81:26, 82:2, 82:3, 83:2,
83:8, 83:18, 84:4, 84:26,
84:29, 85:14, 85:30,
86:18, 86:20
Committee's [3]-60:26, 70:1, 70:6
common [4]-51:20,
51:28, 57:9, 63:30
commonly [2] - 17:15,
36:22
communication [1] 82:16
community [1] - 51:21
company [1] - 80:25
compelling [1] - 72:22
compiled [1] - 28:21
complaint [5] - 48:10,
69:30, 70:14, 70:15,
70:16
complete [4]-27:12, 31:6,
45:23, $88: 1$
completed [2] - 18:25, 27:18
completely [2] - 10:17, 45:17
completeness [1] - 43:15
completion [2] - 40:9, 69:27
compliant [1] - 10:18
comprehensive [3] - 16:3,
25:6, 28:21
computer [1] - 12:29
concern [2] - 60:1, 66:22
concerning [2] - 32:30, 52:28
concerns [5] - 5:5, 5:9,
10:10, 39:24, 67:1
Concerta [2]-13:23, 14:1
conclude [1] - 65:12
CONCLUDED [1] - 87:4
conclusion [1] - 76:1
conclusions [2]-65:22,
65:23
conditions [1] - 70:21
CONDUCT [1] - 1:4
conduct [9]-49:30, 52:28,
65:27, 66:4, 72:2, 73:10,
77:18, 79:18, 84:17
Conduct [13] - 50:5,
53:10, 54:25, 54:28,
55:2, 56:18, 58:30,
60:19, 63:12, 65:16,
65:21, 66:11
conducted [4]-27:22,
30:18, 30:23, 33:28
confidence [2]-73:7,
74:21
CONFIDENTIAL [1] - 1:8
confined [1] - 49:15
confirm [6] - 12:25, 28:25, 44:23, 44:27, 44:28, 60:18
confirmed [3]-12:22,

$$
12: 28,15: 13
$$

confirming [1] - 15:10 confusion [2] - 43:7, 43:29
congestion [1] - 38:28
Conor [1] - 47:17
CONOR [2] - 2:7, 47:26
conscious [4]-16:29,
47:2, 47:4, 81:21
consequences [1] - 43:11 consider [3]-62:12,

## 72:17, 86:22

consideration [3]-72:4, 73:16, 75:13
considered [3]-49:12, 53:30, 66:5
considering [1] - 70:11
considers [1] - 70:3
consisting [1] - 48:9
constant [1] - 82:15
constitute [2]-58:6, 85:10
constitutes [3]-59:5, 63:16, 65:12
consultant [1]-10:21
contacted [1] - 5:4
contain [3]-6:21, 23:11, 36:5
contained [3]-32:9, 50:9, 53:2
containing [4]-32:15, 36:14, 38:21, 61:17
contains [9]-17:8, 18:26, 28:8, 31:24, 32:15, 36:27, 37:1, 38:27, 64:2
content [1] - 44:26
context [6]-7:23, 33:22, 43:17, 54:11, 76:11
continue [4]-17:27, 21:11, 79:2, 79:15
continued [1] - 10:19
continues [2]-14:7, 14:9
continuing [2]-23:2, 41:10
contrary [1] - 62:16
contravention [3]-62:18, 64:13, 77:30
contributed [1] - 86:26
contribution [2] - 46:5, 67:19
contributions [1]-86:28
control [9]-6:6, 6:9, 6:14, 6:16, 7:25, 7:27, 51:2, 57:15, 65:6
Controlled [19]-7:16, 8:9, 19:3, 19:7, 19:17, 19:20, 19:25, 22:4, 22:7, 22:9, 22:13, 22:22, 22:29,

23:7, 24:2, 26:3, 33:5,
33:8, 54:17
controlled [24]-5:8, 7:28,
7:30, 18:27, 18:30,
52:13, 54:2, 54:6, 54:9,
54:16, 54:18, 55:18,
55:20, 55:22, 59:25,
61:9, 62:3, 62:6, 62:10,
62:11, 62:14, 62:17, 64:2, 64:4
conversation [1] - 76:2
conversations [1] - 75:22
converted [1] - 32:16
conviction [1] - 71:6
convictions [2]-74:1
cooperate [1] - 45:25
cooperated [2]-78:14, 82:3
cooperation [3] - 45:23,
78:15, 82:27
cooperative [2] - 45:11, 45:17
copies [2]-21:24, 38:2
copy [3]-20:11, 26:2,
35:19
cordial [1] - 85:17
Core [4]-9:3, 9:10, 22:25, 43:9
correct [81] - 3:6, 8:23,
9:28, 9:29, 14:11, 14:16,
14:17, 14:21, 16:23,
20:28, 21:1, 25:12,
28:18, 29:12, 30:5, 31:2,
41:15, 41:16, 48:7, 48:15, 49:3, 49:4, 49:7, 49:8, 49:12, 49:13, 50:5, 50:6, 50:11, 50:15, 53:3,
53:4, 53:15, 53:16, 53:20, 53:23, 53:29, 54:13, 54:20, 54:24, 55:1, 55:5, 55:11, 55:16, 55:25, 55:26, 56:1, 56:25, 56:26, 56:29, 56:30, 58:21, 58:27, 58:28, 59:1, 59:2, 59:6, 59:9, 60:17, 60:22, 61:1, 61:2, 61:4, 61:7, 63:5, 63:11, 63:14, 63:18,
63:20, 63:21, 65:15, 65:19, 66:2, 66:7, 66:13, 66:17, 76:6, 76:8, 85:6, 85:8, 88:1
correction [1] - 82:7
correctly [1] - 75:24
corresponded [1] - 19:30
correspondence [1] 82:20
cough [1] - 38:28
Council [11] - 52:26,
69:29, 70:13, 71:4, 71:9,
71:12, 71:23, 71:26,
71:27, 72:10, 72:15
Council's [1] - 71:6
Counsel [2]-1:23, 1:25
counsel [2] - 4:18, 86:21
counted [2] - 14:18, 15:5
counter [3]-38:26, 39:16, 40:16
counteract [1] - 39:15
counting [1] - 15:1
couple [1] - 26:12
course [14]-5:20, 8:10,
12:7, 14:9, 15:29, 20:13,
39:17, 39:19, 44:27,
65:5, 71:27, 79:11,
81:24, 86:20
court [3] - 62:10, 62:12, 62:15
Court [2] - 9:4, 49:9
cover [3]-8:12, 29:1,
33:17
covered [1] - 29:2
covering [1] - 23:23
covers [1] - 12:26
creation [1] - 28:16
credit [8]-75:7, 76:25,
78:15, 78:23, 80:12, 80:13
criminal [1] - 73:30
criticism [3]-43:8, 43:12, 60:28
cross [2] - 8:14, 75:30
cross-examined [1] 75:30
cross-talk [1] - 8:14
crystal [1] - 39:1
current [1]-85:3
customer [1] - 40:14
cut [1] - 14:20
CV [2] - 48:27, 48:30
D
damaged [1] - 56:4
Daniels [1] - 1:30
data [1]-31:30
date [27]-5:21, 8:23,
11:15, 11:18, 14:4,
14:15, 15:3, 16:11,
18:12, 23:16, 23:28,
24:3, 24:7, 26:6, 28:21,
28:26, 29:4, 29:9, 31:14,
35:2, 35:7, 40:20, 42:23,
43:25, 76:13, 82:20
dated [6] - 9:28, 20:21,
22:5, 23:9, 28:23, 45:21
dates [9]-11:11, 11:13,
11:14, 12:27, 42:11,
42:13, 42:15, 42:26,
42:28
day-to-day ${ }_{[2]}-6: 9,6: 16$
days [1] - 70:11
deal [18] - 16:24, 16:25,
20:30, 24:9, 25:11,
25:13, 43:4, 47:5, 49:14,
49:24, 52:21, 62:2,
62:20, 65:7, 65:23,
78:10, 78:11, 81:7
dealer [2]-64:12, 77:29
dealing [3] - 48:12, 49:25, 60:30
dealings [1] - 79:27
deals [6]-17:7, 29:26,
48:8, 73:3, 73:4, 73:25
dealt [1] - 16:28
December [1] - 29:19
decides [1]-80:22
decision [2] - 29:29, 84:30
declaration [1] - 38:9
decongestant [1] - 38:29
decongestants [1] - 39:16
definition [3]-37:5, 49:5, 49:6
degree [2] - 50:3, 53:8
Deirdre [1] - 1:30
delay [1] - 86:15
deliberate [1]-74:8
delivery [1]-73:8
demand [3] - 51:30, 52:19, 60:6
demonstrate [2]-71:29, 78:27
demonstrates [1] - 76:21
dental [1] - 34:14
departed [1] - 45:23
Dermot [1]-3:13
Dermott [1]-1:18
description [1] - 77:24
detail [10]-7:11, 12:2,
14:3, 25:13, 26:1, 39:26,
53:25, 54:3, 55:13, 62:4
detailed [6]-19:1, 34:4, 44:30, 47:3, 55:22
details [7]-6:2, 7:5, 11:4, 14:2, 22:3, 33:24, 51:17
detain [1] - 5:27
detained [1] - 20:12
detention [1] - 76:2
deter [1]-72:1
determining [2] - 6:23, 19:8
deterrent [1] - 74:20
develop [1] - 25:18
Dexamfetamine [1] 59:26
Dexamphetamine [1] 35:27
Difene [1] - 64:7
different [3]-51:29, 73:19, 77:25
difficult [2] - 66:30, 85:17
difficulties [1] - 68:24
difficulty [10]-3:22, 3:27, 9:18, 9:21, 9:24, 17:17, 17:20, 17:21, 17:26,
69:17
dilute [2] - 78:22, 78:26
diluted [1] - 76:12
direct [2] - 64:13, 77:30
directly [1]-69:9
discernible [1] - 56:24
disciplinary [1] - 70:18
discrepancies [1] - 27:23
discrepancy [3]-19:26,
25:20, 44:12
discuss [1] - 67:27
discussed [4] - 24:18,
24:19, 31:17, 42:7
discussing [2] - 30:6,
79:23
diseases [1] - 36:16
disgraceful [3]-50:1,
53:6, 56:21
dishonesty [4] - 50:2,
53:7, 73:26, 74:9
dismiss [1] - 70:15
disorder [1] - 17:10
dispense [1] - 65:7
dispensed [4]-41:14,
51:21, 51:25, 54:8
Dispensed [12] - 7:10,
13:3, 13:8, 13:10, 13:13, 13:18, 13:20, 13:30, 14:1, 14:9, 29:17, 29:27
dispensing [8] - 12:19,
14:14, 18:9, 35:10,
35:24, 40:8, 41:11,
41:13
display [1]-11:6
displayed [1] - 22:23
displaying [3] - 13:7,
28:27, 29:23
displays [2]-12:16, 12:17
distribution [1] - 15:25
diversion [4]-5:9, 10:11, 28:10, 39:2
diverted [1] - 51:29
document [18]-7:7, 13:7, 13:21, 13:26, 13:28, 20:24, 20:26, 20:28, 22:19, 22:20, 22:28,
25:26, 26:1, 29:23,
29:26, 40:2, 40:4, 40:29
documentation [4] -
16:30, 17:2, 17:4, 21:27
documents [14]-6:20,
6:21, 6:25, 6:27, 7:4,
7:5, 8:16, 8:17, 11:23,
41:1, 41:3, 41:4, 43:16, 49:20
done [1]-69:16
doubt $[7]-11: 10,16: 30$,
45:1, 72:26, 77:9, 78:12, 80:3
Dowling [2]-72:11, 72:13
down [15] - 13:25, 13:29,
22:20, 22:27, 22:28,
26:4, 26:11, 26:14,
26:26, 29:25, 47:10,
57:7, 83:13, 83:15
Doyle [5] - 6:15, 34:28,
61:30, 66:21, 66:29
DR [3] - 2:7, 47:26, 67:21
drug [30] - 7:20, 7:28, 18:28, 18:30, 24:8,

25:25, 36:29, 37:4,
39:10, 51:17, 51:28,
54:6, 54:17, 54:18,
55:18, 55:20, 56:3, 61:9,
62:10, 62:11, 62:14, 62:17, 63:30, 64:2, 64:4, 64:8, 73:27
Drug [44]-7:7, 7:10,
11:29, 12:10, 12:15, 13:8, 13:10, 13:13, 13:18, 13:20, 13:30, 14:1, 14:10, 16:9, 18:1, 18:7, 19:15, 19:17, 19:22, 19:23, 19:26, 20:20, 20:23, 20:27,
21:30, 22:2, 23:4, 25:7, 25:21, 26:25, 27:2, 27:5, 27:22, 27:25, 27:30, 29:18, 29:27, 31:28, 35:13, 39:20, 42:5, 44:2, 44:5, 54:17
drugs [48]-5:8, 7:17, 7:18, 7:22, 7:26, 7:28, 7:30, 8:2, 16:16, 16:20, 51:11, 51:12, 51:15, 52:1, 52:3, 52:5, 52:19, 54:2, 54:4, 54:5, 54:6, 54:7, 54:10, 55:22, 56:7, 56:8, 57:8, 57:9, 57:10, 59:25, 59:29, 59:30, 60:4, 60:5, 60:7, 60:8, 60:11, 62:3, 62:6, 63:22, 63:23, 63:28, 64:6, 64:10, 64:13, 77:25, 77:29
Drugs [24]-7:16, 8:9,
13:3, 18:29, 19:3, 19:7, 19:20, 19:25, 22:4, 22:8, 22:9, 22:14, 22:22, 22:29, 23:7, 24:2, 26:3, $33: 5,33: 8,33: 9,55: 18$, 55:29, 62:5, 63:3
due [8] - 10:10, 14:8, 18:28, 27:14, 44:27, 74:14, 84:18, 86:20
DUNNE [8]-3:8, 3:30, 4:8, 46:12, 68:21, 68:26, 68:30, 86:10
during [2]-28:20, 83:22
duty [14] - 10:14, 23:16, 23:18, 23:26, 23:28, 24:4, 33:14, 34:27, 42:13, 42:14, 42:26, 42:28, 43:1, 45:17
Duty [8] - 8:11, 23:15, 23:17, 23:20, 33:10, 42:12, 42:18, 42:24 dysfunction [3]-28:9, 32:2, 64:9

| $\mathbf{E}$ | equipment $[2]-57: 26$, <br> $59: 21$ |
| :--- | :---: |
| erectile $[3]-28: 9,32: 1$, |  |
| e.g $[1]-59: 29$ | $64: 9$ |
| ear $[1]-85: 21$ | especially $[1]-65: 1$ |
| early $[1]-45: 11$ |  |

ease [1]-21:10
easiest [2] - 46:22, 72:29
Editor(s [1] - 1:30
Efexor [6] - 10:20, 10:26, $11: 8,32: 2,32: 8,32: 28$
effect [2] - 74:20, 76:4
effectively [2] - 64:9, 77:28
effects [2] - 36:30, 39:7
eight [3]-19:11, 19:12, 19:18
either [8]-15:10, 26:7, 29:8, 38:7, 42:23, 47:9, 63:24, 67:30
elaborate [1] - 21:22
electronic [2]-40:12, 43:20
ellenmarie [1] - 1:29
elsewhere [2] - 58:16, 59:13
emphasise [1] - 77:14
emphasised [1] - 72:14
emphasising [1] - 74:24
employed [1] - 66:20
employment [1] - 67:3
encountered [2]-42:2, 45:15
encouraged [1] - 56:5
end [10] - 31:27, 45:19, 48:20, 48:25, 58:3, 66:9, 66:15, 67:24, 78:4
endorsed [1] - 72:10
enforcement [2] - 5:3, 15:21
engaged [5] - 41:17, 47:2, 53:5, 56:20, 77:18
engaging [1] - 75:26
enhancing [5] - 37:4,
37:14, 37:23, 39:10, 59:28
enormous [2] - 41:30,
77:7
enquiries [1] - 30:7
ensure [1]-7:1
enter [1]-5:26
entered [8]-12:29, 22:7, 22:8, 23:6, 23:11, 24:2, 33:7, 54:17
entire [3]-22:19, 26:2, 29:26
entirely [1] - 83:7
entries [4]-22:4, 22:17, 26:11, 26:29
entry [1] - 26:27
Ephedrine [1] - 39:7
equally [1] - 85:27
equate [1] - 61:20
equates [1] - 40:25
equipment [2] - 57:26,
erectile [3]-28:9, 32:1,
especially [1] - 65:1
essentially [4]-21:7
30:22, 33:4, 69:23
established [1] - 22:1
Eugene [1]-1:21
events [1] - 49:19
eventually [1] - 77:21
Evidence [2]-48:23, 57:10
evidence [50]-3:5, 3:14,
3:27, 5:7, 5:27, 12:11,
17:19, 28:15, 46:1, 47:3,
47:5, 47:13, 47:22,
55:14, 57:6, 61:28,
61:30, 62:22, 66:26,
67:8, 67:19, 69:13,
69:18, 69:30, 72:22,
73:21, 75:17, 76:17
76:18, 76:23, 76:25,
77:13, 77:14, 77:19,
77:23, 78:12, 78:18,
78:19, 78:20, 79:9,
80:26, 80:30, 81:26,
82:4, 82:11, 82:29,
82:30, 86:26
evident [2] - 55:3, 80:3
exactly [4] - 63:24, 67:28,
75:27, 80:8
examine [1] - 30:1
examined [3]-3:18,
47:26, 75:30
example [1]-74:14
excellent [1]-4:25
except [1] - 34:19
exception [1] - 32:28
excerpts [1] - 66:26
executive [2] - 48:5, 48:19
exempt $[4]-33: 19,34: 8$,
35:15, 35:17
exemption [4]-34:11,
37:29, 38:1, 38:13
exemptions [1] - 55:22
exercise [3] - 18:25,
30:28, 42:21
exhibits [2]-46:22, 46:24
existed [1] - 60:11
existing $[1]$ - 79:10
exists [1] - 66:14
expand $[3]-60: 3,61: 14$, 64:28
expect [2] - 65:3, 65:8
expected [1] - 67:6
experience [1] - 17:14
expert [3]-47:7, 77:12, 77:24
explain [16] - 10:3, 10:20, 12:14, 13:5, 15:18, 17:4, 20:10, 22:18, 29:25, 33:20, 36:12, 37:25, 38:24, 43:16, 69:26
explained [7]-10:8, 10:16, 14:10, 16:2, 24:14, 37:10, 37:27
explaining [2]-18:28, 43:9
explains [1] - 30:28
explanation [1] - 43:12
expressed [1] - 76:3
extend [2] - 29:30, 30:24
extended [3] - 29:6, 30:10, 30:24
extending [1] - 31:30
extensively ${ }^{[1]}$ - 53:26
extent [4]-71:30, 75:11,
77:8, 77:21
extremely [6] - 32:25,
32:30, 37:19, 64:22,
76:23, 77:2
eye [1]-51:19

| F |
| :--- |
| $\mathbf{f ) ( a [ 1 ] - 8 5 : 5}$ |
| fact $[14]-41: 5,57: 2,57: 8$, |
| $59: 29,60: 27,63: 7$, |
| $67: 27,75: 26,76: 24$, |
| $79: 22,80: 14,82: 8$, |

82:17, 82:27
factors [4]-73:15, 73:18, 73:19, 83:2
facts [2]-62:29, 81:18
factual [7] - 47:13, 50:18, 53:21, 55:9, 57:1, 59:7, 61:5
failures [1] - 74:10
fair [4]-64:29, 76:5, 80:1, 82:30
fairly [1] - 76:1
fairness [3] - 45:13, 69:20, 80:7
fallen [1]-83:10
familiar [3]-36:24, 36:25, 71:21
families [1] - 56:4
family [1] - 83:13
far [3]-26:9, 83:10, 84:14
Farrell [1] - 81:11
fat [2]-37:4, 39:11
favour [1]-72:23
feature [2]-57:29, 72:20
features [1] - 76:29
feedback [1] - 17:25
felt ${ }^{[1]}$ - 76:8
few [4]-4:19, 28:29, 67:8 86:3
fig [1] - 62:25
figure [1] - 30:15
figures [6]-28:4, 28:21,
30:14, 40:19, 40:23,
44:10
filled [2] - 15:2, $38: 2$
final $[7]-9: 15,20: 2,27: 8$, 28:25, 31:12, 32:14,
32:20
finally [1] - 83:5
findings [8]-17:5, 22:16, 30:29, 33:3, 41:23, 55:4,
71:22, 86:21
fine [2] - 4:24, 49:23
finished [3] - 4:20, 38:16
Finlay [1] - 71:24
first [24]-5:18, 8:21, 9:14,
25:5, 27:9, 27:18, 28:13,
28:24, 28:27, 29:2,
31:14, 31:27, 32:12,
33:13, 33:28, 43:5,
43:23, 45:15, 46:29,
48:8, 63:23, 66:15,
77:14, 79:21
fit [2] - 56:10, 56:15
five [9]-7:19, 28:3, 36:6, 36:7, 37:15, 38:6, 42:15, 42:26, 86:1
flagged [1] - 52:12
focus [1] - 66:14
following [6] - 13:19,
53:24, 56:20, 57:7,
70:17, 79:26
FOLLOWS [2] - 3:2, 68:19
foot [4]-34:13, 40:10,
60:9, 81:16
footprint [1] - 58:10
foreseeable [1] - 80:28
form [2]-34:22, 38:1
formal [1]-81:16
formally [4] - 69:11, 69:21, 85:23, 86:29
forms [6] - 35:20, 38:3,
38:4, 38:5, 38:9, 38:18
four [15]-11:27, 12:2, 16:5, 16:20, 19:21, 19:25, 24:18, 27:27, 28:4, 28:7, 32:2, 38:6,
42:15, 42:26, 71:25
four-tablet [1] - 28:7
Frank [1] - 1:23
fraud [2]-50:2, 53:7
freely [1] - 56:3
front [3]-29:10, 29:11,
48:4
frozen [1] - 3:24
fulfil [2] - 34:15, 38:11
full [4]-25:14, 51:6,
57:20, 82:27
fully [2]-82:4, 84:8
functioning [2]-64:12, 77:29
functions [1] - 4:30
fundamental [1] - 77:26
fundamentally [1] - 74:27
fundamentals [1] - 75:8

| $\mathbf{G}$ |
| :--- |
| Gardai $[1]-10: 11$ |
| Gardaí $77-5: 4,33: 23$, |
| $55: 12,57: 5,59: 12$, |
| $78: 14,82: 27$ |
| general $[1]-34: 9$ |
| generally $[4]-6: 3,6: 30$, |
| $7: 22,38: 1$ |
| generate $[2]-12: 30,13: 14$ |
| generated $[3]-13: 15$, |

43:19, 43:26
generation [1] - 83:19
given [11] - 7:9, 7:12, 8:13,
12:11, 14:12, 23:16,
28:15, 51:17, 51:20,
59:20, 86:26
glad [1]-67:23
Gleeson [8] - 1:21, 81:8,
84:26, 85:11, 85:19,
85:24, 85:27, 85:29
GLEESON [3] - 84:28, 85:7, 85:12
good-bye [1] - 46:4
governance [1] - 6:4
governing [2] - 64:14, 77:30
GP [1] - 10:26
grateful [3]-76:4, 82:28, 82:29
gratitude [1] - 76:3
gravity [5] - 72:4, 74:19,
78:27, 83:1, 84:18
great [4]-21:5, 47:5, 55:13, 60:1
ground [2] - 50:6, 54:25
grounds [9]-49:28, 53:1, 54:27, 56:20, 58:25,
60:14, 63:9, 65:13, 71:5
group [1] - 67:2
guidance [2]-72:27, 74:2
guide [1] - 46:6
$\mathbf{H}$
half [1] $-67: 30$
halfway [2] - 57:7, 59:24
hand [4]-71:3, 82:20, 84:2, 84:25
hands [2] - 68:13, 70:6
handwriting [1] - 12:23
happen.. [1] - 76:9
harm [1] - 73:5
harsh [4]-78:29, 79:22, 80:11
heading [2] - 46:15, 65:21
Health [1] - 15:21
health [1]-73:6
healthcare [1] - 36:15
hear [7]-3:9, 17:19,
17:23, 40:27, 47:19, 67:23, 68:21
heard [10] - 47:5, 47:9, 47:13, 50:22, 53:26, 55:13, 59:23, 61:25, 61:26, 66:25
hearing [2] - 72:6, 86:1
HEARING [3] - 1:4, 68:18, 87:4
held [2] - 6:3, 83:21
HELD [2] - 1:4, 1:13
help [2] - 46:26, 46:27
helpful [11] $-6: 18,8: 18$,
9:12, 9:14, 15:17, 28:12,
37:6, 43:3, 62:20, 67:7,

73:2
herein [1] - 88:2
Herman [1] - 72:10
heroin [1] - 7:23
high [5]-24:25, 37:19,
77:3, 83:20
High [1] - 49:9
highest $[4]-7: 24,7: 27$, 12:5, 17:13
highlight [2] - 79:18, 84:16
highlighted $[3]-64: 30$, 84:9, 84:10
highlighting [1] - 84:16
himself [4]-57:21, 77:27, 83:7, 83:12
hold [1] - 15:26
holding [1] - 80:24
honest [1] - 78:4
hope [4]-29:11, 47:21,
68:21, 79:1
hopefully [1] - 78:16
hopes [1] - 79:2
hoping [1] - 9:3
hormonal [2]-36:16, 36:29
hormonal-type [1] - 36:29
hour [1] - 67:30
hours [1]-8:4
housekeeping ${ }_{[1]}-46: 17$
HPRA [12] - 6:29, 11:26, 15:22, 19:22, 21:25, 27:11, 30:4, 30:6, 35:11, 35:16, 41:18, 42:7 huge [5] - 41:30, 51:24, 52:11, 56:6, 77:7
hypnotic [1] - 63:29

| I |
| :--- |
| idea [1] $-46: 7$ |

ideal [1] - 42:21
identical [1] - 50:9
identified [24] - 5:6, 16:17,
16:21, 22:10, 27:15,
27:23, 33:30, 34:26,
35:6, 40:23, 41:11,
42:25, 53:4, 54:29, 55:2,
58:26, 60:14, 60:26,
63:4, 63:9, 63:12, 65:13, 71:25, 72:18
identify [25]-6:19, 6:27, 12:3, 19:18, 22:5, 25:19, 31:10, 36:2, 39:27, 41:2, 41:4, 49:28, 50:13, 51:10, 53:1, 55:23, 55:27, 55:28, 56:23, 58:29, 58:30, 60:20, 65:11, 65:16, 73:12
IEHC [2] - 72:11, 72:12
ignored [3]-66:22, 67:1, 76:12
ii [1] - 70:21
II [2] - 18:27, 18:30
iii [1] - 70:25
illegal [2] - 56:6, 56:8
illicit [3]-7:24, 37:12, 39:2
image [5] - $37: 4,37: 13$,
37:23, 39:10, 59:28
image-enhancing [1] 59:28
imagine [2] - 17:3, 37:21
immediate [1] - 62:14
immediately [1]-4:14
important [2]-73:9, 86:22
impose [1] - 70:17
imposed [1] - 74:4
impossible [2]-80:21, 80:29
improve [1] - 36:20
improvement [1] - 78:30
IN [2] - 1:4, 1:5
inability [1] - 74:14
inaccuracies [1] - 20:1
inappropriate [3]-58:11, 64:23, 78:3
incident [1] - 72:19
include [11]-6:3, 21:3, 27:1, 27:3, 29:6, 29:30, 30:10, 63:29, 70:2, 70:23, 73:18
included [14]-7:4, 7:10,
11:7, 23:3, 23:7, 23:10, 24:26, 26:19, 26:23, 33:25, 33:28, 38:8, 38:9, 49:6
includes [5] - 7:6, 7:22, 35:12, 35:14, 47:8
including [4]-31:30, 51:2, 53:10, 57:15
incoming [4]-6:27, 7:2, 24:27, 27:1
incompatible [1] - 74:27
increase [1] - 31:21
increased [1] - 32:1
indeed [1] - 79:2
indicate [2]-24:4, 75:24
indicated [3]-79:27, 82:15, 82:23
indication [3]-19:30,
25:1, 78:17
indicator [1] - 79:1
indicators [1] - 24:19
indirectly [1] - 73:24
Indiscernible [1] - 8:14
indistinct [1] - 52:25
individual [9]-7:10, 7:11,
14:12, 19:2, 21:24,
22:10, 51:17, 52:14, 85:9
individually [1] - 65:30
individuals [1] - 56:4
inevitability [1] - 79:29
infamous [3] - 49:30, 53:5, 56:21
inflammatory [1] - 64:7
inform [3] - 14:26, 33:12, 48:1
information [63]-5:11,
6:1, 6:12, 6:29, 7:2,
11:24, 11:25, 15:17,
15:19, 15:26, 15:30,
16:3, 16:5, 16:8, 16:13,
16:16, 17:30, 19:22,
19:24, 21:28, 24:15,
24:17, 25:4, 25:6, 25:8,
25:9, 25:14, 25:16,
25:21, 27:12, 27:17,
27:19, 27:21, 27:24,
28:14, 28:18, 28:19,
28:22, 30:4, 30:7, 30:10,
30:19, 31:7, 31:28, 33:4, 33:23, 34:5, 34:22,
34:29, 35:11, 35:17,
36:1, 37:2, 38:17, 39:19,
40:6, 40:15, 41:19, 42:5,
42:8, 44:3, 79:16
informed [1] - 5:5
informs [2] - 14:10, 14:12
ingredient [3]-17:8, 36:27, 37:1
initial [1]-16:4
initials [1] - 15:5
injection [1] - 33:26
injections [7]-33:26,
34:3, 34:7, 34:26, 37:20, 38:19, 38:21
Inquiry [21] - 3:13, 48:24,
50:9, 50:14, 53:2, 53:18,
54:29, 58:26, 59:4,
60:15, 63:9, 63:16,
65:13, 69:8, 69:28, 82:4,
85:2, 85:3, 86:20, 86:23, 86:29
inquiry [1] - 69:28
insight [3]-5:29, 72:19, 74:14
insofar [3] - 58:29, 66:26, 82:6
inspect [1] - 5:27
inspection [40] - 5:3, 5:23,
5:26, 5:28, 6:19, 8:11,
8:19, 8:20, 8:21, 8:22,
12:8, 13:9, 14:29, 16:11,
17:29, 19:10, 20:14,
21:16, 21:18, 21:23,
21:26, 24:14, 27:11,
28:13, 28:15, 28:20,
29:4, 29:9, 29:28, 30:6, 31:8, 31:14, 32:12, 33:28, 34:2, 35:3, 40:21, 43:29, 45:15, 54:19
inspections [1] - 9:1
Inspector [14]-47:9, 55:14, 57:6, 62:23, 63:20, 75:19, 75:23, 75:30, 76:7, 78:19, 79:24, 80:2, 82:8, 82:29
instance [8] - 14:4, 15:28,
$16: 4,53: 15,61: 3,75: 2$,

75:13, 80:13
instances [1] - 65:29
Instructed [1] - 1:26
instructed [1] - 5:12
instructions [1] - 81:17
intend [2]-53:13, 53:25
intended [2] - 14:30, 62:14
intention [1]-80:9
interaction [1] - 62:30
interest [1] - 52:18
interrupt [3]-3:30, 17:16, 85:22
interrupted [1] - 8:15
intervene [1] - 9:23
introduce [1] - 3:12
introduced [1] - 10:15
inventory [1] - 14:16
investigated [1] - 33:18
investigation [14]-5:13,
5:15, 5:19, 5:20, 11:10,
14:27, 28:30, 33:21,
37:26, 39:25, 45:10,
50:20, 50:23, 53:27
investigations [2]-21:12, 24:10
invoice [9]-20:11, 20:12,
20:19, 20:20, 22:5, 23:8,
23:9, 23:13
invoices [14]-6:28, 6:30,
20:14, 20:16, 20:17,
21:2, 21:24, 21:29,
21:30, 22:3, 22:4, 22:8,
23:3, 23:5
involved [6]-21:29, 22:2,
49:14, 53:7, 62:24,
66:24
involves [1] - 50:1
involving [1] - 74:9
ipsa [2]-62:27
Ireland [6] - 4:28, 15:23,
34:10, 37:28, 56:3,
59:26
IRELAND [2]-1:2, 1:5
Irish [1]-55:28
issue [23]-4:3, 16:25, 16:27, 21:9, 24:21, 25:30, 27:8, 27:9, 30:24, 46:25, 48:28, 49:15,
49:21, 60:4, 62:20,
69:24, 72:14, 78:10,
78:25, 84:14, 86:2
issues [10]-24:29, 33:30,
36:16, 66:22, 69:1,
72:17, 73:3, 73:12,
82:10, 84:30
item [1]-23:12
items [1] - 54:28
itself [4]-9:16, 12:28,
13:13, 43:29
iv [1] - 70:27

| J |
| :--- |
| January [19]-11:12, |

11:17, 12:7, 12:21,
16:11, 16:22, 18:6,
19:13, 19:24, 26:21,
27:27, 29:3, 29:7, 29:18,
30:16, 31:14, 32:22, 35:2, 41:27
Jewell ${ }_{[2]}-1: 18,3: 13$
job [1] - 75:23
John [18] - 6:13, 10:5,
10:14, 13:22, 23:17, 24:3, 38:7, 42:14, 48:11, 50:28, 51:4, 54:15,
57:11, 57:19, 61:8, 66:3,
66:10, 66:19
JOHN [1] - 1:10
join [1] - 68:23
joined [4] - 3:8, 4:29, 46:12, 86:12
joining [1] - 68:27
joins [1] - 69:2
judgment [1] - 71:25
Judy [1] - 1:30
July [2] - 26:29, 27:2
June [13]-22:6, 22:13,
23:9, 23:19, 23:23,
23:24, 26:27, 26:29,
27:2, 27:5, 33:7, 33:15, 71:25

| $\mathbf{K}$ |
| :---: |
| Kane $[7]-1: 19,17: 18$, | 68:22, 68:27, 69:2, 69:7, 84:5

KANE [6] - 17:21, 45:9,
45:26, 69:5, 84:6, 84:23
Keep [1] - 22:28
keep [6] - 26:14, 26:15, 26:26, 60:7
keeping [2] - 47:10, 54:1
Kennedy [1] - 1:25
kept [4] - 19:1, 35:29, 54:6, 54:9
key [1] - 58:3
kind [1] - 35:8
knowledge [3] - 37:12, 37:16, 37:22
known [7] - 52:19, 59:30, 60:5, 60:28, 63:30, 64:13, 77:29

| L |
| :---: |
| lack $21,74: 14,74: 20$ |

lack [2] - 74:14, 74:20
large [13]-27:14, 32:25,
37:9, 38:20, 39:21, 42:9,
42:22, 42:29, 42:30,
54:16, 61:9, 76:23, 77:1
last [9]-26:16, 38:22,
44:16, 46:18, 48:18,
58:14, 65:1, 66:3, 74:7
late [1]-43:10
Lay [1] - 1:19
lead [2]-5:14, 9:23
leadership [1] - 56:6
learning [1] - 9:13
least [3]-12:12, 29:11, 46:24
leaves [1] - 19:5
leaving $[1]-4: 2$
left [3]-11:20, 18:18, 66:29
legal [4]-7:23, 58:20, 59:17, 85:18
Legal [3]-1:21, 84:2, 85:30
legislation [5] - 37:29, 38:13, 54:15, 64:14, 77:30
legitimacy [1] - 34:23
legitimate [6]-7:5, 7:26, 18:21, 24:28, 35:9, 40:6
legitimately [5] - 11:20, 14:13, 18:16, 28:1, 35:24
lengthy [1] - 46:5
leniency [4]-72:9, 73:13, 78:10, 80:12
less [1]-17:14
lesser [2] - 74:20, 79:5
letting ${ }_{[1]}$ - 14:24
level [3]-7:24, 7:27, 72:21
liaised [1] - 30:3
liaising $[1]$ - 35:10
licensed [6]-17:10, 34:12, 34:20, 37:27, 38:27, 55:27
life [3] - 78:17, 79:14, 83:23
light [2] - 64:18, 73:20
likely [3]-61:12, 79:15, 83:11
limitations [1] - 39:2
limited [4] - 11:24, 24:15,
78:19, 79:1
line [3] - 75:19, 75:29, 79:25
list [2]-7:13, 13:9
listed [10] - 30:19, 31:10, 51:11, 51:15, 53:9, 53:11, 57:3, 59:10, 60:4, 64:6
listen [1] - 65:2
listening [1]-48:23
literature [1] - 52:25
locate [4]-15:8, 15:11, 15:12
logger [4]-46:12, 68:29,
68:30, 86:12
look [6] - 11:9, 11:18,
25:30, 71:26, 75:11,
76:17
looked [2] - 30:26, 44:11
looking [7]-6:20, 13:21,
22:22, 37:6, 61:22,
63:28, 71:16
looks [13]-4:12, 16:15,

16:18, 21:7, 69:26,
73:29, 74:2, 75:4, 75:29,
76:18, 77:5, 77:12,
79:21
loquitur [2] - 62:27, 62:28
lose [1] - 83:11
loss [1]-36:16
lost [1]-83:10
lovely [1]-85:17
lower [1] - 51:23
Ltd [2]-1:28, 88:5
lunch [6] - 67:30, 68:2,
68:3, 68:8, 69:11
LUNCHEON [2] - 68:16, 68:18
Lynch [3]-61:28, 66:23, 67:1

| $\mathbf{M}$ |
| :--- |
| main $[2]-16: 8,35: 12$ |
| maintain $[2]-73: 7,73: 9$ |
| maintained $[1]-26: 10$ |
| major $[1]-11: 29$ |
| majority $[1]-31: 21$ |
| man $[2]-83: 8,83: 9$ |
| management $[12]-6: 6$, |
| $6: 7,6: 9,6: 16,51: 2$, |
| $51: 3,57: 15,57: 16$, |
| $57: 27,59: 22$ |

manager [2] - 5:3, 15:7
MANDA [1] - 2:5
manufacturers [1] - 15:24
March [2]-26:21, 26:24
Mark [1] - 1:19
market [1]-55:28
markets [1]-28:11
material [1] - 38:30
matter [18]-5:19, 21:23,
28:30, 46:17, 46:29,
46:30, 52:28, 52:29,
57:8, 59:29, 62:12,
67:25, 67:27, 68:4,
69:30, 78:5, 79:23,
85:13
matters [7]-43:4, 53:26, 70:2, 74:15, 81:6, 84:9, 86:22
maximum [1] - 39:3
McCrystal [16] - 2:7, 47:7,
47:17, 47:18, 47:22,
47:26, 47:28, 48:26,
55:6, 65:11, 67:7, 67:16,
67:21, 77:13, 77:24
McDonnell [3] - 5:4, 5:12, 33:23
mean [4]-17:16, 62:27, 81:13, 85:22
means [1] - $58: 9$
Medical [4]-52:26, 71:23, 71:27, 72:10
medical [4]-34:14, 38:11, 78:19, 78:20
medication [13]-10:24,

11:2, 11:4, 51:24, 52:11, mentioned [2]-31:26, 52:12, 52:17, 52:18,
61:17, 65:5, 65:7, 65:9
medications [3] - 51:6,
57:21, 76:30
medicinal [7]-17:9,
33:19, 34:8, 34:11,
35:15, 58:19, 59:16
medicine [39]-7:9, 7:12,
$7: 14,7: 25,8: 5,10: 22$,
10:28, 11:2, 11:5, 12:3,
12:18, 13:17, 13:24,
14:4, 14:13, 15:15,
16:19, 17:8, 18:26, 19:9,
28:1, 28:8, 29:8, 31:24,
32:2, 32:12, 32:14,
33:27, 36:27, 36:30,
38:22, 38:26, 38:29,
39:9, 39:24, 40:8, 40:13,
55:28, 59:10
medicines [108] - 5:6, 5:9,
6:7, 6:23, 6:24, 6:26,
6:27, 7:6, 7:11, 7:19,
7:24, 10:9, 10:12, 11:16,
11:19, 11:20, 11:25,
11:28, 12:2, 12:17,
13:10, 13:21, 14:17,
14:29, 15:1, 15:6, 15:9,
15:23, 15:27, 16:1, 16:5,
16:10, 16:13, 17:29,
19:2, 21:20, 23:12, 24:5,
24:7, 24:16, 24:18,
24:20, 24:21, 24:26,
25:1, 27:13, 27:20,
27:22, 30:8, 30:14,
30:15, 30:19, 30:23, 30:26, 31:10, 31:11, 31:13, 31:22, 32:4, 32:20, 32:23, 32:25, 32:26, 33:24, 33:27,
34:5, 34:9, 34:17, 34:18, 34:20, 34:30, 35:5, 35:8,
35:10, 35:12, 35:18,
35:21, 35:23, 35:25,
36:5, 36:8, 36:12, 36:14,
36:15, 36:21, 36:25, 37:10, 37:13, 37:27, 38:3, 38:10, 38:17, 38:28, 40:5, 50:27, 51:4, 57:3, 57:17, 58:11, 58:16, 59:13, 59:25, 60:1, 64:6, 64:15, 78:1
Medisource [3]-35:14,
35:19, 38:2
meet [3]-37:30, 52:24, 85:30
meeting [2] - 67:4, 68:27
member [1]-1:19
members [9]-45:8, 67:15,
72:5, 73:10, 78:28,
79:19, 84:4, 84:17,
85:30
Members [1]-1:18
mention [1] - $52: 8$

39:9
messages [8] - 61:20,
62:22, 62:26, 62:30,
63:19, 64:11, 75:20,
75:21
Mesterolone [2] - 36:28 52:3
met [2]-5:19, 54:22
metabolism [1] - 39:11
meth [1]-39:1
Methamphetamine [1] 38:30
Methylphenidate [1] 18:26
methylphenidate [1] -
61:9
mg [10]-12:4, 21:4, 24:22,
24:30, 25:10, 27:14,
27:25, 28:5, 41:13,
61:10
microgram [2]-17:12
micrograms [2]-51:23
microphone [2]-4:9, 4:17
might $[16]-4: 3,4: 12$,
12:13, 14:22, 17:26,
20:9, 24:21, 29:1, 33:12,
40:1, 43:14, 44:23,
44:27, 57:28, 60:18,
82:23
mind [1] - 80:23
minute [1]-61:21
minutes [3]-28:29, 75:21, 86:1
mirrors [1] - 39:7
misconduct [29]-48:21,
48:25, 49:6, 49:10,
49:28, 49:29, 50:7,
50:16, 52:24, 52:29,
53:19, 54:21, 54:29, 55:8, 56:17, 56:19,
56:29, 58:25, 59:5,
60:14, 61:3, 63:6, 63:17,
65:12, 65:30, 66:5, 66:9,
72:1, 85:10
missed [1] - 14:22
missing [1] - 51:25
Misuse [6] - 18:28, 33:9,
55:18, 55:29, 62:5, 63:3
misuse [7]-7:17, 7:18,
7:20, 18:29, 24:25,
32:17, 32:27
misused [1]-36:19
mitigate [1] - 72:18
mitigated [1] - 79:13
mitigating [1] - 83:2
mitigation [12]-72:14,
73:15, 76:13, 78:5,
78:11, 78:25, 79:17,
80:12, 84:8, 84:13,
84:14, 84:19
mobile [1]-5:8
models [1] - 56:5
moment [3]-23:1, 68:28,

85:20
moments [1] - 86:3
Monday [1] - 23:23
months [1] - 65:1
moral [2] - 50:1, 53:7
Moran [1] - 15:8
morning [2]-3:9, 3:12
morphine [2] - 7:26, 32:17
morphine-type [1]-7:26
most [2]-34:17, 36:18
move [7]-38:22, 40:3,
49:22, 49:26, 50:23,
53:17, 56:27
moving [6] - 25:23, 28:30,
37:24, 40:4, 55:6, 59:3
MR ${ }_{[39]}-1: 10,3: 6,3: 26$,
4:17, 4:25, 9:21, 9:25,
17:21, 17:25, 44:28, 44:29, 45:5, 45:9, 45:26, 46:17, 46:29, 47:17,
67:13, 67:23, 69:5,
69:10, 69:17, 69:20,
69:23, 81:13, 81:15,
84:1, 84:6, 84:11, 84:23, 84:28, 85:6, 85:7, 85:11, 85:12, 85:22, 85:26, 87:1, 87:2
MS [13]-3:8, 3:11, 3:16, 3:30, 4:8, 17:23, 45:14, 45:29, 46:12, 68:21, 68:26, 68:30, 86:10
MURPHY ${ }_{[12]}-3: 26,9: 21$, 44:28, 45:5, 67:13, 69:17, 69:20, 81:13, 81:15, 85:11, 85:26, 87:1
Murphy [21] - 3:29, 4:21, 9:17, 44:26, 45:1, 45:7, 46:12, 67:8, 67:28, 69:12, 69:19, 71:24, 75:30, 79:23, 79:25, 80:16, 80:17, 81:14, 83:29, 84:10, 85:7
Murphy's [1] - 76:25
muscle [2]-36:16, 37:5 must [10]-34:10, 49:11, 51:5, 57:20, 58:2, 75:13, 77:9, 78:15, 79:12
muted [1] $-47: 16$

| N | November [2] - 28:23, 44:22 |
| :---: | :---: |
| $\begin{gathered} \hline \text { name }[6]-13: 22,14: 2, \\ 14: 3,15: 2,26: 6,74: 4 \\ \text { named }[1]-26: 22 \\ \text { namely }[2]-16: 6,35: 26 \\ \text { narrative }[2]-47: 8,58: 14 \\ \text { nasal }[1]-39: 15 \\ \text { nature }[11]-38: 25,50: 2, \\ 53: 8,54: 10,60: 7,63: 23, \end{gathered}$ | $\begin{aligned} & \text { NUMBER }[2]-1: 10,1: 11 \\ & \text { number }[16]-10: 20, \\ & 12: 16,13: 16,15: 6, \\ & 20: 17,21: 2,31: 18, \\ & 32: 25,35: 5,38: 8,41: 19, \\ & 46: 21,53: 6,72: 30, \\ & 79: 15,81: 18 \\ & \text { numbers }[1]-73: 4 \end{aligned}$ |
| $\begin{aligned} & 71: 7,71: 30,74: 1,74: 19, \\ & 75: 11 \end{aligned}$ | 0 |
| nearly [1]-52:15 necessary [6] - 22:20, | $\begin{aligned} & \hline \text { O'Brien [1] - 1:30 } \\ & \text { o'clock [2] - 46:7, 68:11 } \end{aligned}$ |

41:7, 44:30, 47:4, 75:15, 84:21
need [4]-25:22, 26:26, 41:2, 78:26
needed [1] - 15:29
needs [4]-34:16, 38:11,
41:7, 44:19
nervous [1]-18:27
net [2]-46:25
never [1]-42:1
NEVIN $[5]$ - 2:5, 3:11, 3:16, 3:18, 45:14
Nevin [30] - 3:6, 3:8, 3:9,
3:27, 4:1, 4:8, 4:18, 17:16, 17:26, 20:5, 25:11, 25:27, 28:12, 28:24, 36:11, 38:16, 40:29, 41:10, 43:3, 44:17, 44:29, 45:5, 45:8, 45:10, 45:30, 47:9,
50:23, 53:28, 77:1, 77:7
Nevin's [3]-3:5, 44:18, 76:18
new [1]-26:25
next $[7]$ - 13:3, 46:15, 46:30, 47:1, 49:24,
51:10, 57:18
Ni ${ }_{[1]}-72: 13$
nine [2] - 38:6, 42:28
nobody [2] - 68:12, 77:23
none [4]-15:10, 35:25,
67:17, 84:4
nonprescription [1] - 40:8
nonsteroidal [1] - 64:7
normal [2]-64:23, 67:6
normally [3] - 6:21, 51:22, 67:5
note [2] - 49:9, 53:18
noted [9]-11:7, 17:28, 20:16, 21:28, 23:4, 23:17, 38:5, 42:8, 42:13
nothing [3] - 45:28, 83:25, 83:30
Notice [13]-50:9, 50:14, 53:2, 53:17, 54:29,
58:26, 59:3, 60:15, 63:9,
63:15, 65:13, 85:1, 85:3
notice [1] - 21:6
notification [1] - 54:8
November [2] - 28:23, 44:22

NUMBER[2]-1.10,1.11 12:16, 13:10, 15:6, 12:16, 13:16, 15:6, 20.17, 21.2, 31.18, 32:25, $35: 5,38: 8,41: 19$ numbers [1] - 73:4
o'clock [2] - 46:7, 68:11

O'Connell [4]-1:20,
17:18, 45:28, 84:24
O'CONNELL [2] - 17:23, 45:29
O'Malley [2] - 1:28, 88:5
O'Meara [66] - 3:26, 5:2,
5:5, 5:10, 5:20, 6:13,
10:14, 10:16, 12:22,
13:14, 13:22, 20:14, 23:17, 23:25, 24:3, 24:5, 32:4, 32:11, 32:28, 33:14, 38:7, 38:18, 42:14, 42:26, 43:1, 45:15, 45:16, 45:22, 45:25, 48:11, 49:15, 49:30, 50:29, 51:5, 53:4, 54:15, 57:11, 57:12, 57:19, 61:8, 61:22, 62:23, 63:1, 63:28, 64:10, 66:10, 66:19, 72:23, 73:23, 75:25, 76:3, 76:14, 77:19, 77:28, 78:13, 78:30, 80:11, 80:14, 80:21, 81:27, 82:17, 82:22, 83:5, 83:22, 83:26
O'MEARA [1] - 1:10
O'Meara's [13] - 5:6, 11:3,
33:25, 35:6, 57:4, 59:11, 61:18, 66:4, 75:6, 76:25, 81:30, 83:1
oath [2] - 3:15, 47:23
objective [1]-71:28
obligation [1] - 72:8
obtain [10] - 16:16, 21:24, 21:26, 24:15, 24:17, 30:14, 34:29, 35:16, 37:2, 79:12
obtained [21] - 6:29, 11:1, 11:26, 13:18, 13:20, 17:30, 24:16, 26:8, 26:9, 27:4, 28:20, 30:9, 31:1, $33: 15,34: 6,34: 12,35: 8$, 35:11, 39:19, 40:5, 40:14
obtaining [5] - 10:22, 10:23, 10:27, 30:7, 34:23
obviously [12] - 22:19, 47:11, 48:23, 48:28, 49:15, 61:22, 65:2, 70:6, 71:26, 72:20, 73:9,
73:16
occasion [2] - 42:2, 45:14 occasionally [2] - 28:10, 36:23
occasions [2] - 42:30 occurred [2] - 10:3, 76:10 OCTOBER [2] - 1:15, 3:1 October [9]-8:22, 29:9, 35:3, 39:26, 40:21, 41:28, 43:25, 43:28, 44:12
OF [2] - 1:2, 1:5
offence [6] - 62:8, 71:6, 71:7, 72:5, 72:18, 78:28 offences [3] - 48:20, 66:8, 76:9
offending [1] - 83:1
officer [4]-4:29, 4:30,
10:6, 15:21
officer's [1] - 9:6
officers [4]-5:25, 30:18,
50:20, 54:19
offices [1] - 21:27
often [2] - 51:22, 51:25
omission [1] - 49:11
ON [2] - 1:15, 3:1
once [5] - 4:19, 4:20,
22:29, 72:2, 72:19
once-off [1] - 72:19
one [46]-4:3, 13:15,
13:23, 16:15, 16:18,
17:28, 18:11, 18:16,
20:24, 21:7, 26:17, 27:4,
32:4, 39:5, 43:23, 43:24, 45:9, 49:26, 49:30, 50:6, 51:18, 52:14, 53:14, 54:28, 57:18, 58:1, 65:20, 69:26, 70:17, 72:5, 72:21, 72:22, 73:29, 74:1, 75:4, 75:18, 75:20, 75:29, 76:18, 77:5, 77:12, 79:21, 80:13
ones [1] - 41:4
onwards [1] - 16:24
open [1]-15:3
operate [3]-64:19, 73:11, 74:6
opinion [23] - 48:1, 48:14, 48:24, 51:8, 54:14, 54:21, 56:10, 56:12, 56:13, 56:14, 56:16, 58:22, 59:1, 59:18,
59:19, 59:20, 60:13,
64:16, 65:22, 65:23,
66:28, 66:29, 71:6
opportunity [1] - 69:14
options [1] - 71:12
order [22]-7:1, 12:16, 24:1, 33:17, 34:14, 34:17, 34:19, 34:21, $35: 19,37: 30,38: 1,38: 3$, 38:4, 38:5, 38:10, 38:18, 42:20, 42:22, 42:24, 78:26, 84:20
ordered [9]-23:12, 23:13, 23:29, 24:3, 24:5, 36:4, 38:17, 42:17, 60:9 orders [7] - 37:25, 38:20, 42:9, 42:11, 43:1
otherwise [1] - 62:17
ourselves [1] - 10:15
outgoing [1] - 24:28
outline [1] - 4:25
outlined [2] - 58:23, 86:19
outlining [1] - 30:8
outside [3] - 65:9, 67:5, 67:6
over-the-counter [2] -
38:26, 39:16
overall $[9]-6: 6,6: 14,7: 8$,
29:6, 43:21, 51:1, 57:14, 65:27, 66:4
Overall [1] - 65:21
overlooked [1] - 75:6
own [2] - 83:8, 83:9
owner [6] - 58:2, 58:18,
59:15, 70:19, 71:9, 73:24
owns [1] - 80:28

| $\mathbf{P}$ |
| :--- |
| pack $[3]-32: 10,39: 3$, |
| $39: 5$ |
| packets $[1]-61: 16$ |
| packs $[23]-19: 11,19: 12$, |
| 19:14, 19:15, 19:18, |
| 19:21, 19:23, 19:27, |
| 20:3, 23:6, 23:10, 24:1, |
| $27: 4,27: 27,27: 28,28: 4$, |
| $36: 6,36: 7,37: 15,42: 10$, |
| $43: 22,52: 15$ |

page [50] - 9:15, 10:1,
13:25, 13:28, 20:24, 26:4, 26:16, 26:19, 27:3, 28:25, 29:15, 29:16, 46:20, 48:7, 50:12, 50:24, 52:30, 53:30, 54:27, 55:24, 55:25, 56:17, 56:28, 58:15, 58:30, 59:4, 59:24, 60:27, 62:3, 63:22, 65:21, 65:25, 66:3, 66:16, 66:18, 73:4, 73:12, 73:15, 73:18, 73:30, 74:2, 75:19, 75:29, 77:15, 77:24, 79:24
Page [1]-2:3
pages [3]-23:22, 26:12, 43:23
painkiller [1] - 32:15
pandemic [1]-65:2
Paracetamol [1] - 32:16
paragraph [59] - 9:30, 12:9, 16:15, 16:18, 16:21, 16:24, 17:5, 21:7, 21:10, 21:13, 23:2, 24:12, 29:14, 29:17, 30:3, 30:20, 30:27, 33:2, 36:3, 37:24, 41:12, 41:17, 41:23, 41:24, 42:3, 42:27, 45:20, 48:13, 48:15, 48:26, 49:2, 49:9, 49:14, 49:27, 50:13, 50:17, 50:26, 51:11, 52:21, 54:14, 55:7, 56:2, 57:7, 58:15, 59:4, 62:21, 63:23,

65:26, 66:3, 66:15,
66:18, 73:4, 76:20,
76:21, 76:29, 77:5, 80:5, 80:8
paragraphs [7]-11:9,
36:11, 38:23, 53:24,
60:15, 73:21, 74:30
parameters [1] - 12:28
pardon [2] - 14:22, 81:14
part [2] - 49:24, 58:3
Part [1] - 5:1
participate [1] - 56:7
particular [12]-7:12, 11:5,
13:7, 14:8, 20:19, 52:1,
58:1, 61:15, 64:18, 65:4,
73:26, 86:2
particularly [4]-32:26, 37:9, 39:21, 75:10
parties [6] - 49:14, 63:1,
63:27, 64:10, 65:10, 84:27
pass [2]-3:20, 4:14
patience [1] - 86:15
patient [17]-7:13, 10:24,
11:2, 11:3, 11:4, 11:5, 14:2, 14:3, 14:5, 14:6, 26:7, 26:22, 34:15, 34:16, 38:12, 39:6, 41:14
patients [3] - 18:9, 28:2, 54:8
pattern [2] - 53:5, 56:21
Pause [1]-4:6
people [2]-36:18, 61:22
per [3]-31:16, 39:5, 49:8
perfect $[4]-4: 5,9: 2$, 47:15, 68:6
performance [6] - 36:20,
37:4, 37:13, 37:23,
39:10, 59:28
perhaps [2] - 32:28, 82:10
period $[43]-7: 9,7: 13$,
11:6, 12:7, 12:20, 14:15, 16:14, 16:21, 18:2, 18:3, 27:27, 29:1, 29:2, 29:3,
29:5, 29:6, 29:7, 29:18, 29:29, 29:30, 30:2,
30:16, 30:23, 30:24, 31:12, 31:13, 32:22,
35:1, 36:4, 41:27, 42:1, 42:3, 42:6, 70:26, 70:28, 71:17, 76:2, 79:1, 79:4, 82:21, 83:22
persistent ${ }_{[1]}-74: 9$
person [8]-24:5, 24:6, 51:5, 56:11, 57:19, 62:9, 62:11, 62:15
personal [5]-56:10,
56:12, 56:14, 61:13, 62:14
persons [1] - 62:25
petition [3]-80:4, 80:6, 80:8
pharmaceutical [2] -

15:24, 23:27
Pharmaceutical [2] - 4:28, 78:14
PHARMACEUTICAL[2] 1:2, 1:5
pharmacies [4]-5:10,
15:28, 73:11, 80:24
Pharmacies [1] - 50:21
pharmacist [53]-4:27,
5:11, 6:5, 6:8, 6:9, 6:13, 6:15, 6:16, 8:12, 23:16, 23:18, 23:26, 23:27, 24:4, 33:14, 34:21, 34:27, 34:28, 37:11, 38:8, 42:14, 42:28, 43:1, 45:17, 50:4, 50:29, 53:9, 55:19, 56:10, 56:15, 57:12, 57:13, 57:14, 60:2, 60:6, 60:12, 64:25, 64:28, 65:8, 67:2, 70:18, 70:22, 71:5, 71:8, 73:23, 74:6, 75:9, 78:2, 78:4, 79:30, 80:10, 83:19
Pharmacist [5] - 1:20, 50:30, 51:1, 58:19, 59:16
pharmacists [14] - 56:5, 56:23, 64:15, 64:17, 64:18, 64:20, 64:30, 65:3, 65:4, 65:7, 66:12, 66:20, 78:1, 83:21
Pharmacists [1] - 56:7
pharmacists' [1]-83:15
pharmacy [174]-5:26,
5:30, 6:2, 6:4, 6:6, 6:8, 6:10, 6:17, 6:23, 6:25, 6:30, 7:4, 7:6, 7:9, 7:12, 7:28, 8:2, 8:6, 8:7, 8:13, 10:10, 10:12, 10:15, 10:22, 10:25, 11:15, 11:19, 11:21, 11:26, 11:28, 12:1, 12:6, 14:14, 14:18, 15:1, 15:2, 15:7, 15:9, 15:15, 15:27, 15:29, 16:14, 18:2, 18:6, 18:9, 18:12, 18:16, 18:17, 18:18, 18:19, 18:22, 19:4, 19:5, 19:10, 19:13, 19:14, 19:21, 19:29, 20:4, 20:13, 20:15, 20:16, 20:18, 20:29, 21:3, 21:19, 22:11, 22:12, 24:7, 24:16, 24:20, 24:29, 25:2, 25:20, 28:1, 28:3, 30:15, 31:8, 31:11, 32:5, 32:12, 32:19, 32:21, 32:26, 32:29, 33:10, 33:29, 34:4, 34:6, 34:10, 34:12, 34:13, 34:17, 34:26, $35: 1,35: 7,35: 9$, 35:23, 35:28, 35:29, 36:4, 36:9, 36:10, 37:11, 37:30, 39:21, 39:23,

39:28, 39:29, 40:6, 40:7, 40:17, 40:20, 40:25, 40:29, 41:13, 41:14, 41:20, 42:1, 42:12, 42:25, 43:2, 43:22, 44:6, 44:9, 44:11, 44:15, 45:24, 51:2, 51:21, 51:26, 52:6, 52:9, 52:12, 52:19, 54:4, 54:5, 54:7, 55:21, 56:9, 56:11, 57:15, 57:28, 58:2, 58:6, 58:9, 58:10, 58:12, 58:17, 58:18, 59:14, 59:15, 59:22, 60:8, 64:21, 66:11, 66:24, 70:19, 70:22, 71:5, 71:9, 73:7, 73:8, 73:22, 73:24, 73:25, 74:6, 76:22
Pharmacy [25]-5:1, 5:14, 5:17, 5:24, 6:14, 10:7, 10:8, 12:20, 16:10, 20:21, 20:23, 27:13, 27:26, 28:6, 30:9, 35:18, 35:20, 41:27, 43:21, 44:4, 50:28, 50:30,
57:11, 57:13, 57:25
Phenergan [2]-15:11, 15:12
physical [1] - 36:21
piece [1] - 82:4
PIEDs [1] - 59:28
place [10]-8:4, 34:19, 65:6, 68:29, 68:30, 81:29, 82:28, 83:14, 83:16, 83:26
placed [6]-37:25, 38:20, 42:11, 42:23, 42:24, 42:29
places [1]-13:16
point [14]-10:18, 21:15,
25:14, 25:18, 32:30,
40:12, 43:20, 72:4,
81:12, 81:17, 84:5,
86:19, 86:25
pointed [1] - 86:27
points [1]-83:26
poor [1]-64:21
portions [2] - 62:1, 77:13
position [18]-21:8, 51:9,
57:23, 57:24, 65:4,
67:29, 71:2, 73:22,
80:16, 80:17, 81:22, 81:30, 82:22, 82:25, 83:7, 86:9
positions [1]-6:4
possess [1] - 55:21
possessed [1] - 62:11
possession [6] - 55:20,
61:11, 62:2, 62:6, 62:9, 62:16
possibility [1] - 10:11
possible [2] - 5:9, 72:9
possibly [1]-22:27
potential [6]-7:20, 18:29,

24:25, 32:27, 39:1, 39:13
potentially [1]-7:1
powers [2]-5:26
practice [3] - 67:6, 70:23,
72:2
practise [2] - 80:5, 80:6
practitioner [4]-34:14,
38:11, 72:1, 72:8
precious [1] - 4:15
precursor [1]-38:30
prejudice [1]-80:14
premises [3]-58:5, 59:21, 61:24
preparation [1]-85:14
prepare [1] - 86:20
prepared [4]-8:29, 13:9,
14:28, 29:24
prescribed [6]-10:20,
10:30, 17:15, 32:30,
36:22, 36:23
prescription [10]-7:29,
32:6, 39:6, 40:23, 57:3,
57:22, 58:16, 59:10,
59:13, 64:6
prescription-only [3] -
57:3, 59:10, 64:6
prescriptions [7]-10:18,
10:23, 10:27, 11:1,
40:10, 60:10
presence [1] - 84:27
present [9]-14:18, 20:16,
20:28, 35:6, 36:10,
40:20, 46:12, 69:2, 74:18
presentation [1]-20:15
presented [5] - 10:6,
15:28, 70:1, 78:16, 85:15
presents [2]-7:7, 30:22
President [1] - 71:24
presumed [1] - 62:15
presuming [1] - 70:3
presumption [1] - 69:25
previous [3]-27:3, 29:28, 30:6
previously [4] - 10:21, 31:2, 35:14, 42:9
primarily [2]-6:26, 50:27
primary [2]-71:28, 75:13
principle [3] - 53:10, 53:11
principles [11] - 50:4,
53:12, 53:13, 55:2,
56:23, 60:20, 63:13, 65:16, 71:21, 71:26, 72:9
PRIVATE [1] - 1:8
private [4]-57:4, 59:11, 60:2, 86:1
Pro [1]-59:27
Pro-viron [1] - 59:27
problem [4]-17:28,
43:19, 45:14, 69:7
procedures [2] - 57:26, 59:21
proceed [2]-21:22, 47:14
Proceedings [1] - 2:3
proceedings [1] - 88:2
PROCEEDINGS [1] - 3:1
process [3] -9:13, 74:22, 81:3
procured [1] - 57:10
product [2]-17:9, 34:11
Product [1]-15:22
production [1] - 38:30
products [7]-23:8, 33:19,
34:9, 34:23, 35:16,
58:19, 59:16
profession [14]-4:27,
53:9, 56:9, 64:22, 66:11,
66:15, 72:5, 73:7, 73:11,
74:21, 83:11, 83:15,
84:17
professional [43]-38:8,
48:20, 48:25, 49:5,
49:10, 49:28, 49:29,
50:1, 50:3, 50:7, 50:16,
51:3, 52:24, 52:29, 53:6,
53:19, 54:21, 54:28,
55:8, 56:13, 56:14,
56:17, 56:19, 56:22,
56:28, 57:16, 58:25,
59:5, 60:13, 61:3, 63:6,
63:16, 64:15, 65:12, 65:30, 66:5, 66:9, 66:22, 73:10, 74:28, 79:9,
83:23, 85:10
PROFESSIONAL [1] - 1:4
proffered [2]-82:5, 82:12
prohibition [12]-70:28,
71:17, 75:3, 75:15, 78:7, 79:6, 80:19, 80:22,
80:27, 81:4, 84:7, 84:20
promote [3]-73:5, 73:6, 73:9
proper [1]-73:10
proportionality [1] - 73:13
propose [6] - 47:10,
48:27, 49:25, 69:17,
70:9, 73:12
Proscar [1]-59:29
protect [6]-71:28, 73:5, 74:11, 78:27, 79:17, 84:20
protecting [1] - 81:2
protection [3] - 71:28,
75:14, 84:15
proven [7]-50:18, 53:22,
55:9, 57:2, 59:8, 61:6,
62:9
provide [12] - 11:27, 16:2,
16:4, 30:28, 33:22,
34:22, 38:2, 48:5, 48:26,
49:6, 56:6, 58:2
provided [12] - 8:12,
11:23, 15:18, 15:19,
16:20, 33:23, 33:24,

42:7, 44:2, 44:20, 49:20, 62:22
providers [1] - 36:15
provides [2] - 5:25, 70:10
providing [1] - 43:21
Proviron [5] - 35:26, 36:7, 36:26, 36:27, 37:15
Pseudoephedrine [5] -
38:27, 39:4, 39:6, 39:14, 77:16
PSI [14] - 4:29, 4:30, 5:25, 6:3, 6:12, 10:6, 21:27,
30:18, 48:10, 50:19,
54:19, 58:13, 82:5,
82:13
PSI's [1] - 81:22
public [21]-56:9, 64:17, 64:19, 64:21, 64:27, 64:29, 65:3, 65:8, 66:15, 71:29, 73:5, 73:6, 73:7, 74:18, 75:14, 78:3, 78:27, 79:18, 81:2,
84:15, 84:20
PUBLIC [1] - 1:4
public.. [1]-74:11
purples [1]-64:1
purpose [13]-10:8, 10:16,
19:8, 37:13, 37:18,
39:17, 62:17, 75:15,
78:21, 79:3, 79:4, 79:12, 81:2
purposes [4] - 3:26, 39:2, 58:5, 82:9
put [23]-12:13, 13:5, 14:20, 14:23, 14:25, 20:9, 23:21, 28:23, 28:28, 28:29, 29:20, 40:1, 41:6, 43:14, 44:1, 44:21, 46:23, 68:12, 72:28, 73:1, 73:2, 82:19
putting [1]-8:26
$\mathbf{Q}$
qualification [1] - 4:26
quantities [24]-6:27, 7:2,
7:8, 11:18, 11:19, 11:27,
16:5, 16:9, 16:19, 24:15,
24:28, 27:1, 27:14, 30:1,
34:5, 34:17, 36:8, 37:9,
37:22, 38:19, 42:29,
52:5, 61:19, 77:2
quantity [25]-7:14, 8:5,
12:17, 12:18, 14:5,
14:18, 15:3, 15:14,
$15: 15,18: 3,19: 4,19: 5$,
19:29, 22:6, 37:19, 39:3,
41:30, 42:15, 54:16,
61:9, 61:11, 62:10, 77:6, 77:8
quarter [3] - 68:9, 68:12, 68:14
queries [1] - 27:7
questioned [2] - 82:6,

82:8
questions [20] $-4: 19$, 4:20, 4:22, 4:23, 13:1, 14:8, 20:26, 45:1, 45:5, 45:8, 45:26, 48:29, 67:9, 67:10, 67:13, 67:15, 67:16, 84:3, 84:5, 86:18
quick [3] - 4:1, 68:23, 68:26
quickly [1] - 10:17
quite [10]-10:16, 24:24,
27:16, 47:1, 47:3, 52:16, 72:22, 77:22, 79:25, 82:19

## R

Raifeartaigh [1] - 72:13
raised [5] - 5:8, 10:10, 39:23, 66:22, 66:30
ramifications [1] - 75:25
range [1]-11:18
rarely [1]-54:5
rather [2]-31:22, 82:11
rationale [1]-71:20
RE [1]-1:10
reach [1]-83:23
reached [1]-52:27
read [7]-60:20, 61:29, 62:1, 63:24, 66:27, 70:8, 71:2
readily [1] - 56:24
reading [1] - 70:9
ready [1] - 69:3
real [2]-78:11, 84:14
realistic [3]-80:1, 82:1, 82:22
really [8] - 37:14, 47:10, 62:29, 75:7, 77:22,
77:26, 85:13
reapplication [1] - 80:27
reapply [1] - 80:23
reason [8]-50:17, 53:21, 60:11, 70:5, 72:17, 80:20, 80:21, 80:22
reasonable [1] - 62:13
receipt [4]-25:8, 26:23, 26:24, 33:6
receipts [3] - 20:18, 21:3, 26:22
received [14]-7:2, 19:26, 25:5, 25:6, 25:21, 27:19, 27:21, 28:18, 30:4, 30:19, 31:6, 35:20, 36:8, 38:3
recent [1]-26:12
reception [1] - 17:18
reckless [1] - 74:8
recommence [1]-69:8
recommend [1] - 82:2
recommendations [3] -
70:4, 71:13, 72:16
recommending [1] - 77:10
reconcile [2] - 30:13,

44:13
reconciliation [5]-21:17, 24:27, 27:22, 31:9, 42:18
reconciling [3] - 28:4, 40:19, 40:23
reconvene [2]-3:4, 68:14
record [23]-6:12, 8:12,
10:24, 11:3, 11:4, 11:8,
26:5, 27:4, 42:13, 61:29,
62:2, 81:18, 81:29,
82:28, 83:6, 83:12,
83:14, 83:16, 83:27, 85:24, 85:26, 88:2
record] [1] - 4:6
recorded [21] - 8:3, 11:2,
11:20, 12:19, 14:13, 18:10, 19:3, 19:19, 19:24, 22:13, 23:17, 23:27, 26:20, 33:16, 39:22, 40:11, 40:15, 42:27, 44:8, 44:13
recording [2] - 10:24, 33:5
records [13]-11:7, 19:1,
19:18, 19:20, 23:16,
26:6, 35:28, 36:9, 40:8,
40:9, 40:13, 40:21,
41:12
redacted [1] - 14:3
refer [24]-13:3, 29:17,
33:10, 37:24, 41:22,
49:27, 50:21, 53:27,
54:1, 54:11, 54:25,
55:12, 56:12, 56:18,
56:19, 57:2, 57:25,
60:19, 66:20, 66:23,
70:8, 72:27, 74:30, 75:17
REFERENCE [1] - 1:11
reference [1]-12:10
referenced [1] - 35:13
referred [4]-41:5, 46:22,
54:22, 56:17
referring [1] - 9:18
refers [5] - 9:5, 65:26,
73:19, 76:19, 77:25
reflection [1]-64:21
refreshingly [1] - 85:16
refuse [1]-71:10
regard [5] - 15:30, 43:8, 62:10, 64:20, 66:10
regarding $[17]-5: 5,5: 9$, 10:11, 11:25, 15:26, 16:1, 16:5, 16:9, 16:13, 24:15, 27:12, 27:20,
33:4, 34:5, 34:29, 35:17, 41:19
regards [6] - 14:27, 44:25, 44:26, 50:12, 60:13, 60:19
Register [29]-7:16, 8:9, 8:10, 8:11, 19:3, 19:7, 19:17, 19:21, 19:25, 22:5, 22:8, 22:9, 22:14,

22:23, 22:29, 23:7,
23:15, 23:18, 23:20,
24:2, 26:3, 33:6, 33:8,
33:10, 42:12, 42:19,
42:24, 54:17, 56:15
register [17]-8:3, 19:30,
20:1, 22:17, 23:11,
23:25, 24:8, 25:25, 26:5,
26:26, 27:3, 33:16, 54:9,
56:11, 70:29, 71:19,
74:5
registered $[15]-4: 27,6: 1$,
6:2, 34:14, 38:11, 58:9,
58:10, 58:12, 58:17,
59:14, 60:2, 60:12,
70:18, 74:28, 78:2
registers [1]-54:1
Registrant [5]-1:25, 4:21,
45:11, 45:13, 74:18
registrant [1] - 71:22
Registrant's [3] - 74:4, 74:27, 84:16
Registrar ${ }_{[14]}-1: 23,4: 18$,
27:17, 48:10, 67:24,
71:16, 77:27, 78:21,
79:2, 81:7, 82:5, 82:12, 82:17
Registrar's [4]-71:1,
80:18, 84:12, 84:13
REGISTRATION [1] - 1:10
registration [13]-38:8,
58:8, 70:21, 70:25,
70:27, 71:4, 71:9, 71:10,
71:17, 71:18, 74:3, 74:7, 79:29
regulate [1] - 15:23
Regulation [1] - 55:19
regulation [3]-7:18, 54:12, 73:8
Regulations [3]-18:29, 33:9, 57:25
regulations [4]-7:17, 62:18, 65:6, 65:9
regulator [1] - 15:23
regulatory [2] - 74:21, 81:2
Regulatory [1] - 15:22
reiterate [1]-81:24
reiteration [2]-33:4, 33:13
rejoined [1]-4:8
rejoining [1] - 4:2
relapse [5]-80:26, 80:30, 81:1, 81:23, 81:25
relate [1]-49:19
related [1]-6:26
relates [1] - 77:5
relation [60]-5:4, 5:19, 6:2, 10:4, 11:11, 13:2, 14:8, 16:16, 16:20, 16:26, 17:17, 20:26, 24:10, 24:11, 24:29,
25:24, 27:9, 28:15, 33:3, 33:21, 39:24, 40:6, 41:1,

41:10, 43:5, 43:6, 48:10,
48:14, 48:28, 48:29,
49:5, 49:21, 51:10,
51:14, 53:2, 53:26,
54:26, 55:6, 56:16, 57:6,
57:26, 58:25, 58:26,
59:20, 59:21, 60:23,
61:27, 62:5, 62:7, 62:20, 63:6, 63:12, 67:25,
69:24, 70:4, 74:12, 77:2,
77:15, 77:16, 77:27
relationships [1] - 85:18
relevance [2] - 11:12,
73:30
relevant [6]-29:2, 29:4,
49:19, 62:12, 71:3,
75:12
relief [1]-67:1
rely [5]-53:24, 55:14,
61:27, 63:19, 86:8
relying [3] - 55:3, 65:17, 73:20
remain [2]-29:4, 84:19
remained [1]-28:5
remains [9]-45:30, 48:24,
51:9, 57:24, 59:19,
67:17, 82:24, 84:25,
86:25
remarkable [1]-77:22
remember [1]-29:1
remind [2] - 49:16, 49:17
remorse [1] - 72:19
REMOTELY ${ }_{[1]}-1: 13$
removed [2] - 74:5, 79:30
repeated [1]-77:15
repeating ${ }_{[1]}-72: 1$
repetition [1] - 33:17
Report [12] - 13:4, 13:8,
13:11, 13:13, 13:18,
13:30, 14:1, 14:10, 18:8, 27:30, 29:18, 29:27
report [77]-9:6, 9:15,
9:16, 9:18, 9:30, 12:11,
12:15, 12:18, 12:27,
12:30, 13:2, 13:3, 16:15, 17:6, 21:7, 21:13, 21:22, 22:25, 25:5, 25:12, 27:9, 27:18, 28:16, 28:21,
28:26, 28:27, 29:3,
29:12, 29:13, 29:15,
29:29, 30:21, 31:27,
33:14, 33:17, 38:24,
41:24, 42:20, 43:23,
43:24, 43:26, 46:20,
46:21, 47:7, 47:11,
47:29, 47:30, 48:4, 48:8,
49:24, 50:12, 50:13,
50:24, 51:15, 51:16, 52:30, 53:18, 56:18,
57:30, 60:16, 60:27,
62:25, 65:20, 65:26,
66:16, 69:28, 69:29,
70:2, 70:11, 70:12,
76:19, 76:29, 77:12,

77:15, 85:15, 86:21
reported ${ }_{[2]}-72: 11,72: 12$
Reports [2]-7:10, 13:20
reports [10] - 8:29, 8:30,
13:14, 13:26, 35:8, 35:9, 35:23, 43:19, 44:10, 46:19
representations [1] 86:28
representing [1] - 81:22
request [2]-13:10, 16:18 requested $[11]-6: 25,7: 4$, 15:30, 16:3, 20:14, 27:11, 28:19, 29:28, 34:4, 34:27, 35:23
requesting [2] - 12:29, 35:21
require [1]-38:1
required [5] - 5:27, 33:8, 34:18, 34:21, 84:15
requirement $[1]$ - $34: 19$
requirements [2] - 58:20, 59:17
res [2]-62:27
research [1] - 36:26
researching [1] - 37:2
residence [7]-5:6, 33:25, 35:6, 57:4, 59:11, 60:2, 60:12
resisting [3]-82:18, 82:24, 83:27
resolve [2]-4:3, 74:15
resort [1]-74:7
respect [24]-25:30, 37:26, 48:11, 50:1, 52:23, 53:6, 56:22, 60:29, 63:20, 63:25, 66:19, 66:26, 69:25, 70:6, 72:23, 75:17, 81:23, 81:25, 81:30, 82:2, 82:17, 82:29, 84:6, 85:8
respectful ${ }_{[1]}-76: 11$
respective [2]-66:27, 85:18
Respondent [1] - 43:8
response [2] - 76:6, 76:7
responsibility [4]-51:6,
57:20, 58:18, 59:15
responsible [1] - 24:6
restoration [2]-70:29, 71:19
restrictions [1] - 70:23
result [5] - 12:2, 20:2,
31:15, 41:25, 42:25
resulted [1]-28:16
results [5] - 13:16, 13:17, 30:22, 31:12, 35:25
resume [2]-46:7, 86:9
RESUMED [1] - 68:18
resumed [1] - 72:2
retail [11]-55:21, 57:28,
58:6, 58:9, 58:12, 58:17, 59:14, 59:22, 60:7,

70:22, 71:5
retained [1] - 6:30
retire [2]-84:29, 85:14
return [1]-86:11
review [17]-10:9, 11:15,
12:1, 14:17, 14:30, 16:1,
18:7, 20:2, 20:16, 21:27,
27:20, 29:30, 30:8, 30:14, 33:28, 35:26, 38:18
reviewed $[24]-6: 25,7: 16$,
8:9, 8:10, 8:11, 8:17,
11:3, 11:23, 17:29, 19:7, 19:17, 22:3, 23:15, 24:26, 29:7, 35:5, 35:8,
36:1, 38:4, 39:26, 40:11, 42:4, 42:12, 48:22
reviewing [6]-6:22,
21:28, 23:3, 26:19,
39:19, 42:8
rightly [1]-79:25
risk [5] - 73:5, 74:18, 81:1, 81:24, 81:27
risks [1] - 84:19
Ritalin [44]-10:30, 11:7, 16:6, 16:26, 16:28, 18:25, 18:26, 18:30, 19:11, 19:18, 19:21, 19:23, 19:27, 19:29, 20:3, 20:7, 20:8, 21:6, 21:9, 21:11, 21:14, 21:23, 21:25, 22:6, 22:11, 22:17, 23:4, 23:6, 23:10, 23:28, 24:1, 24:18, 25:25, 25:30, 26:5, 27:15, 31:16, 33:5, 33:6, 33:15, 59:25,
61:10, 61:27
role [1] - 56:5
Ronan [1]-1:25
room [1]-86:1
rose [1]-31:18
running [3] - 8:5, 26:10
Ruth [2] - 5:3, 33:23
Ryan [13] - 47:9, 62:23,
63:20, 75:19, 75:23, 75:30, 76:7, 78:19, 79:24, 80:2, 82:9, 82:29
Ryan's [2] - 55:14, 57:6

## S

safe $[3]-8: 2,54: 7,54: 18$
safety [1] - 73:6
sale [24]-5:7, 6:22, 6:26, 10:9, 11:16, 24:6, 34:10, 34:20, 37:28, 39:3,
39:26, 39:28, 40:12,
40:28, 43:20, 51:4,
57:17, 58:19, 59:16, 62:3, 62:6, 62:24, 64:14, 78:1
sales [4]-40:11, 43:5, 43:23, 43:24
sanction [16] - 67:25,
69:11, 69:24, 70:4,
72:25, 74:4, 74:7, 74:20,
77:10, 78:7, 79:3, 79:5,
79:12, 80:19, 81:3, 82:18
sanctioning [1] - 71:21
sanctions [2]-70:18, 72:27
sanitise [1] - 78:26
sanitised [1] - 76:13
sat [1]-80:17
satisfied [2] - 62:13, 62:16
Saturday [1] - 23:24
save [1]-81:17
SC [2]-1:23, 1:25
scanned [1] - 40:13
scarier [1] - 44:19
Schedule [7] - 54:4, 54:5, 54:6, 54:16, 55:18, 55:20
schedule $[7]-7: 22,7: 24$,
7:27, 7:29, 18:27, 18:30, 64:3
Schedules [1]-54:1
schedules [1]-7:19
scheme [1]-7:17
screen [11]-3:25, 9:11,
9:12, 12:13, 14:23,
14:25, 20:9, 29:21,
43:14, 44:1, 44:21
scroll [8] - 13:25, 13:29,
22:19, 22:27, 26:4,
26:11, 26:14, 29:25
scrolling [3]-22:28,
26:14, 26:26
Seamus [2]-62:22, 62:23
search [3]-55:12, 57:4, 59:12
second $[23]-8: 22,12: 17$, 28:14, 28:16, 28:20, 29:9, 33:17, 34:2, 34:25, 35:3, 35:7, 39:25, 43:24, 46:30, 48:24, 50:26,
58:14, 65:22, 66:3,
66:18, 66:19, 83:18
Section [6]-5:13, 5:24,
10:7, 55:29, 58:8, 70:10
section [9] - 58:4, 62:7,
62:8, 62:19, 63:2, 69:27, 70:8, 70:9, 70:12
sections [1]-70:8
see $[87]-3: 9,3: 23,3: 24$,
4:10, 5:22, 5:28, 9:5,
9:6, 9:11, 11:9, 12:9,
12:15, 12:22, 13:1,
13:12, 13:15, 13:18,
14:2, 14:7, 15:2, 15:29,
17:22, 17:23, 20:24,
22:15, 23:22, 24:8,
24:11, 25:22, 26:5,
26:18, 26:20, 26:27,
26:29, 27:23, 28:12,
29:10, 30:3, 30:24,

30:27, 33:2, 35:30, 36:2, 37:6, 37:7, 37:11, 37:24, 38:14, 38:23, 40:28,
41:29, 42:3, 43:3, 43:30,
44:2, 46:12, 46:18,
47:18, 51:22, 51:23,
52:21, 56:16, 60:13,
63:2, 64:17, 64:20,
64:27, 65:3, 65:8, 65:21,
68:8, 68:12, 68:22,
68:24, 69:27, 73:4,
73:30, 74:3, 75:7, 75:21,
76:30, 79:24, 81:11,
85:17
seeing [2] - 17:16, 22:24
seem [2]-45:9, 80:11
seized [1] - 33:25
select [2]-11:6, 14:15
selling [1] - 62:17
sense [3]-5:29, 47:15, 68:6
sentence [4]-48:8, 48:18,
57:18, 66:19
separate [2] - 8:30, 25:26
separately [1] - 41:6
September [2]-9:28, 27:19
Sergeant [1] - 62:22
serious [11]-7:20, 48:20,
48:25, 49:12, 52:29,
66:9, 71:30, 74:8, 75:8,
75:23, 76:14
seriousness [4]-52:22, 52:27, 54:23, 77:27
services [1] - 73:8
set $[9]-5: 22,14: 30$, 21:12, 41:24, 49:25, 66:12, 80:16, 82:19,
86:21
sets [1]-7:17
seven [10]-20:19, 20:22, 31:10, 32:9, 48:9, 66:4, 71:17, 78:7, 84:7, 84:21
severe [1] - 17:11
shall [5] - 58:4, 62:15,
69:28, 69:29, 70:13
shareholder [1] - 80:24
Short [2]-46:10, 86:6
short [3]-18:13, 68:3, 79:4
shortly [1] - 10:14
show [5] - 7:5, 19:3, 35:25, 38:18, 62:30
showed [6] - 18:8, 18:10, 25:9, 28:2, 28:4, 66:19
shown [1] - 64:11
shows [4]-20:19, 20:27, 27:30, 33:6
SI [5] - 54:11, 55:19,
55:23, 59:20, 65:11
side [1] - 12:22
sides [1]-85:16
signature [6]-9:26, 9:27, 12:24, 12:25, 29:13,

38:7
signed [6] - 13:15, 13:22,
15:4, 23:25, 38:7, 54:8
significant [5] - 17:3,
51:12, 52:4, 79:28, 83:1
Silk [1]-81:15
similar [7] - 18:25, 21:17, 33:27, 35:7, 36:28, 39:8, 40:5
similarly [2] - 30:5, 32:8
simply [9]-28:25, 43:9,
43:12, 47:30, 63:7,
65:24, 79:4, 79:11,
79:16
single [1] - 48:9
Sinéad [1]-15:7
situation [3] - 54:16,
66:30, 70:10
$\boldsymbol{s i x}[1]-32: 19$
size [1]-32:10
sleeping [5] - 24:23,
24:24, 31:25, 64:3, 64:5
slightly [1] - 43:17
small [1] - 17:17
smaller [1] - 32:10
Smullen [8]-15:18, 15:19, 15:21, 15:28, 16:19,
17:30, 19:10, 24:17
sniff [1] - 39:14
so-called [1] - 59:28
Society [2] - 4:28, 78:15
SOCIETY [2] - 1:2, 1:5
software [2]-41:11, 41:13
sold [2] - 40:14, 52:14
sole [1] - $24: 3$
solicitor [1]-82:16
solution [1] - 68:7
someone [2] - 37:17,
64:24
sometimes [1] - 39:16
soon [1] - 69:2
sorry [34]-3:30, 8:15,
8:26, 9:21, 13:26, 14:23,
16:17, 17:25, 17:26,
22:1, 26:16, 29:14, 31:1,
31:5, 38:14, 38:16,
40:27, 40:28, 41:10,
42:4, 42:20, 43:7, 56:19,
57:27, 60:20, 69:10,
69:14, 71:18, 80:27,
81:13, 84:16, 85:20,
85:22
sought [1] - 15:9
sourced [4] - 37:29, 38:10, 50:28, 57:21
special $[3]-34: 16,34: 21$,
38:11
specialises [1]-35:15
specialist [2]-37:12,
37:21
specific [3]-27:7, 34:13,
34:16
specifically [5] - 46:19,

56:23, 65:26, 73:20,
76:18
specifics [1] - 86:23
specified [3] - 58:7, 70:25, 70:28
specify [1] - 69:30
speech [1] - 52:25
speed [1] - 39:11
Spiropent [8]-35:26,
36:6, 36:25, 36:30,
37:14, 37:16, 39:9,
59:27
spoken [1] - 68:26
staff [3]-57:26, 59:21, 66:20
staffing [2]-5:30, 6:2
stage [2] - 46:7, 68:1
stages [1] - 45:11
staggering [1] - 52:11
staggering" [1] - 77:17
standard [3]-52:25, 67:5, 73:10
standards [2]-83:20, 83:21
stands [1]-72:17
start [6]-4:11, 11:16, 12:10, 16:26, 48:5, 85:14
started [1] - 26:25
starting [1]-17:5
state [9] - 10:17, 12:27, 32:28, 56:2, 56:5, 57:7, 63:16, 83:5, 83:12
State [1] - 56:7
statement [6]-24:12, 45:19, 45:20, 45:21, 53:28, 55:14
statements [6]-25:27, 44:17, 44:18, 44:20, 44:23, 44:24
states [3]-77:7, 77:25, 80:9
statutory [1]-5:22
Stenographer/Logger [1] -1:29
Stenography [2]-1:28, 88:5
step [1] - 84:29
steroid [2] - 36:18, 36:29
steroids [1] - 52:2
stick [1] - 21:11
still [9]-3:23, 13:28,
18:17, 25:16, 28:14, 28:27, 28:30, 47:3, 68:22
Stilnoct [9]-16:6, 16:26, 21:9, 21:18, 24:10, 24:11, 24:22, 24:30, 64:1
stimulant [4]-18:27, 37:3, 39:8
stock [15]-14:16, 14:18, 15:13, 18:12, 18:17, 21:19, 24:29, 25:1,

26:10, 28:3, 33:29, 34:3,
40:20, 44:11, 44:14
stockpiled [1] - 61:12
stood [2] - 39:21, 42:9 stop [2] - 20:5, 67:3 stopped [2] - 54:5, 66:23
store [3]-58:11, 58:16, 59:13
stored [1]-8:2
straightened [1] - 79:14
street [5] - 52:4, 52:20,
59:30, 64:13, 77:29
streets [4]-51:28, 57:9, 60:5, 63:30
strength [4] - 12:5, 17:14, 17:15, 51:21
strengths [2]-17:11, 51:23
strong [1] - 86:27
stuffiness [1] - 39:15
sub [2]-48:9, 53:12
sub-allegations [1] - 48:9
sub-principles [1] - 53:12
subject [6]-3:28, 7:18,
28:10, 32:17, 69:30, 82:7
submission [3] - 76:11, 80:18, 81:11
submissions [11] - 67:25,
68:5, 69:13, 69:24, 70:5,
72:25, 74:24, 78:4, 81:9,
81:16, 84:12
Submissions [1]-2:9
subsection [3]-62:8, 69:29, 71:2
subsequent [6]-21:23,
21:26, 25:3, 25:4, 25:11, 27:11
subsequently [3]-6:29, 11:3, 23:15
substance [1] - 50:12
substantiated [2]-70:15, 70:17
Sudafed [24]-38:23, 38:25, 38:26, 39:20, 39:22, 39:27, 40:10, 40:16, 40:24, 40:26, 40:29, 41:11, 41:13, 41:20, 41:26, 41:30, 42:10, 42:16, 43:6,
43:21, 52:8, 52:9, 77:6
suffered [1] - 81:28
suffering [1] - 43:10
sufficient [1] - 27:6
suggest [3]-68:8, 68:11, 81:1
suggested $[3]$ - 69:10, 84:7, 86:16
suggesting [2] - 79:11, 80:25
suggestion [1] - 4:1
suits [2]-68:1, 68:2
Sulphate [1] - 35:27
summarise [1] - 18:15
summarised [1]-7:8
summary [4]-23:5, 48:5, 48:19, 49:1
Superintendent [4] -
50:30, 51:1, 58:18,
59:15
superintendent [6] - 5:10,
$6: 5,6: 13,57: 13,57: 14$, 73:25
supervising $[3]-6: 8$, 6:15, 34:28
supervision [4] - 6:4, 57:27, 59:22
supplied [50]-7:9, 7:12, 7:14, 7:25, 10:25, 11:28, 12:20, 14:5, 14:13, 15:27, 16:10, 18:1, 18:3, 18:6, 18:9, 18:11, 18:15, 18:16, 18:20, 19:12, 19:14, 19:19, 19:23,
20:27, 22:12, 23:8, 26:9,
27:13, 27:26, 28:1, 28:2,
34:9, 34:13, 35:18,
35:24, 35:27, 37:30,
39:5, 39:23, 40:10,
40:16, 40:22, 41:20,
43:22, 44:3, 44:9, 57:21, 60:9
supplier [1] - 35:14
suppliers [3] - 35:12,
35:13, 38:1
supplies [19]-7:5, 10:22,
11:5, 11:8, 20:17, 20:18, 21:3, 24:28, 26:20, 30:8,
30:25, 34:30, 35:21,
39:20, 39:21, 39:27,
39:30, 40:7, 44:6
supply $[37]-5: 7,6: 7$, 6:22, 6:26, 7:11, 7:23, 10:9, 11:7, 11:16, 14:12, 20:15, 20:19, 20:30,
22:10, 24:6, 26:6, 26:7,
28:11, 34:10, 35:9,
35:19, 36:9, 37:28, 39:3,
39:26, 42:5, 42:7, 51:4,
52:17, 57:17, 58:19,
59:16, 62:3, 62:7, 62:24,
64:14, 78:1
supplying [4]-61:23, 62:18, 64:10, 65:8
support [4]-22:16, 34:23, 66:21, 75:1
supported [2] - 78:18, 79:8
suppose [29]-21:14, 22:15, 23:5, 39:18, 49:16, 51:16, 51:18, 52:1, 52:8, 58:1, 58:2, 60:4, 61:15, 61:20, 64:9, 64:19, 69:25, 71:19, 72:16, 72:21, 73:20, 75:5, 75:6, 78:29, 80:20, 81:18, 82:18, 83:19
suspension [1] - 70:25
system [13]-12:19, 14:14, 18:10, 35:10, 35:24,
40:12, 40:15, 40:22,
40:23, 43:20, 44:8,
44:14
$\frac{\mathbf{T}}{\text { tab [20]-9:5, 12:13, 13:4, }}$
tab [20] - 9:5, 12:13, 13:4
20:8, 22:16, 23:20,
25:23, 28:28, 29:20,
33:11, 39:30, 40:28,
41:5, 43:13, 44:1, 46:20,
46:21, 72:30, 73:1,
76:19
table [9]-30:20, 30:28,
31:4, 31:10, 36:2, 37:6,
51:11, 51:16, 76:20
tablet [5] - 12:6, 28:7,
31:25, 64:3, 64:5
tablets [78]-11:1, 12:4,
14:1, 15:12, 16:6, 16:7, 17:12, 17:13, 18:1, 18:2, 18:5, 18:8, 18:10, 18:12, 18:19, 18:22, 18:23, 18:25, 19:27, 20:3, 20:20, 21:4, 21:25, 22:7, 22:11, 22:17, 23:4,
23:10, 24:22, 24:23, 24:24, 24:30, 25:10, 27:14, 27:15, 27:25, 28:2, 28:3, 28:5, 31:16, 31:18, 31:19, 31:23, 31:24, 33:7, 33:15, 36:6, 36:7, 36:27, 37:16, 37:17, 39:4, 40:24, 40:26, 41:13, 41:20, 41:26, 42:17, 43:22, 44:3, 44:12, 44:15, 61:10, 61:17, 62:24, 77:6
tabs [1] - 46:19
Tadalafil [1] - $28: 8$
talk-back [1] - 85:21
talks [1] - 58:1
tally [1]-32:20
teams [1] - 85:18
teasing [1] - 82:10
technical [1] - 68:24
technician [1] - 15:7
telephone [1] - 5:8
template [3]-13:8, 14:28, 29:24
ten [8]-24:1, 27:4, 31:16, 42:28, 71:17, 78:8, 84:7, 84:21
terms [4]-61:26, 65:1, 82:22, 82:30
terribly [3]-75:8, 79:21
tested [1]-76:27
testimony [1]-61:18
testosterone [18]-33:26,
$34: 3,34: 7,34: 26,36: 6$,

36:14, 36:17, 36:18,
36:23, 36:28, 36:29,
37:18, 37:19, 37:20,
38:21, 52:3, 77:2
Testovis [5]-34:8, 35:26,
36:5, 38:19, 59:27
thanked [1] - 45:22
thankfully [1] -84:30
THE [5] - 1:4, 1:5, 68:18, 87:4
themselves [1]-62:29
therefore [3]-7:27, 24:25, 52:13
thinks [1]-3:28
third $[5]-63: 1,63: 27$, 64:10, 65:9, 72:4
three [17]-17:11, 18:13, 18:17, 21:29, 21:30, 22:3, 23:3, 49:28, 50:20, 53:1, 58:26, 60:14, 63:8, 65:13, 79:1, 79:4
three-year [2]-79:1, 79:4
threshold [3]-52:22, 52:26, 54:22
throughout [3] - 45:18, 45:23, 45:25
Thursday [1] - 23:24
tightly [3] - 52:13, 54:9, 65:6
today [6] - 47:29, 49:15,
76:18, 77:13, 77:16,
83:7
together [3]-15:4, 46:24, 66:5
tolerated [1] - 64:24
top [6]-52:30, 54:14, 54:27, 55:25, 56:28, 63:22
total [7]-7:8, 15:14, 32:23, 37:7, 38:6, 42:29, 43:21
touch [1] - 72:21
towards [1]-45:19
transaction [4] - 8:4, 19:2, 39:5, 52:14
transactions [3]-8:3,
26:13, 26:18
transcript [3]-60:18, 79:25, 88:1
Transcript [1] - 1:28
transpired [1]-80:29
treat [2]-17:1, 36:16
treatment [4]-28:9,
34:15, 38:28, 64:9
trouble [1] - 75:23
trust [6]-56:9, 64:27,
66:14, 73:22, 74:9, 78:3
trusting [1]-64:30
truth [1] - 76:13
try [1]-4:2
trying [1] - 22:27
turn [1]-4:9
turned [1] - 78:17
turpitude [2]-50:2, 53:7
two [19]-8:29, 8:30, $11: 29,22: 8,23: 5,23: 22$, 31:8, 43:4, 43:23, 44:20, 46:18, 53:24, 65:20, 68:9, 68:12, 68:14 75:17, 77:13
Tylex [3] - 32:14, 32:15, 32:18
type [2] - 7:26, 36:29
U
ultimate [1] - 82:18 ultimately [4]-22:11, 82:2, 82:23, 83:25
unable [1] - 15:8
unaccounted [35] - 6:24,
12:6, 19:9, 20:3, 21:20,
22:12, 25:2, 25:10,
27:16, 28:6, 30:2, 30:15,
30:26, 31:11, 31:17, 31:21, 31:22, 31:25, 31:29, 32:3, 32:11, 32:14, 32:18, 32:21, 32:26, 37:20, 40:25, 41:26, 42:1, 50:27, 52:5, 52:10, 52:16, 52:17, 77:17
unauthorised [1] - 33:19 uncontroverted [3] -
76:23, 76:24, 77:19
under [24]-4:30, 5:13, 5:24, 9:4, 10:7, 14:17, 16:1, 18:17, 27:20, 29:30, 30:8, 30:14, 33:8, 34:15, 35:25, 37:28, 38:12, 50:13, 55:18, 58:8, 62:6, 62:8, 62:19, 65:20
underlined [1] - 58:3
undermine [1] - 74:21
understandable [1] 33:18
understandably [1] - 47:8 unequivocally [1] - 45:19 unfortunately [4] - 78:25, 79:8, 81:15, 83:22
Uniphar [22]-11:29, 16:8, 18:3, 19:13, 19:19, 20:30, 21:2, 21:30, 22:1, 22:2, 25:8, 25:16, 26:24, 27:1, 27:20, 28:19, 31:30, 35:13, 39:20, 42:5, 44:4, 44:5
United [26]-11:29, 16:9, 18:1, 19:14, 19:22, 19:23, 19:26, 20:20, 20:23, 20:27, 21:29, 22:2, 23:4, 25:7, 25:21, 26:24, 27:2, 27:5, 27:21, 27:25, 31:28, 35:13, 39:20, 42:5, 44:2, 44:4 units [6] - 27:30, 32:23,

37:7, 76:22, 77:1
unlawful [2] - 62:3, 62:6 unless [6] - 27:6, 68:9,
71:6, 81:6, 81:7, 81:8 unlicensed [7] - 33:19,
34:25, 35:12, 35:15,
35:21, 36:22, 59:26
unlikely [2]-61:24, 80:20 unmute [1]-4:9
unreported [1] - 71:24
unusual [1]-51:22
unwillingness [1] - 74:15
up [33]-7:17, 9:12, 12:13
13:5, 14:20, 14:23,
14:25, 16:17, 20:9, 21:7, 23:21, 25:25, 28:21, 28:23, 28:29, 29:20,
33:12, 39:11, 40:1, 41:6, 43:14, 43:25, 44:1, 44:21, 52:12, 68:11, 68:12, 72:28, 73:1, 73:2, 77:21
up-to-date [1] - 28:21
update [1] - 68:26
urgency [1] - 27:17
Usage [3] - 7:7, 12:10, 12:15
users [4] - 37:4, 39:10, 39:14, 39:17
usual [1] - 86:8
$\frac{\mathbf{V}}{\text { valid } 21-00: 9,60: 10}$
valid [2] - 60:9, 60:10
Vallely [2]-1:26, 82:16
value [3]-59:30, 64:13, 77:29
various [3]-35:11, 82:10, 83:26
versus [1]-24:28
via [1] - 21:25
view [9]-6:23, 48:19,
48:21, 48:22, 52:22,
64:21, 66:8, 71:30, 84:13
viewing [1] - 61:25
viron [1] - 59:27
virtue [1] - 31:8
vision [1] - 3:24
visit [19]-5:20, 10:4, 10:9, 10:16, 10:19, 15:29, 25:3, 25:4, 29:17, 30:6, 31:15, 33:29, 34:2, 34:25, 39:25, 45:16, 45:20, 45:25
visited [1] - 5:17
visits [1]-31:9
volume [1] - 41:29
$\frac{\mathbf{W}}{\text { waiting [3] - 28.14 } 68.22}$
waiting [3]-28:14, 68:22,
86:11
Ward [1] - 1:29

WEDNESDAY [2] - 1:15, 3:1
week [1]-23:23
welcome [3]-3:3, 46:14, 69:7
WhatsApp [8] - 61:20,
62:22, 62:30, 63:19,
63:27, 64:11, 75:20
whatsoever [1] - 9:22
whereby [1] - 68:10
whilst [2]-80:11, 81:24
whole [1]-64:22
wholesaler [4]-20:23, 25:7, 26:8, 34:18
wholesalers [17]-6:28 11:26, 11:29, 15:24, 15:25, 15:26, 16:8, 16:20, 21:25, 24:17, 26:22, 27:12, 30:8, 31:7, 34:29, 35:17, 36:1
wholly [1] - 78:2
Wicklow [22] - 5:17, 5:30, 6:13, 10:6, 12:20, 16:10, 20:21, 20:22, 27:13, 27:26, 28:6, 30:9, 32:21, 35:18, 35:20, 41:26, 43:20, 44:3, 50:28, 50:30, 57:11, 57:13 wish [4]-3:15, 72:28, 80:4, 80:6
wished [2] - 69:12, 69:13
wishes [6]-81:7, 81:8,
83:5, 83:12, 83:13, 83:15
WITNESS [9] - 3:22, 3:25, 4:5, 4:11, 4:16, 45:4, 46:3, 47:20, 47:24
witness [9]-4:24, 9:23, 41:2, 46:16, 46:18, 46:30, 47:1, 82:6, 82:8
witnesses [1] - 66:27
wondering [1] - 45:12
word [2] - 44:19, 52:11
words [1] - 76:3
works [1] - 4:10
worried [1] - 72:30
worry [1] - 23:1
writing [3]-25:5, 25:19, 36:25
written [3]-13:15, 27:18, 69:28
wrongdoing [2]-77:9, 77:22
wrote [1] - 12:25

| $\mathbf{X}$ |
| :---: |
| Xanax $[35]-12: 3,12: 4$, |
| $12: 5,16: 6,16: 25,17: 7$, |
| $17: 15,17: 28,18: 1,18: 2$, |
| $18: 5,18: 18,18: 23,20: 6$ |
| $20: 17,20: 20,20: 22$, |
| $21: 4,24: 18,27: 14$, |
| $29: 27,31: 18,51: 19$ |


[^0]:    D. O'Malley Stenography Ltd.

[^1]:    D. O'Malley Stenography Ltd.

[^2]:    D. O'malley Stenography Ltd.

